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ABSTRACT 
 
Extracellular vesicles (EVs), exosomes and microvesicles, transfer endogenous RNAs 
between neurons over short and long distances. We have explored EVs for siRNA delivery to 
brain. (1) We optimized siRNA chemical modifications and siRNA conjugation to lipids for EV-
mediated delivery. (2) We developed a GMP-compatible, scalable method to manufacture active 
EVs in bulk. (3) We characterized lipid and protein content of EVs in detail. (4) We established 
how protein and lipid composition relates to siRNA delivering activity of EVs, and we reverse 
engineered natural exosomes (small EVs) into artificial exosomes based on these data. 
 We established that cholesterol-conjugated siRNAs passively associate to EV membrane 
and can be productively delivered to target neurons. We extensively characterized this loading 
process and optimized exosome-to-siRNA ratios for loading. We found that chemical stabilization 
of 5'-phosphate with 5'-E-vinylphosphonate and chemical stabilization of all nucleotides with 2'-
O-methyl and 2'-fluoro increases the accumulation of siRNA and the level of mRNA silencing in 
target cells. Therefore, we recommend using fully modified siRNAs for lipid-mediated loading to 
EVs. Later, we identified that α-tocopherol-succinate (vitamin E) conjugation to siRNA increases 
productive loading to exosomes compared to originally described cholesterol.  
 Low EV yield has been a rate-limiting factor in preclinical development of the EV 
technology. We developed a scalable EV manufacturing process based on three-dimensional, 
xenofree culture of mesenchymal stem cells and concentration of EVs from conditioned media 
using tangential flow filtration. This process yields exosomes more efficient at siRNA delivery 
than exosomes isolated via differential ultracentrifugation from two-dimensional cultures of the 
same cells.  
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 In-depth characterization of EV content is required for quality control of EV preparations 
as well as understanding composition–activity relationship of EVs. We have generated mass-
spectrometry data on more than 3000 proteins and more than 2000 lipid species detected in 
exosomes (small EVs) and microvesicles (large EVs) isolated from five different producer cells: 
two cell lines (U87 and Huh7) and three mesenchymal stem cell types (derived from bone marrow, 
adipose tissue and umbilical cord Wharton’s jelly). These data represent an indispensable resource 
for the community. Furthermore, relating composition change to activity change of EVs isolated 
from cells upon serum deprivation allowed us to identify essential components of siRNA-
delivering exosomes. Based on these data we reverse engineered natural exosomes into artificial 
exosomes consisting of dioleoyl-phosphatidylcholine, cholesterol, dilysocardiolipin, Rab7, AHSG 
and Desmoplakin. These artificial exosomes reproduced efficient siRNA delivery of natural 
exosomes both in vitro and in vivo. Artificial exosomes may facilitate manufacturing, quality 
control and cargo loading challenge that currently impede the therapeutic EV field. 
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PREFACE 
 
The Khvorova laboratory is very collaborative within the lab as well as outside the lab. We 
work like a theatre troupe that puts on many shows, where each show has a different lead actor 
and stage director. The troupe is led by the main theater director, Anastasia. Anastasia likes to 
work with very independent people, who don’t always listen to her and often follow their own 
scientific minds. Data presented in this dissertation is the result of six projects, where I played lead 
actor and stage director and worked together with the team to put the show on stage. Team work 
makes us efficient and allows us to conduct experiments that cannot be performed by an individual. 
Team work is the present and the future of investigative life sciences. 
Data, figures and text in Chapters II–VI has been published / submitted in the form of six 
research articles, where I am either first author or co-first author. In case of co-first author articles 
(Sections 3.1 and 3.3) I worked together with chemists, who developed and synthesized new 
siRNAs, whereas I performed biological experiments.  Detailed contributions can be found in the 
chapter–specific prefaces. Chapters I and VII are unpublished original work of mine that I wrote 
specifically for this dissertation.
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CHAPTER I INTRODUCTION 
1.1 RNA THERAPEUTICS 
 
The most abundant nucleic acids in nature are ribonucleic acids (RNAs)1-3, which occur in 
the form of oligonucleotides or polynucleotides. RNAs are versatile molecules, able to store 
genetic information, able to form delicate three-dimensional structures, and able to exhibit 
enzymatic activity3.  RNAs can interact with DNA, RNA, proteins and lipids4. RNAs are involved 
in all levels of regulation of life3. These diverse activities of RNAs are enabled by a diverse 
landscape of naturally occurring chemical modifications: methylation of the 2'-hydroxy ribose 
backbone or the nucleotide bases, conjugation of other small molecules to RNA, forming 
alternative bases via isomerization, reduction, replacement of oxygen with sulfur etc3. 
Increasing understanding of the functional and chemical diversity of RNAs in the past 
decades led to the birth of a new therapeutic concept: if chemically modified natural RNAs can 
regulate all stages of life, then exogenously synthesized, chemically modified RNAs may regulate 
health and disease.  
1.1.1 Classes of RNA therapeutics 
 
The diversity of RNA therapeutics is comparable to the diversity of natural RNA activities. 
RNA therapeutics can be classified according to the mode of action (requires exogenous protein, 
endogenous protein or no protein to act), the location of action (nucleus, cytoplasm or extracellular 
space), target (DNA, RNA or protein), and secondary structure (single stranded or double 
stranded). Most RNA therapeutics are synthesized using solid phase synthesis, but some are 
synthesized using in vitro transcription (i.e. mRNAs). Most RNA therapeutics inhibit the activity 
of its target molecule, but some activate it (i.e. mRNA, small RNA-mediated transcriptional 
Chapter I Introduction 
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activation). A list of major classes of RNA and oligonucleotide therapeutics can be found in Table 
1.1 
 Mode of action Location of action Target  
Secondary 
structure 
Reference 
Mechanism first 
identified in (species) 
siRNA 
Endogenous 
protein (Ago2) 
cytoplasm mRNA Double stranded 5-6 C. elegans 
siRNA 
Endogenous 
protein (Ago2) 
cytoplasm mRNA Single stranded 7 M. musculus 
miRNA 
Endogenous 
proteins  
cytoplasm mRNA Single stranded 8-9 C. elegans 
Small RNA-
mediated 
transcriptional 
inhibition / 
activation 
Endogenous 
proteins 
nucleus Pre-mRNA Single stranded 10-12 
N. tabacum 
H. sapiens 
ASO –  
RnaseH 
dependent 
Endogenous 
protein 
(RNaseH) 
nucleus Pre-mRNA Single stranded 13 Rous sarcoma virus 
mRNA 
Endogenous 
proteins 
(ribosome) 
cytoplasm - Single stranded 14-15 E. coli 
CRISPR sgRNA 
Exogenous 
protein (Cas) 
Nucleus or 
cytoplasm 
DNA or 
RNA 
Single stranded 
with duplex 
region 
16-17 S. pyogenes 
aptamer - extracellular protein 
Single stranded 
highly structured 
18 In vitro 
ASO – steric 
blocker 
antimiR 
- cytoplasm miRNA Single stranded 19-20 H. sapiens 
ASO – steric 
blocker 
Splice switching 
- nucleus Pre-mRNA Single stranded 21 H. sapiens 
ASO – steric 
blocker 
Triplex forming 
- nucleus DNA Single stranded 22-23 In vitro 
ASO – steric 
blocker 
Anti-telomerase 
- nucleus RNA Single stranded  24 H. sapiens 
ASO – steric 
blocker 
Translation 
blocking 
- cytoplasm mRNA Single stranded 25 O. cuniculus 
Ribozyme - Nucleus/cytoplasm 
DNA or 
RNA 
Single stranded 26-28 E. coli 
 
Table 1.1 List of RNA and oligonucleotide therapeutic classes. 
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Beyond diversity of potential therapeutic activity, a major advantage of RNA therapeutics 
is sequence-specificity. Most RNA therapeutics (except mRNAs and aptamers) use Watson-Crick 
base pairing to bind their nucleic acid targets. Thus, the alteration of the RNA therapeutic targeting 
sequence does theoretically enable the targeting of the entire human genome and/or transcriptome. 
Unlike small molecule drugs or therapeutic proteins, the sequence specificity of RNA therapeutics 
makes a large array of undruggable targets accessible for therapy.  
1.1.2 Chemical modifications of siRNAs 
 
RNA interference, in which short double stranded RNAs (siRNAs) trigger the cleavage of 
complementary mRNA, was discovered in 1998 in C. elegans5 and in 2001 in mammalian cells6. 
siRNAs have since become a widely used research tool to silence mRNAs. The promise of siRNAs 
for a sequence-specific gene silencing therapy was substantial and excitement was amplified by 
the co-occurring Human Genome Project (1990-2003). The first clinical trial was initiated only 3 
years after the discovery of mammalian RNAi29. However, early clinical trials of siRNAs either 
failed to show gene silencing30 or induced immune stimulation31-32,  dampening initial enthusiasm 
in RNAi therapeutic development33-35.  With the failure of these early clinical trials the importance 
of chemical modifications of therapeutic siRNAs began to emerge.  
Natural (unmodified) RNAs are suboptimal as drugs due several reasons: (i) RNAs are 
substrates of endo- and exonucleases and their half-life in plasma is less than a minute36. (ii) Small 
double stranded RNAs are recognized by the innate immune system and induce an immune 
response37-40, and (iii) RNAs are negatively charged large molecules, therefore cannot passively 
penetrate the cell membrane. The siRNA field tried to overcome these challenges using chemical 
modifications adopted from early development of antisense oligonucleotides41.  
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Rational design of chemically modified siRNAs requires a detailed understanding of how siRNAs 
interact with proteins outside and inside of the cell. In the extracellular space the siRNA is substrate 
to 3'-to-5' processive exonucleases42-43, RNase A type endonucleases44-46, and recognized by Toll-
like receptor 3 of the innate immune system47-48. Upon cellular uptake, siRNAs are recognized by 
endosomal Toll-like receptor TLR749-50 as well as  intracellular double stranded RNA sensors: 
interferon-induced, double-stranded RNA-activated protein kinase (PKR)39, 51 and retinoic acid-
inducible gene I (RIG-I)52. After overcoming these challenges, siRNAs associate with the RNA-
induced silencing complex (RISC) in the cytoplasm53. Thermodynamic bias defines a guide strand 
and a passenger strand in the 21-nucleotide long siRNA duplex: guide strands have less stable base 
pairs at the 5' terminus 54-55. Therefore the 5' terminus of the guide strand can tolerate a wide variety 
of chemical modifications56. The guide 
strand loads in the enzymatically active 
component of RISC, Ago257, whereas the 
passenger strand is released, typically 
following cleavage58-59. Subsequently, 
guide strand containing RISC performs 
multiple rounds of binding and cleaving 
complementary mRNAs60. Events of 
RNAi in the cytoplasm are depicted in 
Figure 1.1. 
Figure 1.1 Schematic of RNA interference 
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Chemical modifications introduced into siRNAs are aimed to reduce immunogenicity, 
increase nuclease resistance, help cellular uptake, and promote correct selection of the guide 
strand, while preserving interactions with proteins necessary to exhibit silencing activity. The 
modifications developed to address these needs can be classified as (1) modifications of the 
phosphodiester backbone, (2) modifications of the ribose 2'-hydroxyl group, and (3) modification 
of the ribose ring. Generally, positions 2-16 of the guide strand are the least tolerant for chemical 
modifications, since only this portion of the guide strand base pairs with the target mRNA61. A 
selection of the most frequently used modification is depicted in Figure 1.2.  
Among modifications of the phosphorodiester backbone, phosphorothioate62, 
phosphorodithioate63 and boronophosphate64 have all proved useful to increase siRNA stability. 
All these backbone modifications decrease the thermostability of the RNA duplex63, 65-67. 
Phosphorothioates also promote non-specific binding to proteins68. However, extensive 
phosphorothioate modification reduces silencing activity69, may induce toxicity65-66, and 
phosphorothioates are only tolerated in certain positions62, 65-66, 69. Yet, phosphorothioates are 
among the most commonly used chemical modifications of siRNA and are incorporated in all 
current clinical stage compounds70. Phosphorothioate modification introduces a chiral phosphorus 
into the siRNA backbone71. Stereopure (R diastereomers only) synthesis of phosphorothioate 
siRNAs increases both nuclease stability and silencing activity71. 
2'-ribose modifications are more diverse, with 2'-fluoro and the naturally occurring 2'-O-
methyl being most widely used. 2'-O-methyl and  2'-fluoro are tolerated in any individual position 
of an siRNA72, but fully modified 2'-O-methyl or 2'-fluoro guide strands are either completely 
inactive or exhibit substantially reduced activity73. Therefore, initial patterns included 
modifications at the terminal nucleotides only74, at every other nucleotide75 or at every 
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pyrimidine36, 65. 2'-O-methyl and 2'-fluoro modifications modulate duplex thermostability76, 
promote nuclease stability74-75, 77-78 and repress immunogenicity49, 72, 79-80.  
 
Figure 1.2 Selected modifications used in siRNAs. Adapted from Bramsen and Kjems: 
Development of therapeutic-grade small interfering RNAs by chemical engineering. Frontiers in 
Genetics. 201281. RNA: ribonucleic acid, PS: phosphorothioate, PS2: phosphorodithioate, EA: 2'-
aminoethyl, DNA: deoxyribonucleic acid, 2'-F: 2'-fluoror, 2'-OMe: 2'-O-methyl, 2'-MOE: 2'- O-
methoxyethyl, 2'-FANA: 2'-deoxy-2'-fluoro-β-D-arabinonucleic acid, HM: 4'-C-hydroxymethyl-
DNA, LNA: locked nucleic acid, carboxylic LNA: 2',4'-carboxylic-LNA, OXE: oxetane-
LNA,UNA: unlocked nucleic acid, 4'-S: 4'-thioribonucleic acid, F-SRNA: 2'-deoxy-2'-fluoro-4'-
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thioribonucleic acid, Me-SRNA: 2'-O-methyl-4'-thioribonucleic acid, 4'S-FANA: 2'-fluoro-4'-
thioarabinoribonucleic acid, HNA: hexitol nucleic acid, ANA: altritol nucleic acid, B: base.  
 
Bulkier 2'-modifications, such as 2'-aminoethyl and 2'- O-methoxyethyl (2'-MOE) are best 
tolerated at the 3'-ends of the strands82, where they can fine-tune duplex thermostability and 
asymmetry83. Locked nucleic acid (LNA)84 ,oxetane-LNA83, and unlocked nucleic acid (UNA)85 
all increase nuclease stability. LNA increases86, whereas UNA decreases87 duplex thermostability, 
which may improve off-target effects88-89. 
Ribose alternatives have also been introduced to siRNAs.  2'-deoxy-2'-fluoro-β-D-
arabinonucleic acid (2'-FANA) modification90 and its thioated version91 is similar to DNA, 
decreases thermostability and is mostly tolerated in the passenger strand90-91. Other ribose 
alternatives, such as hexitol nucleic acid (HNA)92 or altritol nucleic (ANA)93 can also be 
incorporated to 3'-ends of the siRNA strands, where they increase nuclease stability and modulate 
duplex thermostability. Finally, 4'-thio modified riboses have also been successfully incorporated 
into siRNAs, where they increased nuclease stability, duplex thermostability and silencing 
acitivity94-96. 
This large chemical toolbox enables the combinatory application of different modifications 
and fine-tuning of siRNA properties. Yet, 2'-O-methyl, 2'-fluoro and phosphorothioate 
modifications dominate the field97. A combinatory screen of these three modifications has been 
carried out in various industrial and academic laboratories in order to optimize in vivo stability, 
geometry, and thermodynamics, while preserving the silencing activity of siRNAs. Both 2'-O-
methyl and 2'-fluoro modifications favor C3'-endo ribose conformation and therefore A-form helix 
Chapter I Introduction 
25 
 
structure of RNA98-99. Because fluorine has a higher electronegativity than oxygen, 2'-fluoro ribose 
slightly overwinds the helix compared to natural 2'-hydroxyl ribose in RNA. Similarly, because 
carbon has a lower electronegativity than oxygen, 2'- O-methyl ribose slightly underwinds the 
helix compared to natural 2'-hydroxyl ribose in RNA. Thus, a combinatorial pattern of 2'-O-methyl 
and 2'-fluoro modifications can be used for thermodynamic tuning of an siRNA100. For example 
three 2'-O-methyls or three 2'-fluoros in a row101 in the context of alternating 2'-O-methyls and 2'-
fluoros77 may improve silencing activity of siRNAs. Generally, an optimized siRNA guide strand 
should have a flexible 5' end102, a higher affinity seed region and a lower affinity 3' region54, 103 to 
promote correct selection of the guide strand, binding of guide strand to target mRNA and the 
release of the cleaved target mRNA. Full modification (e.g. modification of every ribose in the 
duplex) of siRNAs is essential for conjugate-mediated delivery of siRNAs 104, where this 
modification pattern enables a 10 000-fold increase in tissue accumulation compared to partially 
modified siRNAs104. However, when siRNAs are encapsulated into lipid nanoparticles for 
delivery, chemical modifications are substantially less beneficial36, 105. Optimization of siRNA 
chemical modification for extracellular vesicle mediated delivery is described in Chapter III. 
1.2 EXTRACELLULAR VESICLES 
 
Most cell types in culture or in vivo release various types of extracellular vesicles (EVs). The 
first description of extracellular vesicles from non-neuronal origin dates to 1967: “platelet-dust” 
comprised of vesicles with coagulation activity that sediment at 134 000 g but not at 18 000 g from 
plasma and may originate from α-granules (a multivesicular body – related organelle) of 
platelets106. In 1970, EVs were purified from cartilage tissue107 , in 1971 from erythrocytes108 and  
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in 1981 from various cell lines109. These initial studies all isolated EVs via differential 
centrifugation and found enzymatic activity associated to the vesicles.  
The term “exosome” is often used in this dissertation and generally, in the context of 
extracellular vesicles. “Exosomes” were initially defined as vesicles sedimenting from conditioned 
media at 310 000 g but not at 10 000 g and containing 5'-nucleotidease activity109. The notion that 
exosomes originate from the multivesicular body was first posed in 1987110 in a study about 
reticulocyte EVs. This speculation was based on the orientation and trafficking properties of 
transferrin in EV membranes111. However, the concept that multivesicular bodies (MVBs) may 
undergo exocytosis predates the exosome definition by 30 years: in the first report on 
multivesicular bodies in 1957, Robertis et al described a catechol secretion mechanism via MVBs 
in the adrenal gland 112.  
Extracellular vesicles encompass several, partially overlapping vesicle subclasses other than 
exosomes. “Microvesicles”, another frequently used term in this dissertation, has been used in the 
1970s to refer to erythrocyte and platelet derived EVs playing a role in coagulation108-109, 113, and 
formed by plasma membrane budding114. However, these initial microvesicles were smaller than 
100 nm, sedimented at centrifugation speeds higher than 100 000 g but not at speeds lower than 
20 000 g108-109, 113. Thus, these initial microvesicles would rather fit the definition of an exosome 
today. The first microvesicles, which sedimented at centrifugation speeds lower than 100 000 g, 
were reported in 1982115. 
Other extracellular vesicles types have been named somewhat arbitrarily after either their 
release mechanism (ectosome116), source cell type (oncosome117), source organ (prostasome118), 
extracellular space consistency (matrix vesicle107), state of source cell (apoptotic body119-120) etc. 
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The two EV terms used in this dissertation, exosomes and microvesicles, may be defined 
according their intracellular origin or their isolation protocol. Exosomes are traditionally 
considered to form upon exocytosis of the multivesicular body, while microvesicles are thought to 
form upon plasma membrane budding121. However, the size range, sedimentation properties, and 
protein markers (see also Chapter V) of these EV subclasses are greatly overlapping. Therefore, 
no current protocol can sufficiently differentiate vesicles originating in the multivesicular body 
from vesicles shed from the plasma membrane. Thus, this dissertation uses an EV definition based 
on isolation protocol: vesicles sedimenting at 10 000 g will be referred to as microvesicles, and 
vesicles sedimenting at 100 000 g will be referred to as exosomes.   
1.2.1 Endogenous activity of EVs 
 
EV release is conserved throughout evolution and occurs in bacteria122, fungi123, plants124, 
nematodes125, flies126 and mammalian cells109. Such evolutionary conservation indicates that EVs 
play a role in both single-cell and multi-cell organisms. The first suggested function of EVs was 
regulated removal of intracellular and membrane components during reticulocyte maturation110. 
This observation led to a long-lasting but inadequate view of extracellular vesicles as cellular 
waste121, 127. However, a role of EVs in intercellular communication has been showed as early as 
in 1984128 and evidence has been growing since then127. Intercellular signaling of EVs was 
discovered in immune presenting cells in the 1990s129-131 and this discovery marked a shift in the 
general view of EVs: from cellular waste to intercellular signaling devices. EVs have been shown 
to exhibit intercellular signaling not only in health, but also in disease, by for example promoting 
tumor metastasis132. 
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Intercellular signaling activity of EVs can be used in clinical applications in three ways: 
(1) Content of EVs may indicate the state and/or type of producer cell and thus be used as a 
biomarker133. (2) EV activity modulating the immune system130 or promoting tissue 
regeneration134 may be used in disease. (3) EVs may be used to deliver engineered cargo to 
recipient cells135-136. Table 1.2 shows past and present clinical trials involving EVs classified 
according to the above mechanisms of action. Biomarker trials have clearly been the focus (83 % 
of trials), whereas regenerative, immunomodulatory and delivery focused trials each represent less 
than 10% of trials. 30% of EV biomarker trials detects protein(s) and 70% detects RNA(s) as EV 
cargo of diagnostic relevance. 
Clinical Trial ID Producer Cell Cargo 
Mechanism 
of Action 
Disease 
NCT02957279 Blood - Biomarker Sepsis 
NCT02393703 Blood, Pancreas - Biomarker Pancreatic Cancer 
NCT01779583 Serum, Tumor - Biomarker Gastric Cancer 
NCT03109873 Blood - Biomarker Head and Neck Cancer 
NCT02226055 Blood - Biomarker Chronic Kidney Disease 
 NCT02051101 Blood, Skin - Biomarker Port Wine Stain 
NCT03392441 Blood - Biomarker Type 1 Diabetes 
NCT02977468 Blood - Biomarker Breast Cancer 
NCT03228277 Bronchoalveolar Lavage DNA Biomarker Lung Cancer 
NCT03267160 Blood, Urine Protein Biomarker Sepsis 
NCT02147418 Oropharingeal Rinse Protein Biomarker 
Oropharyngeal Squamous Cell 
Carcinoma 
NCT03222986 Blood, Urine Protein Biomarker Sepsis 
NCT02662621 Blood, Urine Protein Biomarker Cancer 
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NCT03106246 Blood Protein Biomarker Diabetes mellitus 
 NCT02921854 Serum Protein Biomarker Cancer 
NCT03381482 CSF Protein Biomarker Alzheimer’s Disease 
NCT03262311 Blood Protein Biomarker Hypoxia 
NCT02327403 Urine Protein Biomarker Kidney Transplant 
NCT01860118 Blood, Urine Proteins Biomarker Parkinson’s Disease 
NCT03108677 Blood RNA Biomarker Lung Metastases of Ostersarcoma 
NCT02702856 Urine RNA Biomarker Prostate Cancer 
NCT03478410 Epicardial Fat RNA Biomarker Cardiac Arrythmias 
NCT01344109 Tumor RNA Biomarker Breast Cancer 
NCT03102268 Tumor RNA Biomarker Cholangiocarcinoma 
NCT02890849 Tumor, Blood RNA Biomarker Lung Cancer 
NCT03236675 Blood RNA Biomarker Lung Cancer 
NCT03236688 Plasma RNA Biomarker Prostate Cancer 
NCT03027726 Blood RNA Biomarker Type 2 Diabetes 
NCT03264976 Serum RNA Biomarker Diabetic Retinopathy 
NCT03031418 Urine RNA Biomarker Prostate Cancer 
NCT03280576 Blood RNA Biomarker Sepsis 
NCT02464930 Blood RNA Biomarker Barrett’s Esophagus 
NCT03227055 Urine RNA Biomarker Chronic Kidney Disease 
NCT03384433 Mesenchymal Stem Cell miR-124 Delivery Acute Ischaemic Stroke 
NCT01294072 Plant curcumin Delivery Colon Cancer 
NCT01159288 Dendritic Cells 
Tumor 
Antigens 
Delivery Lung Cancer 
NCT02138331 Mesenchymal Stem Cell - 
Immune 
Modulation 
Type 1 Diabetes 
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NCT01668849 Plant (Grape) - 
Immune 
Modulation 
Oral Mucositis 
NCT02565264 Plasma - Regenerative Wound  
NCT03437759 Mesenchymal Stem Cell - Regenerative Macular Holes  
 
Table 1.2 List of past and present clinical trials involving extracellular vesicles. 
 
1.2.2 EVs as delivery vesicles 
 
The idea of using EVs as delivery vesicles for RNA therapeutics stems from three key 
findings: (1) some EVs exhibit cell-type-specific targeting137; (2) EVs contain RNA138; and (3) the 
regenerative effect of mesenchymal stem cells can partially be attributed to EV-mediated miRNA 
delivery139. EVs display several further advantages as delivery vesicles: The high membrane 
rigidity of EVs may enhance stability at neutral pH in circulation140. EV membrane proteins may 
protect from complement activation141 and phagocytosis142. Since EVs occur naturally in all bodily 
fluids, the exogenous administration of EVs is expected to be safe.  
A major challenge in the EV-mediated delivery field is efficient loading of therapeutic 
cargo into EVs. Loading strategies can be classified according to the timing of intervention, which 
can occur either before EV isolation (e.g. modifying producer cell), or after EV isolation (e.g. 
modifying isolated EVs). RNA cargo loading into EVs has been achieved by  overexpressing RNA 
in producer cells with an EV-specific zipcode132, 143-144 (cis-acting regulatory sequence associated 
to RNA enrichment in EVs, trans-acting proteins responsible for this enrichment are unknown143) 
or heterogenous nuclear RNP A2B1 binding motif145, tethering RNA to EV-enriched proteins via 
the MS2 bacteriophage coat protein system146-147 or via the transactivator-of-transcription-trans-
activating-response (Tat-TAR) system148, electroporating RNA into EVs136, 149-150, transfecting 
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RNA into EV producer cells151 or into EVs directly152, and tethering lipid-conjugated RNAs to the 
EV membrane135, 153-155 (see also Chapter III). All these strategies can promote efficient RNA 
transfer to recipient cells and they are independent of RNA cargo sequence. However, each 
strategy has its specific caveat. Electroporation of RNAs may induce RNA aggregation156, 
transfection of EVs may disrupt EV membrane152, level of loading cannot be controlled in all 
expression – based methods. Loading of lipid-conjugated RNAs to EVs is a well-controlled, simple 
and scalable process (Chapter III and 135). However, RNAs associated to the EV membrane 
decrease the surface charge of the vesicles (Chapter III and 135) and it remains unknown whether 
this surface charge change interferes with EV trafficking activity. Finally, genes can be 
productively loaded into EVs in the form of non-enveloped viruses, such as AAV157-159 or hepatitis 
A160, a strategy that promotes better spread and escape from neutralizing antibodies157-160. A further 
iteration of this strategy is Gag-expression-induced virus-like extracellular vesicles, which do not 
contain a viral genome161. These virus-like EVs can efficiently deliver ribonucleoproteins to 
various cell types in vivo162. 
Proteins are traditionally loaded to EVs by expressing proteins in producer cells fused to 
EV-associated or membrane-associated proteins or protein domains. For example, proteins and 
peptides can be fused to CD9163, Lamp2b149, 164, CD63165, lactadherin166 or ARRDC1148 for EV-
targeting. A modification of this approach makes protein-CD9 fusion light-inducible and thus 
allows an additional level of control over cargo loading into EVs163. Fusing proteins to 
palmitoylation signals167, myristylation signals168,  phosphatidylinositol-(4,5)-bisphosphate 
(PIP(2))-binding domain168, WW-motifs148 and to transmembrane domain of platelets-derived 
growth factor receptor (PDGFR)167 can also drive enrichment of protein cargo in EVs. Another 
approach is to modify the EV surface after EV isolation. Freeze-thawing, sonicating or extruding 
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EVs with protein cargo or saponin-mediated permeabilization of EV membrane for the uptake or 
protein cargo have all been useful for EV loading169. Primary amines (present on lysine residues) 
are prone to amine-specific cross-linking reactions, which has been used to modify EV surface 
proteins for CLICK-chemistry-based attachment of ligands170. Chapter VI describes a strategy, 
which uses amine-specific cross-linking to load proteins on vesicles surfaces. Cysteines can also 
be used for orthogonal bioconjugation of ligands to nanoparticles171. Surface functionalization of 
EVs is a very promising intersection between synthetic chemistry and synthetic biology. However, 
bioconjugation reactions will have to be optimized to (1) maximize conjugation yield, and (2) 
avoid interference of chemical reaction with the biological activity of EVs and/or conjugated 
ligands (see Chapter VI). 
RNAs or proteins associated to the surface of EVs can serve as cargo as well as targeting 
ligand. For example, cholesterol-conjugated siRNAs represent surface associated cargo that can 
be efficiently delivered to recipient cells153-154, 172, whereas cholesterol-conjugated aptamers can 
serve as targeting ligands driving therapeutic EVs to tumors155. Similarly, proteins or peptides 
fused to membrane proteins can constitute cargo148, 166, fluorescent labeling146, and targeting to 
certain receptors149, 164. 
Electroporation has been also used to load small molecules, such as curcumin173, 
doxorubicin164, anti-inflammatory Stat3-inhibitor174 into EVs. Applying a pH gradient between 
intravesicular and extravesicular space may also drive loading of small molecules175. Another 
strategy to load doxorubicin (or possibly any cargo) into EVs is to re-construct EV-like vesicles 
from the plasma membrane by serial extrusions176. Similar experiments have been conducted to 
re-form vesicles after disruption of the plasma membrane using nitrogen cavitation175, extrusion 
through microfluidic devices177-178,  and centrifugation through a membrane with micro-sized 
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pores179. The versatility and high vesicle yield of this approach is appreciated; however, plasma-
membrane derived vesicles may lack the target cell specificity of natural EVs. 
1.3 RATIONALE 
 
EV-mediated siRNA delivery is a promising approach to treat diseases of the brain, because 
(1) abundant EVs transfer RNAs and proteins between neurons and glial cells180-185; (2) most 
neurodegenerative diseases are genetically defined and therefore ideal targets for RNA 
therapies186-188185-188; and (3) brain diseases often involve neuron loss and neuroinflammation, 
targets of intrinsic neurotrophic and immunomodulatory activity of EVs139, 189-190. Drug delivery 
to brain is very challenging, a fact that justifies the effort invested in EV manufacturing and 
engineering.  
This dissertation focuses on EV-mediated siRNA delivery to silence Huntingtin in neurons. 
Huntington’s disease is the third most common neurodegenerative disease, with underlying 
autosomal dominant trinucleotide repeat expansion in the huntingtin gene 191. Silencing both the 
normal and mutant copies of Huntingtin represents a therapeutic benefit192, whereas discrimination 
between mutant and wild-type copies is also possible via either targeting SNPs187, 193 or the 
expanded CAG repeat194. Currently there are two ongoing clinical trials targeting huntingtin with 
either a non-allele-selective188 or an allele-selective antisense oligonucleotide187. EVs may play a 
role in Huntington’s disease pathology185, 195, whereas stem cell-derived EVs can be therapeutic196. 
Thus, EV-mediated siRNA therapy for Huntington’s disease would combine the intrinsic 
therapeutic effects of EVs with gene-specific RNA interference.  
Desired characteristics of an ideal delivery vesicle would be minimal toxicity and broad 
therapeutic window, specific cell-targeting, efficient and controllable loading of EVs with cargo, 
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and cost-effective and scalable vesicle manufacturing. This dissertation addresses some of the 
above questions and focuses on (1) chemical optimization of RNA cargo for EV-mediated 
delivery, (2) developing large-scale manufacturing for active EV production, (3) characterization 
of EV components, and (4) understanding the EV composition – activity relationship in order to 
reverse engineer EVs.  
CHAPTER II METHODS 
2.1 PREPARATION OF OLIGONUCLEOTIDES 
 
Oligonucleotides were synthesized on an Expedite ABI DNA/RNA Synthesizer following 
standard protocols.  For each synthesis the different synthesized lipophilic conjugated CPG197-198 
was used (Figure 22A-22B compound 4, 8, or 9) or a commercial C6 amino CPG (ChemGenes, 
Wilmington, MA) (for the post-synthetic conjugation of α-tocopheryl succinate) for the sense 
strand or at a 10 µmoles scale using a Unylinker® terminus (ChemGenes, Wilmington, MA) for 
the antisense strand. 2´-O-methyl phosphoramidites (ChemGenes, Wilmington, MA), 2´-fluoro 
phosphoramidites (BioAutomation, Irving, Texas), Cy3 labeled phosphoramidites (Gene Pharma, 
Shanghai, China) and synthesized E-Vinyl Phosphonate phosphoramidites199 were prepared as 
0.15 M solutions in acetonitrile. Phosphoramidite coupling time was 250 s for all amidites using 
5-(Benzylthio)-1H-tetrazole (BTT) 0.25 M in acetonitrile as coupling activator. Detritylations 
were performed using 3% dichloroacetic acid (DCA) in dichloromethane for 80 s and capping 
was done with a 16% N-methylimidazole in THF (CAP A) and THF:acetic anhydride:2,6-
lutidine, (80:10:10, v/v/v) (CAP B) for 15 s. Sulfurizations were carried out with 0.1 M solution 
of 1,2,4-dithiazole-5-hione (DDTT) in acetonitrile for 3 minutes. Oxidation was performed using 
0.02 M iodine in THF:pyridine:water (70:20:10, v/v/v) for 80 s. In the case of 5′-phosphate 
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compounds, the Chemgenes chemical phosphorylation reagent bis-cyanoethyl-N,N,diisopropyl 
CED phosphoramidite was used to introduce the 5′-monophosphate. After completion of the 
automated synthesis, the solid support was washed with 0.1 M piperidine in acetonitrile for 10 
min, then washed with anhydrous acetonitrile and dried under argon.  
For the coupling of vinylphosphonate phosphoramidite, a 4-fold excess of phosphoramidite was 
loaded on the solid support, and phosphoramidite condensation was carried out for 20 min. A 
solution of 3% trichloroacetic acid in dichloromethane was used to remove the dimethoxytrityl 
group from the 5’ hydroxyl group of the nucleotide. A solution of 0.25 M 5-(Ethylthio)-1H-
tetrazole in anhydrous acetonitrile was used as an activator for the coupling step.  
Phosphorothioate linkages were introduced using a 0.05 M solution of 3-
((dimethylaminomethylene)amino)-3H-1,2,4-dithiazole-5-thione in pyridine:CH3CN (1:1) and a 
5 min contact. Solid support was washed with anhydrous acetonitrile then anhydrous 
dichloromethane and flushed with argon.  
2.2 DEPROTECTION AND PURIFICATION OF OLIGONUCLEOTIDES 
 
For vinylphosphonate strands a solution of bromotrimethylsilane and pyridine in 
dichloromethane (0.75 ml bromotrimethylsilane and 0.53 ml pyridine dissolved in 28.2 ml 
CH2Cl2, 0.5 ml per mmol of solid support) was circulated through the vessel containing the CPG 
for 30 min at room temperature. 
Sense strands were cleaved and deprotected using 1 mL of 40% aq. methylamine at 45 °C 
for 1h. Antisense strands were first deprotected with a solution of bromotrimethylsilane/pyridine 
(3:2, v/v) in dichloromethane (5 mL) for the E-Vinyl Phosphonate deprotection and then cleaved 
and deprotected with 10 mL of 40% aq. methylamine at 45 °C for 1h. For both sense and antisense 
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strands, the oligonucleotide solutions were frozen in liquid nitrogen for a few minutes and dried 
under vacuum in a Speedvac overnight. The resulting pellets were suspended in water and purified 
using an Agilent Prostar System (Agilent, Santa Clara, CA). For the sense strand a Hamilton HxSil 
C18 column (150 x 21.2) was used (conditions: Buffer A: 50 mM sodium acetate in water with 
5% acetonitrile, Buffer B: acetonitrile ; gradient = 90% A, 10% B to 10% A, 90% B in 18 minutes 
; Temperature: 70°C ; Flow rate: 5 mL/min) and for the antisense strand, a Dionex NucleoPac PA-
100 (9 x 250) was used (conditions = Buffer A: 30% acetonitrile in water, Buffer B: 1 M 
perchlorate de sodium in water with 30% acetonitrile, Gradient: 100% A to 20% A, 80% B in 30 
minutes, Temperature: 65°C, Flow: 10 mL/min). The pure oligonucleotides were collected, 
desalted by size-exclusion chromatography using a Sephadex G25 column (GE Healthcare Life 
Sciences, Marlborough, MA) and lyophilized. For the attachment of α-tocopheryl succinate 
variants, the 3´ end C6 amino or the 3´ PC amino sense strands were dissolved in water and a 
solution of 1M sodium bicarbonate (pH 8.5) was added to obtain a 0.1M sodium bicarbonate final 
concentration. Then, a solution of N-hydroxysuccinimide-α-tocopheryl succinate (10 to 100 
equivalents) (Figure 22) in DMF was added to the solutions containing the sense strand. The 
mixtures were incubated overnight at room temperature. A solution of 3M sodium acetate (pH 5.2) 
was added to obtain a 0.3M sodium acetate final concentration. Then, 3x of ethanol (95%) of the 
whole volume were added. The mixtures were vortexed, placed at 80°C for 1h and centrifuged 30 
minutes at 5200g. The supernatants were removed and the lipid conjugated sense strands were 
purified and desalted as described previously. 
2.3 ANALYSIS OF OLIGONUCLEOTIDES 
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The identity of oligonucleotides was established by Liquid Chromatography-Mass 
Spectrometry (LC-MS) analysis on an Agilent 6530 accurate-mass Q-TOF LC/MS (Agilent 
technologies, Santa Clara, CA) using the following conditions: buffer A (9mM 
triethylamine/100mM hexafluoroisopropanol in water), buffer B (9mM triethylamine/100mM 
hexafluoroisopropanol in MeOH), column: Agilent AdvanceBio oligonucleotides 2.1x50 mm 
(Agilent technologies, Santa Clara, CA), gradient for sense strand: 0-2 min (1% B - 40% B), 2-
10.5 min (40% B - 100% B), gradient for the antisense strand: 0-2 min (1% B - 12% B), 2-10.5 
min (12% B - 30% B), 10.5-11 min (30% B - 100% B).  
2.4 MRNA QUANTIFICATION FROM CELLS AND TISSUES 
 
HeLa cells (ATCC, #CCL-2) were plated in DMEM (Cellgro, #10-013CV) supplemented 
with 6% fetal bovine serum (FBS; Gibco, #26140) at 10,000 cells per well in 96-well tissue culture 
plates. hsiRNA was diluted in OptiMEM (Gibco, #31985-088) and added to cells, resulting in 3% 
FBS. Cells were incubated for 72 hours at 37°C, 5% CO2. Primary neurons were plated at 100,000 
cells per well density in NeuralQ medium (Sigma-Aldrich, St. Louis, MO, #N3100). hsiRNA, 
hsiRNA-loaded exosomes or liposomes were resuspended in NeuralQ medium, added to cells and 
incubated for 7 days at 37°C, 5% CO2 post treatment. Cells were then lysed and mRNA 
quantification was performed using the QuantiGene 2.0 assay kit (Affymetrix, #QS0011, Thermo 
Fisher Scientific, Waltham, MA) according to manufacturer’s instruction and as described 
previously 200.  
For in vivo experiments, mice were euthanized and organs placed in RNAlater (Thermo 
Fisher Scientific, Waltham, MA, #AM7021) at 4°C overnight. Then tissue punches (approximately 
10 mg) were taken using 1.5mm disposable biopsy punch with plunger (Integra, Miltex, # 33-31A-
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P/25). Brain punches were taken fresh from 300 µm thick brain slices, punches placed in RNAlater 
(Thermo Fisher Scientific, Waltham, MA, #AM7021) and incubated at 4°C overnight. Tissue 
punches were then lysed and mRNA quantification was performed using the QuantiGene 2.0 assay 
kit (Affymetrix, #QS0011, Thermo Fisher Scientific, Waltham, MA) according to manufacturer’s 
instructions and as described previously 200.  
Catalog numbers for probes used in QuantiGene 2.0 assay kit were as follows: human HTT 
(Affymetrix, #SA-50339), mouse Htt (Affymetrix, #SB-14150), human PPIB (Affymetrix, #SA-
10003), mouse Ppib (Affymetrix, #SB-10002), human HPRT (Affymetrix, #SA-10030), mouse Hprt 
(Affymetrix, #SB-15463). Data sets were normalized to housekeeping gene HPRT. In Section 3.1, 
hsiRNAPPIB was used as non-targeting control (NTC) for HTT silencing, and hsiRNAHTT was used 
as non-targeting control (NTC) for PPIB silencing.  
2.5 PNA (PEPTIDE NUCLEIC ACID) BASED ASSAY FOR QUANTITATION OF SIRNA AND 
DETECTION OF SIRNA METABOLITES 
 
siRNA guide strands in tissue and cell lysates were quantified using a peptide-nucleic acid 
(PNA) hybridization assay 28-197, 201-203. PNAs are oligonucleotides, where the sugar-phosphate 
backbone is replaced with a charge-neutral polyamide backbone. PNAs have therefore a high 
hybridization energy to RNA. Tissues punches or cells were either lysed in 100 µl MasterPure™ 
Tissue Lysis Solution (EpiCentre®) in the presence of proteinase K (2mg/ml; Invitrogen, #25530-
049) or leftover lysates from mRNA level quantitations were used. SDS in lysates was precipitated 
with 3 M KCl and pelleted at 4,000 × g for 15 min. siRNA guide strands in cleared supernatant 
were annealed to a complementary Cy3-labeled PNA strands (either fully complementary or 
containing one mismatch) (PNABio, Thousand Oaks, CA) by heating to 95°C for 15 min, 
incubating at 50°C for 15 min, and cooling to room temperature. Tissue lysates containing PNA-
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guide strand hybrids were injected into HPLC DNAPac® PA100 anion-exchange column (Thermo 
Scientific, Carlsbad, CA), Cy3 fluorescence was monitored, and peaks were integrated. The mobile 
phase for HPLC was Buffer A (50% water, 50% acetonitrile, 25 mM Tris-HCl, pH 8.5, 1mM 
EDTA) and Buffer B (800mM NaClO4 in buffer A). For hsiRNA guide strand quantitation, a steep 
gradient of Buffer B (10% to 100 % in 2.5 minutes) was used, and for hsiRNA guide strand 
metabolite detection a shallow gradient of Buffer B (10% to 100 % in 18 minutes) was applied. 
For calibration curves, known amounts of hsiRNA duplex was spiked into the tissue lysis solution 
derived from untreated mice before annealing to PNA. Sequences of PNAs used in this dissertation 
are as follows: hsiRNAHTT: CY3– (OO) –TATATCAGTAAATAGATTAA (mismatch marked in 
bold), hsiRNAPPIB: Cy3 – (OO)–AACAGCAAATTCCATCGTGA, hsiRNAsFLT: Cy3–(OO) –
CTCTCGGATCTCCAAATTTA. Introduction of one mismatch enables the elimination of long 
purine stretches from the PNA, which promote PNA aggregation. Hence, pyrimidine-rich siRNA 
guide strands can be detected and quantified using mismatched PNA probes. The PNA 
hybridization assay has been shared with eight other labs, constitutes a part of thirteen manuscripts 
(see Appendix A) with currently 84 citations (May 8th, 2018).  
2.6 ANIMAL EXPERIMENTS 
 
All animal experiments were performed in accordance with guidelines of University of 
Massachusetts Medical School Institutional Animal Care and Use Committee (IACUC, protocol 
number A-2411). Mice were 6- to 10-weeks old at the time of experiments. All animals were kept 
on a 12-hour light/dark cycle in a pathogen-free facility, with food and water provided ad libitum.  
For systemic administration of hsiRNA, FVBNj mice were injected with either phosphate 
buffered saline (PBS) or with different amounts of hsiRNA resuspended in PBS, either through 
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the tail vein or subcutaneously at the nape of the neck. For administration of compounds into brain, 
ALZET® osmotic pumps (ALZET Osmotic Pump, Cupertino, CA; #1003D) were prefilled with 
100 µl of sample following manufacturer instructions and primed overnight at 37°C in a water 
bath. Osmotic pumps were loaded with either PBS (100 µl per pump), or 6.6 x 1010 vesicles loaded 
with cholesterol-siRNA (3000 copies per vesicle, total dose 0.33 nmol) (100 µl per pump), or 
equivalent amount of cholesterol-siRNA only (0.33 nmol, 100 µl per pump). Wild-type FVBNj 
mice were deeply anesthetized with 1.2% Avertin (Sigma, St Louis, MO; #T48402). ALZET® 
osmotic pumps were then placed using a stereotactic device (World Precision Instruments, 
Sarasota, FL, #502610) into the right lateral ventricle (coordinates relative to bregma: 0.2 mm 
posterior, 0.8 mm lateral, 2.5 mm ventral). Pumps delivered their content for 3 days at 1 µl / hour 
rate. Mice were administered 4 mg/kg of meloxicam SR subcutaneously for pain management. 
Osmotic pumps were removed 5 days after infusion ended (8 days after placement) and wound 
closed with 7mm wound clips. 
After a time of incubation— indicated on individual figures—mice were euthanized with 0.1% 
Avertin or with isoflurane overdose followed by cervical dislocation. Brains were cut in 300 µm 
thick coronal sections at 4℃ on a vibrotome, and 2 mm punches taken from striatum and motor 
cortex ipsilateral to the infusion. 3 punches were collected for mRNA quantification (immediately 
placed in RNAlater® (Thermo Fisher Scientific, Waltham, MA, #AM7021). Other organs were 
harvested and stored in RNAlater (Thermo Fisher Scientific, Waltham, MA, #AM7021) for later 
use. 
2.7 IN VITRO XRN1 RESISTANCE ASSAY 
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 hsiRNA guide strands (30 pmol) were incubated in water or with 1 µl Terminator™ 
(EpiCentre) exonuclease for 2 hours at 37°C in buffer A (EpiCentre, provided with Terminator™ 
enzyme). Then Novex® high-density TBE sample buffer (5x) (Thermo Fisher Scientific) was 
added to samples and loaded to polyacrylamide gel. Denaturing polyacrylamide gels (24%) were 
made in house using a mixture of 4 ml 10x TBE (Tris/borate/EDTA buffer), 17 g urea, 14 ml 
acrylamide:bis-acrylamide (19:1) 40% solution (Bio-Rad), 400 µl of 10% APS (ammonium 
persulfate) and 30 µl of TEMED (tetramethylethylanediamine). Urea-PAGE was performed in 1x 
TBE at 500V at room temperature (SE600 system, Hoefer) for approximately 6 hours. Gels were 
stained with SYBR® Gold Nucelic Acid Gel Stain (Thermo Fisher Scientific) and imaged with 
ImageQuant LAS 4000 (GE Healthcare).  
2.8 CELL CULTURE 
 
Umbilical cord, Wharton’s jelly-derived mesenchymal stem cells (PCS -500-010, ATCC, 
Manassas, VA), adipose tissue derived mesenchymal stem cells (PCS-500-011, ATCC, 
Manassas, VA), and bone marrow derived mesenchymal stem cells (Poetics™, PT-2501, Lonza, 
Basel, Switzerland) were cultured in appropriate stem cell medium (PCS-500-030, ATCC, 
Manassas, VA, for umbilical cord and adipose tissue derived cells, and MSCGM™, PT-3238, , 
Lonza, Basel, Switzerland for bone marrow derived cells) in the presence of supplements 
containing serum and growth factors (PCS-500-040, ATCC, Manassas, VA and PT-3001, Lonza, 
Basel, Switzerland) at 37°C, 5% CO2. Medium was changed every three days, and cells 
expanded until passage 12, to reach a total of 3000 cm2 surface in T500 triple flasks. For serum 
deprivation medium was changed to RPMI (GIBCO™ RPMI 1640, Thermo Fisher Scientific) 
with no FBS or other supplements added for 24 hours. HeLa cells (ATCC, #CCL-2), U87 
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glioblastoma (ATCC, #HTB-14) and Huh7 hepatocellular carcinoma cells were cultured in 
DMEM (Cellgro, #10-013CV) supplemented with 10% fetal bovine serum (FBS; Gibco, 
#26140). 
For three- dimensional cultures, spinner flasks (250-ml) containing 3.2 g (1150 cm2 total 
surface area) of Star-Plus Microcarriers (SoloHill®, Pall Life Sciences, Port Washington, NY) 
were autoclaved. Umbilical cord-derived mesenchymal stem cells were seeded to a density of 8000 
cells/cm2 in umbilical cord-derive stem cell medium, the impeller speed set to 36 rpm, and cells 
were cultured at 37°C. When cells were homogenously spread on microcarriers, medium was 
removed, microcarriers washed in PBS twice and 250 ml of serum-free and xenofree StemPro® 
medium was added (A1067501, Life Technologies, Carlsbad,CA), and cells were cultured at 37°C 
and 36 rpm impeller speed. 
2.9 PREPARATION OF EVS 
 
Before EV purifications, medium on cells was changed to exosome-depleted medium 
(centrifuged at 100 000 g for at least 17 hours) or serum-free medium (GIBCO™ RPMI 1640, 
Thermo Fisher Scientific) (Section 3.3 and Chapter VI) and incubated for 48 hours. Conditioned 
medium was collected from culture of approximately 80% confluency and EVs prepared by 
differential ultracentrifugation204. Briefly, cell debris was pelleted at 300 g (10 min). Larger 
vesicles (microvesicles) were pelleted at 10 000 g (30 min), then supernatant filtered through a 
0.2 µm membrane (Nalgene® aPES, Thermo Fisher Scientific, Waltham, MA) and small vesicles 
(exosomes) pelleted at 100 000 g (90 min) using 70 ml polycarbonate bottles (Beckman Coulter, 
Brea, CA; #355622) and Type 45 Ti rotor (Beckman Coulter, Brea, CA; #339160). Exosome 
pellet was then washed once in 1 ml sterile PBS and centrifuged again for 90 min at 100 000 g in 
a tabletop ultracentrifuge using a TLA-110 rotor (Beckman Coulter, Brea, CA; #366730). 
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Microvesicle pellets were washed in 1 ml sterile PBS and centrifuged again for 30 min at 10 000 
g. EVs were frozen for later use in 0.1M sucrose, 1x protease inhibitor (cOmplete™ Mini, 
Sigma-Aldrich) in PBS.  
For tangential flow filtration, 250 ml of conditioned medium (StemPro®,A1067501, Life 
Technologies, Carlsbad,CA) was collected after 48 hours from spinner flasks. Collection was 
performed four times; conditioned medium was stored at 4℃ and subsequently pooled together 
(final volume 1L). The conditioned medium was filtered through a 0.2 µm polyethersulfone 
(PES) membrane. Conditioned medium was then subjected to ultrafiltration in a tangential flow 
filtration system using a 500 kDa cutoff TFF cartridge (MidiKros® mPES 115 cm2, D02-E500-
05-S, Spectrum Labs, Rancho Dominguez, CA). A feed flow rate of 120 mL/min, transmembrane 
pressure of <3.5 psi and a crossflow rate >10:1 were maintained throughout the filtration 
operation. The conditioned medium was concentrated 9-fold and then buffer exchanged with 6x 
volume of PBS. The exosomes were 0.2 µm filtered (PES membrane) and stored in 0.1M sucrose 
in a  polyethylene terephthalate glycol (PETG) bottle at -80℃.  
2.10 CHARACTERIZATION OF EXOSOMES 
 
Nanoparticle Tracking Analysis (NanoSight NS300, Malvern, Malvern, UK) was used to 
measure concentration and size distribution of EVs. Briefly, samples were diluted in PBS 1:100 – 
1:1000, manually injected into the instrument and videos acquired at ambient temperature at 
camera level 11 for 1 minute per sample, N=3. N depicted in figure legends represents biological 
replicates (independent EV preparations) and not technical replicates (repeated NTA 
measurements). 
Transmission Electron Microscopy of exosomes was conducted at Mass General Hospital. 
Samples and grids were prepared at room temperature. An equal volume of 4% paraformaldehyde 
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was added to the exosome sample and incubated for 2 h. 3 µl aliquots of exosomes were dropped 
onto grids and incubated in 2% paraformaldehyde for 20 min. The grids were transferred to a wax 
strip and washed with 100 µl PBS. The grids were incubated in 50 mM glycine/PBS for 5 min and 
blocked in 5% BSA/PBS for 10 min and washed with 3x PBS followed by incubation in 1% 
glutaraldehyde for 5 min. Following 8 washes of 2 min with H20, the grids were incubated for 5 
min in uranyl oxalate and in 1% methyl cellulose:4% uranyl acetate (9:1)  for 10 min on ice. Excess 
liquid was removed with a filter paper and the grids were air dried for 5 to 10 min. Exosomes were 
examined in a JEOL 1100 transmission electron microscope (JEOL, Peabody, MA) at 60 kV and 
images were obtained with an AMT digital camera (Advanced Microscopy Techniques, Corp., 
Woburn, MA).  
For Western blot analyses, EVs or cell pellets were suspended in RIPA buffer (Pierce® 
899000, Thermo Fisher Scientific, Waltham, MA) containing PMSF (36978, Thermo Fisher 
Scientific) and protease inhibitor cocktail (cOmplete Mini, 11836153001, Roche, Indianapolis, 
IN), and samples were sonicated for 15 min. Insoluble material was pelleted by centrifugation for 
15 minutes at 10 000 g, 4°C. Proteins (50µg) were loaded onto NuPAGE 4–12% Bis-Tris gels 
(Thermo Fisher Scientific, Waltham, MA). After transfer to PVDF (BioRad, Hercules, CA), 
membranes were incubated with antibodies, washed, and images captured using an Odyssey® 
system (Li-Cor, Bad Homburg, Germany) according to manufacturer’s instructions. Primary 
antibodies used were Calnexin (C5C9, Cell Signaling, Danvers, MA), CD63 (H5C6, BD 
BioSciences, San Jose, CA), Tsg101 (4A10, Abcam, Cambridge, MA), CD81 (B11, Santa Cruz 
Biotechnology, Dallas, TX), CD9 (C4, Santa Cruz Biotechnology, Dallas, TX), Desmoplakin 
(ab109445, Abcam, Cambridge, MA), AHSG (ab112528, Abcam, Cambridge, MA), Rab7 
(ab137029, Abcam, Cambridge, MA). 
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2.11 LIPOSOME PREPARATION 
 
Conventional liposomes: Dioleoyl-phosphatidylcholine (DOPC) (#850375, Avanti Polar 
Lipids, Alabaster, AL) and cholesterol (, #700000, Avanti Polar Lipids, Alabaster, AL) were 
diluted in chloroform at a concentration of 50 mg/ml. 35 µl of DOPC and 15 µl of cholesterol 
was transferred into a glass vial and chloroform was evaporated under argon flow. The resulting 
lipid film was rehydrated in 500 µl of PBS (#21-031-CV, Dulbecco’s Phosphate Buffered Saline, 
Corning, Manassas, VA), sonicated for 15 minutes in water bath (#BB5510, Branson ultrasonic 
cleaner 40 kHz, Cleanosonic, Richmond VA), and the extruded using Mini-Extruder 
(#610000,Avanti Polar Lipids, Alabaster, AL) through a 50 nm pore sized polycarbonate 
membrane (#WHA800308, Whatman® Nucleopore™, MilliporeSigma, St Louis, MO). 
Liposomes were always used fresh, never frozen. 
Cardiolipin containing liposomes: Cariolipin (#840012, Avanti Polar Lipids, Alabaster, 
AL), monolysocardiolipin (#850081, Avanti Polar Lipids, Alabaster, AL) and dilysocardiolipin 
(#850082, Avanti Polar Lipids, Alabaster, AL) were diluted in chloroform at a concentration of 
10 mg/m. 20 µl DOPC, 15 µl cholesterol and 75 µl cardiolipin, or monolyoscariolipin or 
dilysocardiolipin were mixed together and liposomes prepared as for conventional liposomes. 
This composition is equivalent to 40:30:30 w/w ratio of DOPC:cholesterol: 
cardiolipin/monolysocardiolipins/dilysocardiolipin. 
Proteoliposomes; Purified proteins were purchased as follows: Rab7 (TP301776, 
OriGene, Rockville, MD), AHSG (TP723089, OriGene, Rockville, MD), Rab5 (TP303873, 
OriGene, Rockville, MD ), Desmocollin (TP322207, OriGene, Rockville, MD), ARRDC1 
(TP307160, OriGene, Rockville, MD), Dermcidin (TP309352, OriGene, Rockville, MD), Histone 
1 (TP301249, OriGene, Rockville, MD), Desmoplakin (RPU51172, Biomatik, Wilmington, DE). 
Lyophilized proteins (AHSG and Desmoplakin) were dissolved in 0.1M sodium bicarbonate in 
PBS (pH=8.5). Proteins delivered in Tris-based buffers (Rab5, Desmocollin, ARRDC1, 
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Dermcidin and Histone 1) underwent buffer exchange using 2K MWCO cutoff membrane 
dialysis devices (Slide-A-Lyzer™ Mini, #69553, Thermo Fisher Scientific, Waltham, MA) 10 µl 
of sample against 1 l of 0.1M sodium bicarbonate in PBS (pH=8.5) at 4℃ overnight. Palmitic 
acid N-hydroxysuccinimide ester (palmitoyl-NHS) (P1162, Sigma-Aldrich, St. Louis, MO) was 
added to protein samples in a 1:1 molar ratio to the amount of lysines (lysine frequency was 
estimated to be 7%) and incubated on a rotating wheel at 4℃ overnight. Palmitoyl-NHS – 
protein reaction mixture (equivalent of 1 µg protein) was then incubated with preformed 
conventional liposomes or dilysocardiolipin liposomes for 1 hour at 37℃ and proteoliposome 
samples centrifuged at 100 000 g for 70 min to remove non-loaded proteins. To prepare artificial 
exosomes, palmitoylated Rab7, AHSG and Desmoplakin were combined and loaded together to 
dilysocardiolipin liposomes.  
2.12 LOADING HSIRNAS INTO EXOSOMES AND LIPOSOMES 
 
Known numbers of exosomes or liposomes was co-incubated with 10,000 copies of 
hsiRNA per vesicle (if not indicated otherwise) at 37°C for one hour in 500 µl PBS (i.e. loading 
mixture). Then the exosome-hsiRNA mixture was centrifuged at 100 000 g for 90 min and 
supernatant containing unloaded hsiRNA removed (supernatant). Pellet was taken up in 500 µl 
PBS for fluorescence measurement or in 300 µl Neural Q medium for treatment of primary 
neurons. To quantify loading of Cy3-labeled hsiRNA a 200 µl aliquot was taken from resuspended 
exosome pellet or from the supernatant. Fluorescence was assessed at 550 nm excitation, 570 nm 
emission on TECAN instrument. Percent of loaded hsiRNA was calculated as follows: pellet / 
(pellet + supernatant). To estimate hsiRNA copy number per exosome, the following formula was 
used: (percent of loaded hsiRNA) * (amount of hsiRNA initially mixed in with exosomes (mol)) 
* (Avogadro number) / (number of exosomes initially mixed in).  
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To quantify loading of not fluorescently labeled hsiRNA, a PNA hybridization-based assay 
was used201, 205. Briefly, a 10 µl aliquot of resuspended exosome pellet loaded with hsiRNA was 
diluted in 90 µl RIPA buffer (Pierce® 899000, Thermo Fisher Scientific, Waltham, MA) and 
sonicated for 15 min. Then 30 µl of 3M KCl was added to precipitate SDS from the lysate and 
precipitated SDS was pelleted at 5000 g for 15 min. Supernatant was then removed and a Cy3 
labeled PNA oligonucleotide (PNA Bio, Newbury Park, CA) fully complementary to hsiRNA 
guide strand added to the exosome lysate and annealed at 95 ℃ for15 min followed by incubation 
at 50 ℃ for 15 min and cooling to room temperature. Then PNA-annealed exosome lysate was 
injected to HPLC anion exchange column (Dionex DNAPac PA100, Thermo Fisher Scientific, 
Waltham, MA) using an autosampler (1260 Infinity system, Agilent, Santa Clara, CA). The mobile 
phase used for HPLC was 50% acetonitrile, 25 mM Tris-HCl (pH 8.5), and 1 mM EDTA in water; 
and 0-800 mM NaClO4 salt gradient was used to elute the hsiRNA-PNA hybrid. Quantification 
was performed using a calibration curve of known amounts of hsiRNA. 
2.13 MEASUREMENT OF LIVE SIRNA UPTAKE IN NEURONS 
 
For the analysis of siRNA uptake in vitro, primary neuron nuclei plated in 35 mm glass 
bottom dishes (MatTek, Ashland, MA, #P35G-1.5-10-C) were stained with NucBlue™ live cell 
stain (Thermo Fisher Scientific, Waltham, MA, #R37605) and neuron were treated with 
fluorescently labeled siRNA targeting Ppib or Htt gene. Images were acquired with a Leica DM 
IRE2 (Leica Microsystems Inc., Buffalo Grove, IL) confocal microscope using a 40x oil-immersion 
objective and Dapi channel (exposure time 50 ms) as well as mCherry channel (exposure time 200 
ms). Images were processed using ImageJ software206 (NIH, Bethesda, MD). The relative uptake 
of siRNA, loaded in UC-exosomes or TFF-exosomes, was estimated based on pixel integrated 
density of 5 images for each timepoint.  
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2.14 PREPARATION OF PRIMARY CORTICAL NEURONS 
 
Primary cortical neurons were isolated from E15.5 mouse embryos of wild-type FVBNj 
mice. Pregnant females were anesthetized by either intraperitoneal injection of Ketamine (100 
mg/kg, KETASET®, Zoetis, Kalamazoo, MI) - Xylazine (10 mg/kg, AnaSed®, AKORN, Laker 
Forest, IL, #NDC59399-111-50) or isoflurane (Isoflurane, USP, Piramal Cricital Care, Betlehem, 
PA, #NDC66794-013-010) and cervical dislocation followed. Embryos were removed and 
transferred to ice-cold DMEM/F12 medium (Invitrogen, Carlsbad, CA; #11320). Brains were 
removed from DMEM and meninges were carefully detached under a microscope. Cortices were 
isolated and transferred into pre-warmed (37˚C) papain-DNase solution for 30 min at 37˚C, 5% 
CO2 to dissolve the tissue. Papain (Worthington, Lakewood, NJ; #54N15251) was dissolved in 2 
ml Hibernate E (Brainbits, Springfield, IL; #HE) and supplemented with 0.25 ml of 10 mg/ml 
DNase1 (Worthington, Lakewood, NJ; #54M15168) in Hibernate E. After 30 min incubation, the 
papain solution was removed and 1 ml NeuralQ (Sigma-Aldrich, St. Louis, MO, #N3100) 
supplemented with 2.5% FBS was added to the tissue. Tissues were then dissociated by trituration 
through a fire-polished, glass Pasteur pipet. Neurons were counted using Neubauer chamber and 
diluted at 106 cells/ml.  105 neurons per well were plated on 96-well plates pre-coated with poly-
L-lysine (BD BIOCOAT, Corning, NY; #356515). After overnight incubation at 37˚C, 5% CO2, an 
equal volume of NeuralQ supplemented with anti-mitotics, 0.484 µl/ml of 5'UtP (Sigma, St Louis, 
MO; #U6625) and 0.2402 µl/ml of 5'FdU (Sigma, St Louis, MO; #F3503) was added to prevent 
the growth of non-neuronal cells. Half of the volume of media was replaced with fresh NeuralQ 
containing anti-mitotic every 48 hours until the experiments were performed.  
2.15 PROTEOMICS 
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Protein extraction from EVs followed the same protocol as for Western blotting. Total 
protein (100µg) was applied to an SDS-PAGE gel. Once the entire protein sample entered the 
stacking gel, electrophoresis was stopped, and the portion of gel containing proteins was excised 
and stained with Coommassie brilliant blue. The fixed gel fragments were processed by University 
of Massachusetts Medical School Mass Spectrometry Core. Gel slices were cut into 1 x 1 mm 
pieces and placed in 1.5-ml microcentrifuge tubes containing 1 ml water and incubated for 30 min.  
The water was replaced with 200 µl of 250 mM ammonium bicarbonate and 25 µl of 45 mM DTT 
and the samples were incubated for 30 min at 50°C.   Samples were then cooled to room 
temperature and alkylation was performed by adding 25 µl of 100 mM iodoacetamide and 
incubating for 30 min.  The gel slices were washed twice in water, then incubated in 1ml of a 50:50  
solution of 50mM Ammonium Bicarbonate: Acetonitrile for one hour at room temperature.  The 
solution was replaced with 200µl acetonitrile and incubated until the gels slices turned opaque 
white.  The acetonitrile was removed and gel slices were further dried in a Speed Vac.  Gel slices 
were rehydrated in a 100 µl solution of 50mM Ammonium Bicarbonate containing 0.01% 
ProteaseMAX Surfactant (Promega) and 2ng/µl trypsin (Sigma).  Additional bicarbonate buffer 
was added to ensure complete submersion of the gel slices. Samples were incubated for 21 hours 
at 37°C. Supernatants were transferred to a fresh 1.5-ml tube.  Gel slices were further dehydrated 
with 200 µl of an 80:20 solution of acetonitrile: 1% formic acid.  The extract was combined with 
the supernatants of each sample. The combined supernatants containing digested proteins were 
then dried in a Speed Vacc and pellets were redissolved with 25 µl of 5% acetonitrile in 0.1% 
trifluroacetic acid.  A 3.5 µl aliquot was directly injected onto a custom packed 2cm x 100µm C18 
Magic 5µm particle trap column.   Peptides were then eluted and sprayed from a custom packed 
emitter (75µm x 25cm C18  Magic 3µm particle) with a linear gradient from 95% solvent A (0.1% 
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formic acid in water) to 35% solvent B (0.1% formic acid in acetonitrile) at a flow rate of 300 
nanoliters per minute for 120 minutes on a Waters Nano Acquity UPLC system.   Data dependent 
acquisitions were performed on a Q Exactive mass spectrometer (Thermo Scientific) according to 
an experiment where full MS scans from 300-1750 m/z were acquired at a resolution of 70,000 
followed by 10 MS/MS scans acquired under HCD fragmentation at a resolution of 17,500 and an 
isolation width of 1.6 Da.  Raw data files were processed with Proteome Discoverer (version 1.4) 
before using Mascot Server (version 2.5) to search against the Uniprot_Human protein database.  
Applied search parameters were fully tryptic with 2 missed cleavages, parent mass tolerances of 
10 ppm and fragment mass tolerances of 0.05 Da, and allowed for fixed modification of 
carbamidomethyl cysteine and variable acetyl-group modifications at the N-termini, e.g. 
pyroglutamate for N-term glutamine, and oxidation of methionine.  Search results were loaded into 
the Scaffold Viewer (Proteome Software, Inc.) to validate and quantify peptides.   
2.16 LIPIDOMICS 
  
MV and exosome samples were pelleted at 10 000 g and 100 000g, respectively. Pellets were 
frozen at -80°C, and transferred to BERG LLC (Framingham, MA) on dry ice for lipid composition 
analysis. 
Aliquots of each sample were combined with a cocktail of deuterium-labeled and odd chain 
fatty acid standards. Standards were chosen that represent each lipid class and were at designated 
concentrations expected to provide the most accurate quantitation of each lipid species. Lipids 
were extracted with 4 mL of a 1:1 (v/v) solution of chloroform:methanol as previously 
described207, using a automated custom sequence routine on a Star Hamilton Robotics system 
(Hamilton, Reno, NV). Lipid extracts were dried under nitrogen and pellets were dissolved in 300 
µl of a 1:1 (v/v) solution of chloroform:methanol per mg of protein. Samples were flushed with 
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nitrogen and stored at -20°C. For MS analysis, samples were diluted 50-fold in 3:3:3:1 (v/v/v/v) 
isopropanol:methanol:acetonitrile:water containing 2mM ammonium acetate to enhance 
ionization efficiency in positive and negative modes. Electrospray ionization-MS was performed 
on a SCIEX TripleTOF® 5600+ (SCIEX) coupled to a customized direct injection loop system on 
an Ekspert microLC200 system. 50µl of sample was injected at a flowrate of 6µl/min. Lipids were 
analyzed using a customized data independent analysis strategy on the TripleTOF® 5600+ 
allowing for MS/MSALL high resolution and high mass accuracy analysis as previously 
described208. Lipids were quantified using an in-house library on MultiQuant™ software. 
2.17 STATISTICAL ANALYSIS 
 
siRNA uptake, mRNA silencing, cell viability, and lipidomics data (Chapter VI only) 
were analyzed using GraphPad Prism 7, version 7.04 (GraphPad Software Inc., La Jolla, CA). In 
in vitro siRNA uptake experiments curves were fitted using “exponential growth equation” (PNA 
hybridization assay data) or “one phase association” (confocal microscopy data). In in vitro 
silencing experiments dose-response curves were fitted using “log(inhibitor) vs. response – 
variable slope (three parameters)” equation. Curves were compared using two-way ANOVA 
with Tukey multiple comparison for main column effect. In in vivo silencing experiments in 
brain and cell viability assay groups were compared using one-way ANOVA with Tukey 
multiple comparison test. For in vivo systemic silencing, the significance was calculated using 
Kruskal-Wallis One-Way ANOVA with Dunn′ s multiple comparisons. To compare hsiRNA 
guide strand concentrations measured by PNA assay upon systemic administration, the data were 
analyzed by One-Way ANOVA with Tukey′ s multiple comparisons. For in vivo duration of 
effect, the data were analyzed by Two-Way ANOVA with Holm-Sidak correction. When 
comparing candidate proteins between control and stressed conditions two-way ANOVA with 
multiple comparison for row effect according to the original FDR method of Benjamini and 
Hochberg. During lipidomics the amount of lipids were normalized to protein content of 
Chapter II Methods 
52 
 
samples. Lipid classes in control versus stressed EVs or cells were compared using two-way 
ANOVA with Tukey multiple comparison for compare rows within columns. Fatty acid tail 
properties were correlated with enrichment score using linear regression. 
Proteomics and lipidomics data (Chapters IV-VI) were analyzed using Microsoft Excel, 
Scaffold Viewer (Proteome Software Inc.), R and DAVID version 6.7 209-210, NIH. Label-free 
quantification of proteins was performed via the iBAQ (intensity-based absolute 
quantification211) method in. Briefly, precursor ion intensities of peptides matching to each 
particular protein were divided by the theoretical number of peptides that could be derived from 
each particular protein by trypsin digestion. This method normalizes signal to the number of 
tryptic sites in a protein. Lipidomic quantitation of molecular species and lipid classes were 
normalized to protein content of samples. Comparison of total protein profiles (individual iBAQ 
values), and lipid profiles (nmol of lipid species normalized to total protein content) of 
exosomes, microvesicles and source cells was performed by pairwise Pearson’s correlation in 
Microsoft Excel. Principal component analysis was performed in R (‘prcomp’ command) after 
normalization of protein (individual iBAQ values) and lipid (nmol of lipid species normalized to 
total protein content) profiles of exosomes and microvesicles to the protein and lipid profile of 
their source cells. Volcano plots and heatmaps were generated in R using “ggplot2”, “pheatmap” 
and “heatmap3” packages. Gene Ontology analysis to annotate biological function to proteins 
enriched in EVs was conducted using DAVID, version 6.7 209-210, NIH). 
Differences in all comparisons were considered significant at p-values < 0.05.  
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CHAPTER III ENGINEERED RNA FOR DELIVERY VIA EVS 
3.1 5′VINYLPHOSPHONATE IMPROVES TISSUE ACCUMULATION AND EFFICACY OF CONJUGATED 
SIRNAS IN VIVO. 
3.1.1 Preface 
 
Text and Figures are reproduced from 
▪ RA Haraszti*, L Roux*, AH Coles, AA Turanov, JF Alterman, D Echeverria, BM 
Godinho, N Aronin, A Khvorova. 5′vinylphosphonate improves tissue accumulation 
and efficacy of conjugated siRNAs in vivo. Nucl Acid Research, 2017 June 7. 
 
Anastasia Khvorova conceptualized this project. siRNAs used in this study were synthesized and 
duplexed by Loic Roux and Dimas Echeverria. I was assisted by Andrew Coles, Bruno Godinho 
and Anton Turanov with animal injections. Julia Alterman performed experiments in HeLa. I 
performed all animal harvests and in vivo silencing measurements, siRNA level quantification, 
mass spectrometry and chromatography of siRNA metabolites, in vitro exonuclease stability assay 
and statistical analysis. Anastasia Khvorova and I wrote this manuscript. 
3.1.2 Abstract 
 
5′vinylphosphonate modification of siRNAs protects them from phosphatases and improves 
silencing activity. Here we show that 5′vinylphosphonate confers novel properties to siRNAs.  
Specifically, 5′vinylphosphonate (1) increases siRNA accumulation in tissues, (2) extends duration 
of silencing in multiple organs and (3) protects siRNAs from 5′-to-3′ exonucleases. Delivery of 
conjugated siRNAs requires extensive chemical modifications to achieve stability in vivo. Because 
chemically modified siRNAs are poor substrates for phosphorylation by kinases, and 5′ phosphate 
is required for loading into RNA-induced silencing complex, the synthetic addition of a 5′ 
phosphate on a fully modified siRNA guide strand is expected to be beneficial. Here we show that 
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synthetic phosphorylation of fully modified cholesterol-conjugated siRNAs increases their 
potency and efficacy in vitro, but when delivered systemically to mice, the 5′ phosphate is removed 
within 2 hours. The 5′-phosphate mimic 5′ -(E)-vinylphosphonate stabilizes the 5′ end of the guide 
strand by protecting it from phosphatases and 5′ -to-3′ exonucleases. The improved stability 
increases guide strand accumulation and retention in tissues, which significantly enhances the 
efficacy of cholesterol-conjugated siRNAs and the duration of silencing in vivo. Moreover, we 
show that 5′ -(E)-vinylphosphonate stabilizes 5′ phosphate, thereby enabling systemic delivery to 
and silencing in kidney and heart.  
3.1.3 Introduction 
 
Small interfering RNAs (siRNAs) guide the sequence-specific cleavage of targeted 
mRNAs5, 212. The ability to design and chemically synthesize an siRNA against virtually any target 
gene offers a powerful therapeutic strategy to treat genetic diseases, particularly those for which 
small molecule drugs do not exist (such as Huntington′ s disease and other neurodegenerative 
diseases). The sequence of an siRNA determines its target, but the chemical architecture 
determines its pharmacokinetic behavior 56. Thus, siRNAs can readily be tailored to fit the needs 
of personalized medicine. 
The clinical utility of siRNA therapeutics has been limited by in vivo stability and safe, 
efficient delivery to tissues. Both challenges are being met by advances in oligonucleotide 
chemistry 73, 77, 213-214. Hydrophobic conjugates—e.g., cholesterol—drive efficient cellular uptake 
of siRNA via a general mechanism213, 215, which may expand the range of tissues that can be 
targeted. Extensive chemical modification of conjugated siRNAs improves stability and activity 
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in vivo 213, 216-217. siRNA compounds currently in clinical studies are modified using a combination 
of 2′ –fluoro (2′–F) and 2′–O–methyl (2′–O–Me) modifications 77, 216, 218.  
The guide strand of an siRNA duplex must bear a 5′ phosphate to bind the effector protein 
of the RNA-induced silencing complex Argonaute 2 (AGO2) 219-222. The in vivo phosphorylation 
state of a synthetic siRNA depends on the balance of kinase and phosphatase activity. A 
dephosphorylated siRNA must be phosphorylated for effectiveness in vivo; however, fully 
chemically modified siRNAs are poor substrates for intracellular kinases 223. Therefore, to preserve 
proper 5′ phosphorylation, phosphonates can be used as metabolically stable phosphate analogs. 
The stability resides in the carbon-phosphorus bond of phosphonates that resists phosphatases, 
which hydrolyze oxygen-phosphorus bonds224. Among phosphonates tested, 5′ -(E)-
vinylphosphonate appears to be the most effective phosphate analog 7, 225-227. Indeed, both single 
stranded siRNAs and GalNAc-conjugated double stranded siRNAs benefit from 5′ -(E)-
vinylphosphonate modification 228-231. 
Here we evaluate how chemical phosphorylation of hydrophobically modified siRNAs 
(hsiRNAs) with either phosphate, or the metabolically stable phosphate analog 5′-(E)-
vinylphosphonate, impacts efficacy and duration of effect in vitro and in vivo. We show that 5′ 
phosphate and 5′-(E)-vinylphosphonate equally enhance hsiRNA activity in vitro. When 
administered in vivo, 5′ phosphate hsiRNAs are de-phosphorylated within hours, but metabolic 
stabilization with 5′ -(E)-vinylphosphonate significantly increases retention of hsiRNAs in tissues, 
silencing activity, and duration of effect. The 5′-(E)-vinylphosphonate, cholesterol-conjugated 
hsiRNAs remain active in liver and kidneys for at least 6 weeks after single administration. 5′-(E)-
vinylphosphonate hsiRNAs silences target genes in the heart, a tissue previously not accessible by 
conjugated siRNAs. Finally, we show that 5′-(E)-vinylphosphonate not only resists phosphatases 
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in vivo, but also resists 5′-phosphate-dependent exonucleolytic destruction by XRN1, contributing 
to overall stabilization of the guide strand in tissues. 
3.1.4 RESULTS 
 
5′ chemical phosphorylation enhances hsiRNA efficacy in vitro 
Figure 3.1 5′ 
phosphorylation of 
hsiRNAs increases 
activity in vitro.  
A. Cartoon of hsiRNA 
chemical scaffold. B. 
Graphs showing the levels 
of PPIB (left) or HTT 
mRNA (right) in HeLa cells 
treated with 5′ hydroxide 
(5′-OH) or 5′phosphate (5′-
P) hsiRNAPPIB (left) or 
hsiRNAHTT (right) or non-
targeting control (NTC) hsiRNAs. mRNA levels measured by QuantiGene® 2.0 assay are 
normalized to the level of a control HPRT mRNA and shown as percent of the untreated (UNT) 
control. The IC50 for the experimental hsiRNAs are indicated in the legend. N=3 for each 
datapoint. 
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Hydrophobically modified hsiRNAs (Figure 3.1A) are asymmetric siRNAs with 
alternating 2′–F and 2′–O–Me modification of each ribose to resist endonucleases and avoid innate 
immune activation. The 2′–F and 2′–O–Me modifications offset each other in the short (15 base-
pair) double-stranded region. Phosphorothioate linkages at the ends of both strands and throughout 
the single-stranded 3′ tail of the guide strand enhance cellular uptake of hsiRNAs. A cholesterol 
group linked to the 3′ end of the passenger strand drives unassisted cellular uptake. hsiRNAs 
rapidly (within minutes) and efficiently enter cells through an EE1-related endocytosis pathway232, 
and they show in vivo efficacy after local administration 202, 213, 233. 
hsiRNAs targeting PPIB (peptidylprolyl isomerare B or cyclophilin B) and HTT 
(huntingtin) were synthesized with 5′-hydroxide and 5′-phosphate on the guide strand (see Table 
3.1 for sequences and chemical modification patterns of hsiRNAs used in this study). Chemical 
phosphorylation at the 5′ end significantly increased the level of target mRNA silencing and 
hsiRNA potency (2.7 fold for hiRNAPPIB, p<0.001 and 1.6 fold hiRNAHTT, p=0.01) compared to 
5′hydroxide hsiRNA (Figure 3.1B). Thus, chemical phosphorylation significantly contributes to 
the overall potency of hsiRNAs in vitro in passive uptake, with the level of impact showing 
sequence dependence.  
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Table 3.1 Sequences and chemical modification patterns of hsiRNAs. 
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hsiRNAs are quickly dephosphorylated in vivo after systemic administration.  
Figure 3.2 5′ phosphorylated hsiRNA 
is rapidly dephosphorylated upon 
systemic administration. A. Cartoons 
of predicted metabolites synthesized. 
For color code see Figure 1.A. B. HPLC 
traces of Cy3-PNA/hsiRNA hybrids in 
liver lysates from mice injected with 5′ -
P hsiRNA (red-filled traces). Black 
traces depict traces corresponding to 
control guide strands: intact guide strand 
(full) or the synthesized putative 
metabolites (1 to 5) indicated in panel A. 
C. Mass spectrometry profiles of 5′ -P 
hsiRNA metabolites in liver lysates of mice injected with 5′ P hsiRNA. Mice were harvested 2, 
24, and 120 hours after intravenous injection. 
Delivery of conjugated hsiRNA requires chemical modifications that are resistant against 
metabolic cleavage. To evaluate metabolic stability of chemically introduced 5′-phosphate in vivo, 
we administered 10 mg/kg of 5′-phosphate hsiRNA systemically into mice by tail vein injection. 
We analyzed the livers of injected mice after 2 hours, 24 hours, or 120 hours for the presence of 
hsiRNA guide strand metabolites. For comparison, we also analyzed a series of predicted guide 
strand metabolites (references), which we added into liver lysates from PBS treated animals 
(Figure 3.2A and Figure 3.3).  Tissues were lysed and hsiRNA guide strand metabolites were 
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detected using a peptide nucleic acid (PNA)-based hybridization assay203 and anion exchange 
chromatography. Correlation of elution times between the references and metabolites extracted 
from mouse livers identified major hsiRNA degradation products.  
We failed to detect intact hsiRNA guide strands in livers harvested 2 hours after injection 
(Figure 3.2B), indicating that systemically administered hsiRNAs, in spite of being fully modified 
by 2′–F and 2′–O–Me, are rapidly metabolized in vivo. At each time point, we observed two major 
chromatography peaks whose elution times correlated with that of a 5′hydroxide full-length (20-
nucleotide) guide strand and a 5′hydroxide 19-nucleotide metabolite with one nucleotide removed 
from the 3′ end (Figure 3.2B). Mass spectrometry analysis confirmed the identity of both 
metabolites (Figure 3.2C), and resolved additional products, including a 5′phosphate metabolite 
trimmed at the 3′ end by 1 nucleotide (product 2, Figure 3.2A) and further 5′hydroxide products 
trimmed at the 3′ end by 2 or 3 nucleotides (products 4 and 5 in Figure 3.2A). At 2 hours after 
injection, most of the hsiRNA guide strand was dephosphorylated at the 5′end, and by 24 hours 
the levels of full-length 5′phosphate guide strand could not be distinguished from noise. The 
primary degradation events in vivo appear to be eliminating of the 5′ phosphate and trimming the 
3′ end. Although RISC should be able to load a phosphorylated guide strand trimmed by one or 
two 3′ nucleotides234, dephosphorylated guide strands are expected to be significantly less active, 
thereby limiting in vivo efficacy.  
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Figure 3.3 Cartoons and HPLC 
anion exchange chromatograms of 
synthesized metabolites. For color 
code, see Figure 3.2 
 
 
 
 
 
 
 
 
5′ -(E)-vinylphosphonate modification could be added to all sequences of hsiRNA and is fully 
active in vitro 
We sought to compare the stability and activity of hsiRNAs with 5′–phosphate or a 
metabolically stabilized 5′–(E)–vinylphosphonate. The unsaturated C-C bond of 5′–(E)–
vinylphosphonate restricts the torsion angle to 180°, and the resulting trans—or E—configuration 
mimics the optimal electronic and spatial positioning of 5′ -P phosphate226 (Figure 3.4A). We 
synthesized the phosphoramidite of 5′ -(E)-vinylphosphonate 2′ –O–Me-Uridine and incorporated 
it into the guide strand as a last coupling during the 3′ -5′ oligonucleotide chemical synthesis. Since 
5′ terminal base is not involved in RISC-target  mRNA interaction 231, 235, the 5′ -(E)-
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vinylphosphonate 2′–O–Me-Uridine phosphoramidite can be used to incorporate 5′-(E)-
vinylphosphonate in any siRNA independently of target gene and sequence (Figure  3.4 and 3.5). 
When tested in vitro by passive uptake, 5′ -(E)-vinylphosphonate hsiRNAs were just as effective 
as 5′-phosphate hsiRNAs, confirming that 
the 5′ -(E)-vinylphosphonate modification is 
well tolerated by the RNA-induced silencing 
complex (RISC) assembly (Figure 3.4B). 
Figure 3.4 Stabilization of the 5′ end by 5′ 
-(E)-vinylphosphonate supports RISC 
loading and activity. 
A. Chemical structures of 5′ -phosphate (5′-
P) and 5′ -(E)-vinylphosphonate (5′-VP). B. As in Figure 1.B., except that HeLa cells treated with 
5′ -P or 5′ -VP modified hsiRNAs, as indicated in the legend. 
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Figure 3.5 Chemical synthesis of the 5’ stabilized 
antisense stand.  
A) (E)-vinylphosphonate Uridine phosphoramidite 
coupling and deprotection procedure of the 5’ 
modified oligonucleotides antisense strand. B) 
Synthesis pathway of the (E)-vinylphosphonate 
Uridine phosphoramidite. 
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5′ -(E)-vinylphosphonate hsiRNA outperforms 5′phosphate hsiRNA in kidney and heart, and 
is comparable in liver and spleen 
Figure 3.6 5′ -(E)-
vinylphosphonate 
modification 
enhances hsiRNA 
efficacy in liver, 
kidneys and heart. 
Column scatter 
plots showing Ppib 
or Htt mRNA levels 
in the livers, 
kidneys and hearts 
of mice (n=5 per 
group) treated with 
5′ hydroxide (5′-
OH), 5′ phosphate 
(5′-P), or and 5′ -
(E)-
vinylphosphonate (5′ -VP) hsiRNAs by intravenous (IV) of subcutaneous (SC) injection. mRNA 
levels measured by QuantiGene® 2.0 assay, were normalized to Hprt mRNA and expressed as 
percent of mRNA levels in PBS-treated animals. NTC, non-targeting control. T, targeting hsiRNA. 
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Significance calculated by ANOVA with Bonferroni′ s correction: ns, non-significant; *, p≤0.05; 
**, p≤0.01; ***, p≤0.001; and ****, p≤0.0001. 
 
Current clinical stage siRNAs accumulate in liver 214, 217. Therefore, we first compared the 
efficacy of 5′hydroxide-, 5′phosphate, and 5′-(E)-vinylphosphonate hsiRNAs in the liver after 
intravenous or subcutaneous administration. We used previously identified hsiRNA sequences that 
efficiently silence Ppib or Htt mRNAs (Table 3.1; 213, 233). All 5′ variants of hsiRNAHtt reduced 
Htt mRNA levels in liver by ~60% when administered subcutaneously and by ~40% when 
administered intravenously (Figure 3.6). In contrast, 5′-(E)-vinylphosphonate modified 
hsiRNAPpib silenced Ppib mRNA substantially better (66% when administered subcutaneously and 
57 % when administered intravenously) than 5′phosphate or 5′hydroxide hsiRNAs (30-50% when 
administered subcutaneously and 25-30% when administered intravenously) (Figure 3.6).  
The cholesterol moiety conjugated to hsiRNAs is highly hydrophobic and drives non-
specific uptake of hsiRNA by many cell and tissue types such as muscle 215 and eye 213. We 
therefore asked whether subcutaneous delivery of hsiRNA could promote silencing in other 
organs.  We specifically looked at kidney as this is prime location for drug clearance, spleen as a 
major member of the reticuloendothelial system, and heart as a clinically interesting target organ. 
Since hsiRNA accumulation was expected to be substantially lower in these organs (i.e. kidneys, 
heart and spleen) than in liver, we used a higher dose (20mg/kg) to ensure sufficient hsiRNA 
accumulation in secondary tissues to support silencing. Subcutaneous administration of 
5′phosphate hsiRNAPPIB silenced Ppib mRNA by 28% in spleen (Figure 3.7) but did not lead to 
silencing in kidney and heart. 5′ phosphate hsiRNAHTT did not result in silencing Htt mRNAs in 
kidney, spleen or heart (Figure 3.6). The 5′ hydroxide hsiRNAs supported 50% silencing of Ppib 
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and 20% silencing of Htt in kidney, 15% Ppib silencing but no Htt silenicing in spleen (Figure 
3.7) and no Ppib silencing but 35% Htt silencing in heart (Figure 3.6). The metabolically stabilized 
5′-(E)-vinylphosphonate hsiRNAs showed the highest activity, showing 64% Ppib mRNA 
silencing and 40% Htt mRNA silencing in kidney (Figure 3.6), 32% Ppib silencing and 25% Htt 
silencing (p=0.06) in spleen (Figure 3.7), as well as 46% Ppib silencing and 51% Htt silencing in 
heart (Figure 3.6).  
Figure 3.7 5′ -(E)-
vinylphosphonate 
hsiRNA is comparable 
to 5′-phosphate 
hsiRNA in spleen.  
Column scatter plots showing Ppib or Htt mRNA levels in the spleens of mice (n=5 per group) 
treated with 5′ hydroxide (5′-OH), 5′ phosphate (5′-P), or and 5′ -(E)-vinylphosphonate (5′ -VP) 
hsiRNAs by intravenous (IV) of subcutaneous (SC) injection. mRNA levels measured by 
QuantiGene® assay, were normalized to Hprt mRNA and expressed as percent of mRNA levels 
in PBS-treated animals. NTC, non-targeting control. T, targeting hsiRNA. Significance calculated 
by ANOVA with Bonferroni′ s correction: ns, non-significant; #, p≤0.1; p*, p≤0.05; **, p≤0.01; 
***, p≤0.001; and ****, p≤0.0001. 
5′ -(E)-vinylphosphonate improves hsiRNA accumulation in multiple tissues  
Using the PNA-based hybridization assay to quantify hsiRNA levels in tissue lysates, we 
found that the metabolically stable 5′-(E)-vinylphosphonate hsiRNAs accumulated to significantly 
higher concentrations (up to 22 fold) than 5′ hydroxide hsiRNAs in liver, kidney, heart, and spleen 
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(Figure 3.8A and B). When administered intravenously, the positive impact of 5′-(E)-
vinylphosphonate modification on hsiRNA concentration was the highest in heart (Figure 3.8B).  
In all tissues examined, 5′-(E)-vinylphosphonate hsiRNAs accumulated to higher levels than 5′ 
phosphate hsiRNAs, regardless of the administration route or hsiRNA sequence (Figure 3.8A and 
B). Hence, the metabolic stabilization of the 5′ phosphate via 5′-(E)-vinylphosphonate has resulted 
in overall increase of guide strand tissue accumulation, which could explain improved in vivo 
activity of 5′-(E)-vinylphosphonate hsiRNAs. 
Figure 3.8 Metabolic 
stabilization of the 5′ 
phosphate increases retention 
in both primary and secondary 
tissues. 
A. Bar graphs showing the 
concentrations of 5′ hydroxide 
(5′-OH), 5′ phosphate (5′-P), or 
and 5′ -(E)-vinylphosphonate (5′ -
VP) hsiRNA guide strands and 
their metabolites in liver (primary 
tissue), kidneys, heart, and spleen 
(secondary tissues), one week 
after intravenous (IV) or subcutaneous (SC) injection. Concentrations measured by PNA 
hybridization assay. Bar graphs show the mean±SD, n=5 mice per group. B. Summary of fold 
change in concentrations of 5′ -P and 5′ -VP hsiRNA guide strands compared to 5′ -OH hsiRNA 
Chapter III Engineered RNA for delivery via EVs 
68 
 
guide strand. Fold changes are color-coded: high fold changes in red and low fold changes in white. 
Fold changed were calculated by dividing average hsiRNA concentrations in respective organs 
from n=5 mice per group. 
5′ -(E)-vinylphosphonate modification of hsiRNA confers resistance to phosphatases and to 
5′ -to-3′ exoribonuclease XRN1 
The improved retention and silencing activity of 5′-(E)-vinylphosphonate hsiRNAs in vivo 
could reflect protection from natural phosphatases and nucleases. 
 
Figure 3.9 5′ -(E)-vinylphosphonate 
infers resistance against phosphatases in 
vivo and 5′ -3′ exonuclease in vitro. 
A. HPLC traces of Cy3-PNA/hsiRNA 
hybrids in liver lysates from mice 
harvested 1 week after intravenous (IV) or 
subcutaneous (SC) injection with 5′ 
hydroxide (5′-OH), 5′ phosphate (5′-P), or 
and 5′ -(E)-vinylphosphonate (5′ -VP) 
hsiRNA. The “spike-in” (left) panels show 
control traces of Cy3-PNA/hsiRNA 
hybrids after full-length guide strands were 
spiked into liver lysates from untreated mice. 5′-P spike-in guide strands elute more slowly than 5′ 
-OH guide strands, corresponding to the difference of one charge (phosphate). Metabolite profile 
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in liver lysates clearly show dephosphorylation of 5′ -P hsiRNA but partially intact 5′ end of 5′ -
VP hsiRNA. B. Urea-PAGE of 5′ hydroxide (5′-OH), 5′ phosphate (5′-P), or and 5′ -(E)-
vinylphosphonate (5′ -VP) hsiRNAs resolved on an 7 M urea/24% polyacrylamide gel after 12 
hours incubation in the absence (–) or presence (+) of Terminator™ enzyme. 5′-P and 5′-VP (no 
PS) compound had the same nucleotide modification pattern (2′-F, 2′-O-Me) as 5′ -P, 5′ -OH, and 
5′ -VP, but did not contain phosphorothioate (PS) internucleotide linkages. 5′ -VP hsiRNA is 
protecting against degradation by Terminator™ enzyme, whereas 5′ -P hsiRNA is degraded, and 
phosphorothioate internucleotide linkage interferes with enzyme processivity.  
 
Phosphonate bonds have been shown to resist snake venom phosphatase 224, 226 and 5′-(E)-
vinylphosphonate siRNAs have performed better in vivo than 5′ hydroxide siRNAs (Figure 3., 229-
230) consistent with phosphatase resistance. However, no direct evidence exists to date that 5′-(E)-
vinylphosphonate resist phosphatases in vivo in a mouse. We therefore used a PNA-based 
hybridization assay 203 to resolve phosphorylated and dephosphorylated hsiRNA metabolites in 
liver lysates from mice injected with 20mg/kg 5′ hydroxide, 5′ phosphate, or 5′-(E)-
vinylphosphonate hsiRNAs. As a control, we analyzed untreated liver lysates, into which we added 
intact hsiRNAs with 5′ hydroxide, 5′ phosphate, or 5′-(E)-vinylphosphonate end. The control 
chromatography shows 5′ phosphate and 5′-(E)-vinylphosphonate hsiRNAs elute with overlapping 
profiles, and 5′ hydroxide hsiRNAs elute earlier, reflecting the difference of one charge (the 
phosphate) absent in the 5′hydroxide hsiRNA (Figure 3.9A, left panels). In livers harvested from 
mice 1 week after injection, however, we found that chromatography profiles of 5′ phosphate 
hsiRNA converged with the profile of 5′ hydroxide hsiRNA, whereas 5′-(E)-vinylphosphonate 
hsiRNA guide strand eluted later (Figure 3.9A, middle and left graphs), regardless of 
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administration route or sequence. These findings are consistent with rapid dephosphorylation (and 
3′ trimming) of 5′phosphate hsiRNA and protection of 5′-(E)-vinylphosphonate hsiRNAs from 
dephosphorylation.  
Nucleic acids with a 5′ phosphate are sensitive to the 5′ -to-3′ exoribonuclease Xrn1 236. 
Furthermore, Xrn1 and Xrn2 play a role in miRNA stability237-239, especially if miRNA is taken 
up from the extracellular space 240. Xrn1 also regulates accumulation of viral dsRNA 241. Taken 
together with the observation that 5′-(E)-vinylphosphonate hsiRNA showed higher concentrations 
in several tissues than 5′ phosphate hsiRNA, we hypothesized that 5′-(E)-vinylphosphonate 
hsiRNA may have improved stability due to Xrn1 resistance. To test whether 5′-(E)-
vinylphosphonate modification protects against 5′-to-3′ exoribonuclease-mediated degradation, 
we treated 5′ phosphate, 5′ hydroxide, and 5′-(E)-vinylphosphonate hsiRNA guide strands with 
Terminator™ 5′-phosphate-dependent exoribonuclease (i.e., recombinant XRN1) overnight and 
then resolved potential metabolites by denaturing polyacrylamide gel electrophoresis. Whereas we 
detected a 5′ phosphate hsiRNA guide strand metabolite shortened by ~1 nt, the 5′ hydroxide and 
5′-(E)-vinylphosphonate hsiRNA guide strands—regardless of sequence—remained intact 
(Figure 3.9B). This finding indicates that 5′-(E)-vinylphosphonate protects against turnover by 5′ 
phosphate-specific exoribonucleases. We hypothesized that the 19mer metabolite of 5′ phosphate 
hsiRNA could be a result of interference between phosphorothioate internucleotide linkage with 
XRN1 processivity. Therefore, we synthesized 5′ phosphate and 5′-(E)-vinylphosphonate 
hsiRNAs fully modified with 2′-O-Me and 2′-F but containing no phosphorothioates. The guide 
strand of 5′ phosphate hsiRNA lacking phosphorothioates was fully degraded by Terminator™, 
whereas 5′-(E)-vinylphosphonate hsiRNA guide strand containing no phosphorothioates was 
protected (Figure 3.9B). These data suggest that 5′-(E)-vinylphosphonate modification is 
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sufficient to protect hsiRNA guide strand from degradation by 5′ -to-3′ exoribonuclease. Overall, 
resistance to phosphatases and to the exoribonuclease XRN1 underlie the improved in vivo stability 
of 5′-(E)-vinylphosphonate -modified hsiRNAs, leading to improved silencing performance. 
5′ -(E)-vinylphosphonate modification improves hsiRNA duration of effect in vivo 
The improved in vivo stability and silencing performance of 5′ -VP hsiRNA could translate 
into improved duration of effect. We tested this hypothesis by subcutaneously injecting a single 
20mg/kg dose of 5′ hydroxide or 5′-(E)-vinylphosphonate hsiRNAPpib and monitoring the levels 
of Ppib mRNA and hsiRNA in mouse kidney and liver at different time points. We found that the 
silencing of Ppib mRNA and hsiRNAPpib concentration in kidney and liver gradually decreased 
with time, but the level of Ppib mRNA silencing and retention of 5′-(E)-vinylphosphonate hsiRNA 
exceeded that of 5′ hydroxide hsiRNA at each time point (Figure 3.10). Metabolically stable 
phosphate containing 5′-(E)-vinylphosphonate hsiRNA maintained significant silencing in liver 
and kidney, from ~70% Ppib mRNA silencing in both tissues after 1 week to ~24% (liver) and 
~17% (kidney) silencing after 6 weeks. The 5′hydroxide hsiRNA showed ~50% target mRNA 
silencing after 1 week in both liver and kidney, but lost significant silencing activity within 4 
weeks in liver and within 2 weeks in kidney (Figure 3.10A). The 5′-(E)-vinylphosphonate hsiRNA 
concentration remained 2 to 4 times higher than the concentration of 5′hydroxide hsiRNA in liver 
and kidney at each time point (Figure 3.10B). Hence, stabilization of 5′ end by 5′ -(E)-
vinylphosphonate supports increased tissue content, increased silencing activity and increased 
duration of effect when compared to 5′hydroxide hsiRNA. 
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Figure 3.10 Stabilization 
of 5′ phosphate increases 
duration of effect and 
corresponding tissue 
accumulation of hsiRNA 
in vivo. 
A. Column scatter plots 
showing Ppib mRNA 
levels in the livers and 
kidneys of mice (n=5 per 
group) at the indicated 
times after subcutaneous 
injection of PBS or 5′ -OH or 5′ -VP hsiRNAs. mRNA levels measured by QuantiGene® assay 
were normalized to Hprt mRNA and expressed as a percent of mRNA levels in PBS-treated 
animals. Significance calculated by ANOVA with Bonferroni′ s correction, significance was 
calculated in comparison to PBS-treated animals: *, p≤0.05; **, p≤0.01; ***, p≤0.001; and ****, 
p≤0.0001. Mean±SD. B. Bar graphs showing the concentration of 5′ -OH and 5′ -VP hsiRNA guide 
strands in liver and kidney, as measured by the PNA-based hybridization assay at the indicated 
time points after subcutaneous injection. Mean±SD, N=5 
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3.1.5 Discussion 
 
Here we have shown that 5′-(E)-vinylphosphonate modification confers clinically useful properties 
to siRNA drugs. These properties include increase in siRNA tissue concentration and duration of 
silencing, which in turn may allow lowering of dose and frequency of administration. We have 
identified two underlying mechanisms: resistance to phosphatases and resistance to  
5′-to-3′ exonucleases. We and others have shown that 5′-(E)-vinylphosphonate is recognized as a 
phosphate mimic by AGO2 (a nuclease in the RNA-induced silencing complex, RISC) and allows 
or even facilitates loading of siRNA guide strand into RISC 229, 231. However, our data suggests 
that 5′-(E)-vinylphosphonate is not recognized as a phosphate mimic by the main cytoplasmic 5′-
to-3′ exonuclease, XRN1. Hence, 5′-(E)-vinylphosphonate modification improves both the 
pharmacodynamic (better loading to RISC) and pharmacokinetic (slower degradation) behavior of 
an siRNA through altering protein binding.  
The impact of 5′-(E)-vinylphosphonate on siRNA silencing activity showed sequence-
dependence in liver but not in kidney and heart. Different hsiRNA-to-target mRNA ratios could 
explain this observation. In mouse liver, Ppib mRNA is expressed at a fifty times higher level than 
Htt mRNA (FPKM ~184 versus FPKM ~4; Proteinatlas.org), whereas hsiRNAPPIB and hsiRNAHTT 
concentrations were very similar (~200ng/mg). Therefore, the injected dose of 5′phosphate or 
5′hydroxide hsiRNA may be above the level needed to fully silence Htt in liver, but below the 
level needed to fully silence Ppib. Increased concentration of  5′-(E)-vinylphosphonate hsiRNA 
would therefore improve silencing of Ppib but not that of Htt. hsiRNA concentrations are 
approximately six times lower in kidney and twenty times lower in heart than in liver, while mRNA 
expression levels are within the same range. We propose that 5′-(E)-vinylphosphonate only 
improves silencing activity when hsiRNA-to-target mRNA ratios are below the level of saturation. 
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We observed that modification of the 5′end of hsiRNAs influenced silencing activity 
differently in vitro and in vivo. First, 5′-(E)-vinylphosphonate hsiRNA was equally active in vitro 
compared to 5′phosphate hsiRNA, but significantly more active in vivo. This is explained by rapid 
dephosphorylation of 5′phosphate hsiRNA in vivo (Figure  S1. and 242) In parallel, 5′hydroxide 
hsiRNA was less active in vitro but more active in vivo compared to 5′phosphate hsiRNA.  Indeed, 
unmodified 5′hydroxide siRNA has been found to be more efficacious in vivo than unmodified 
5′phosphate siRNA243. Furthermore, all siRNAs showing efficacy to date in clinical trials have 
5′hydroxide ends 218, 244-245. The mechanism why 5′hydroxide siRNA performs superior to 
5′phosphate siRNA in vivo is unclear.  We propose that the 5′end of the guide strand may influence 
protein binding profile of the siRNAs in subcutaneous extracellular space or in serum or in lymph. 
siRNA-bound proteins or peptides can alter the trafficking 246 and phosphorylation 242 of siRNAs. 
The different impact of 5′end of the guide strand on silencing activity in in vitro and in vivo 
experimental settings may be explained by exposure to a different protein environment.  
Concentration of 5′-(E)-vinylphosphonate hsiRNA was 4-22-fold higher than 
concentration of 5′hydroxide hsiRNA, while silencing of 5′-(E)-vinylphosphonate hsiRNA was 
only 0.9-3.3-fold higher than silencing of 5′hydroxide hsiRNA. This phenomenon has been 
observed before 229 and indicates a non-linear relationship between tissue concentration and 
silencing activity. Resistance to exonucleases shown in this paper is only one contributor to the 
concentration – silencing activity relationship. Other factors may be proteins or peptides 
differentially binding to the different 5’ends of hsiRNAs and influence phosphorylation 242 or 
endosomal release 247.  
We found better silencing activity following subcutaneous administration compared to 
intravenous administration, as has been observed in the case of GalNac-conjugated siRNAs as well 
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214. Subcutaneous administration results in slower release and longer residence time of the hsiRNA 
compared to intravenous administration. We speculate that certain serum proteins carry hsiRNAs 
to the organs and the hsiRNA binding capacity of the serum is saturated upon intravenous 
administration. Binding to the proper carrier protein may enable a productive cellular entry 
pathway.  
In this study we used hsiRNA modified with a combination of 2′-F, 2′-O-Me and 
phosphorothioates. These siRNA modifications can support a duration of silencing up to 6 months 
in vivo 218. The mechanism may be explained by enhanced nuclease stability and formation of an 
intracellular depot, which is slowly releasing siRNAs for continuous reloading of Ago2 248. 
However, recent findings suggest that reduction of 2′-F modification of an siRNA could improve 
safety profiles 218, 249-250. Thus, carefully fine-tuning the amount of 2′-F modifications in 5′-(E)-
vinylphosphonate hsiRNA might be crucial to ensure clinical safety and success. 
5′-(E)-vinylphosphonate hsiRNA leads to long-lasting Huntingtin mRNA silencing in 
liver, heart and kidneys. Lowering Huntingtin mRNA could be beneficial in treating peripheral 
symptoms and improving quality of life of patients with Huntington’s disease 251-253. 
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3.2 OPTIMIZED CHOLESTEROL-SIRNA CHEMISTRY IMPROVES PRODUCTIVE LOADING INTO 
SMALL EXTRACELLULAR VESICLES. 
3.2.1 Preface 
Figure 3.11 is reproduced from 
• MR Hassler*, AA Turanov*, JF Alterman*, RA Haraszti, AH Coles, MF Osborn, D 
Echeverria, M Nikan, WE Salomon, L Roux, BMDC Godinho, DV Morrissey, PD Zamore, 
SA Karumanchi, MJ Moore, N Aronin, A Khvorova. Comparison of fully and partially 
chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucl Acid Research. 
2018 Febr.8. 
 
In Figure 3.11 Julia Alterman and Matthew Hassler designed, Matthew Hassler, Dimas Echeverria, 
Mehran Nikan and Loic Roux synthesized, Anton Turanov and Andrew Coles injected siRNAs 
and I measured siRNA levels in all tissues using PNA hybridization assay. 
Text and figures 3.12 – 3.17 are reproduced from a submitted manuscript 
▪  RA Haraszti, R Miller, MC Didiot, A Biscans, JF Alterman, MR Hassler, L Roux, D 
Echeverria, E Sapp, M DiFiglia, N Aronin, A Khvorova. Optimized cholesterol-siRNA 
chemistry improves productive loading into small extracellular vesicles. 
 
Marie Didiot and I conceptualized this project. siRNAs used in this study were synthesized by 
Loic Roux, Annabelle Biscans, Matthew Hassler and Dimas Echeverria. I duplexed singe strands. 
I was assisted by Rachael Miller in exosome production. Marie Didiot contributed intellectually 
to exosome loading with cholesterol-siRNAs and Julia Alterman contributed intellectually in 
designing siRNAs with cleavable linkers. Ellen Sapp and Marian DiFiglia performed transmission 
electron microscopy. I performed all vesicle loading experiments, liposome production, primary 
neurons preparation, silencing measurements, siRNA level quantification, nanoparticle tracking 
analysis and Western blotting. Anastasia Khvorova and I wrote this manuscript. 
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3.2.2 Abstract 
 
Exosomes are promising delivery vesicles for therapeutic RNAs. siRNA conjugation to 
cholesterol enables efficient and reproducible loading of exosomes with the therapeutic cargo. 
siRNAs are typically chemically modified to fit an application. However, siRNA chemical 
modification pattern has not been specifically optimized for exosome-mediated delivery. Here we 
used cholesterol-conjugated, asymmetric siRNAs (hsiRNAs) to evaluate the effect of backbone, 
5′-phosphate, and linker chemical modifications on productive hsiRNA loading into exosomes.  
hsiRNAs with a combination of 5′-(E)-vinylphosphonate and alternating 2′-fluoro and 2′-
O-methyl backbone modifications outperformed previously used partially modified siRNAs in 
exosome-mediated Huntingtin silencing in neurons. Between two commercially available linkers 
(TEG and C7) widely used to attach cholesterol to siRNAs, TEG is preferred compared to C7 for 
productive exosomal loading. Destabilization of the linker completely abolished silencing activity 
of loaded exosomes. The loading of cholesterol-conjugated siRNAs was saturated at ~3000 siRNA 
copies per exosome. Overloading impaired the silencing activity of exosomes. 
The data reported here provide an optimization scheme for the successful use of 
hydrophobic modification as a strategy for productive loading of RNA cargo into exosomes. 
3.2.3 Introduction 
 
Exosomes are small extracellular vesicles being explored for therapeutic RNA delivery due 
to (i) their small size (50-150 nm) allowing penetration through some biological barriers 254-255, 
(ii) their unique protein composition enabling target-cell specificity 137, 256, and (iii) their natural 
capacity to transfer RNA between cells 132, 138.  Exosomes specifically transfer protein and RNA 
cargo between neurons and glial cells 180-185; therefore exosomes are believed to be a promising 
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approach for therapeutic RNA delivery to brain 135. Short interfering RNAs (siRNAs), a subclass 
of therapeutic RNAs, are capable of selective gene silencing 5. Thus, siRNAs offer a therapeutic 
option for genetically defined diseases, such as Huntington′s disease. However, delivery to target 
tissues remains the bottleneck for clinical application of therapeutic RNAs, including siRNAs. 
Exosomes represent a strategy to overcome the delivery challenge 135-136.  
Cholesterol-conjugation mediated loading of siRNAs into exosomes is among the most 
reproducible and scalable loading strategies 135, 153-154, characterized by efficient transfer of the 
loaded cholesterol-siRNA to target cells. However, productive gene silencing induced by the 
transferred cholesterol-siRNA was variable. We speculate that these variations are due to 
differences in siRNA chemical modification patterns (45-71% of riboses modified), cholesterol 
placement position (5′ or 3′ of the sense strand), siRNA-to-exosome loading ratio (100s vs 1000s 
siRNAs/exosome) and siRNA concentrations used in silencing studies (~50-1500 nM) 135 153 154.  
All studies used a version of pyrimidine-modified siRNAs, which have been shown to provide 
stabilization against nucleases in vitro in serum 74, 213, 257.  
Advances in oligonucleotide chemistry have enabled the expansion of siRNA use from in 
vitro serum-rich environments to systemic delivery in vivo 75, 77-78, 213-214. In particular, siRNAs 
with modification of all riboses 77, 202, 214, 218, 244, 258 (with 2′-fluoro and 2′-O-methyl) were 10,000 
fold more active in vivo (Figure  3.11)104 than partially modified siRNAs similar to siRNAs 
originally used for exosomes loading 135, 153-154. A second type of modification, 5′-(E)-
vinylphosphonate, also improved the activity of systemically administered conjugated siRNAs 201, 
229-230. However, full chemical modification did not affect the activity of non-conjugated siRNAs 
delivered in cationic liposomes 78, 259-260. Exosomal delivery of hsiRNAs combines principles of 
siRNA conjugation and lipid nanoparticle technology. The impact of siRNA chemical 
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modifications on efficacy of exosomal delivery is therefore difficult to predict and remains 
unknown. 
Figure 3.11 Systemic 
administration of fully modified 
siRNAs shows enhanced tissue 
accumulation.   
Guide strand tissue quantification 
by PNA hybridization-based assay 
in liver, kidney and spleen after 10 
mg/kg intravenous (IV) tail vein 
injection (A, C and E) or 10 
mg/kg subcutaneous (SC) 
injection (B, D and F).  mean ± 
SD, N=3 mice. hsiRNA: partially 
modified siRNA (70% of 
nucleotides modified), FM-
hsiRNA: fully modified siRNA 
(100% of nucleotides modified), 
DHA: docosahexaenoic acid GalNAc: N-Acetylgalactoseamine. 
 
Among many synthetic approaches on cholesterol attachment to the siRNA, TEG (triethyl 
glycol) and C7 (2-aminobutyl-1-3-propanediol) linkers are frequently used and commercially 
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available. In the amino linker class, the C7 linker was optimal for siRNA passive uptake 261. 
Despite the common use of both linkers, no systematic comparison has been published to date.  
Here we evaluated the impact of siRNA chemical modification patterns, cholesterol 
attachment via different linkers, and siRNA-to-exosome loading ratio on functional exosome-
mediated delivery of siRNAs. We used siRNA concentrations ranging from 23 nM to 1500 nM in 
all experiments. Furthermore, we used a therapy relevant exosomal cell source (umbilical cord, 
Wharton-s jelly derived mesenchymal stem cells), siRNA target gene (Huntingtin) and exosomal 
recipient cells (neurons). 
3.2.4 Results 
 
Linker chemistry influences efficiency of cholesterol-mediated loading of siRNAs into 
exosomes. 
Figure 3.12 Triethyl 
glycol linker for 
cholesterol is favorable. 
Fluorescent, fully 
modified hsiRNA was 
loaded into exosomes, primary murine cortical neurons treated for one week and target Htt mRNA 
silencing measured using QuantiGene (Affymetrix). A. hsiRNA conjugated to cholesterol with 
either a TEG (triethyl glycerol) or a C7 (2-aminobutyl-1-3-propanediol) linker was loaded into 
exosomes at varying hsiRNA-to-exosome ratios. B. Huntingtin mRNA silencing in primary 
neurons one week after treatment with varying concentration of hsiRNA-loaded exosomes. 
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UNT=untreated, N=3 mean ± SEM C. Level of silencing from panel B was normalized to hsiRNA 
content of loaded exosomes. 
 
To compare two commercially available strategies to conjugate cholesterol to siRNAs 
(TEG and C7 linkers), we used a previously developed asymmetric siRNA scaffold 213, 233, 
characterized by a short duplex region (15 base pairs) and a fully phosphorothioated tail assisting 
membrane association 213, 232, 262 (hsiRNAs). hsiRNAs are either partially modified with 2′-fluoro 
pyrimidines on the antisense strand and 2′-O-methyl pyrimidines on the sense strand, or are fully 
modified using alternating 2′-O-methyl and 2′-fluoro pattern providing endonuclease stability and 
protection from innate immune response 263-265. We synthesized fully modified cholesterol-
hsiRNAs targeting Huntingtin mRNA 233 using either  TEG or a C7 linkers (Figure  3.12). 
Cholesterol-hsiRNA variants were loaded into exosomes at increasing hsiRNA-to-exosome ratios 
(Figure 3.12A) Both variants showed efficient loading into exosomes with saturation kinetics 
(Figure 3.12A) Cholesterol-TEG-hsiRNAs loaded more efficiently into exosomes than 
cholesterol-C7-hsiRNA at all ratios tested (Figure 3.12A, p=0.0059).  More efficient loading led 
to more potent   Huntingtin mRNA silencing, when primary neurons were treated with exosomes 
loaded to saturation (cholesterol-TEG IC50~ 8*106 exosomes, cholesterol-C7 IC50~ 22*106 
exosomes, p=0.0008, Figure 3.12B). Normalization to hsiRNA content eliminated the observed 
differences (p>0.05, Figure 3.12C). Thus, silencing potency of the two hsiRNA variants were the 
same. Improved silencing activity upon exosomal delivery could be fully explained by better 
exosomal loading of cholesterol-TEG-hsiRNA. Therefore, cholesterol-TEG-hsiRNA was used for 
subsequent experiments.  
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Optimization of cholesterol-hsiRNA-to-exosome ratio: one to three thousand hsiRNA per 
exosome is preferred.  
Figure 3.13 Loading of 
hsiRNA to exosomes is a 
partially saturatable 
process.  
A. Cholesterol-hsiRNA was 
loaded into exosomes at 
different hsiRNA-to-
exosomes ratios. The loading 
curve shows and initial 
saturation phase followed by a secondary linear phase. Transmission electron microscopy images 
correspond to hsiRNA loaded exosomes at an hsiRNA-to-exosome ratio of 3000, 10 000 and 100 
000. Scale bar represents 500 nm. B. Loading efficiency at varying hsiRNA-to-exosome ratios. C. 
Particle concentration as assessed by nanoparticle tracking analysis after loading at varying 
hsiRNA-to-exosome ratios. C. Huntingtin mRNA silencing in primary neurons one week after 
treatment with exosomes loaded with hsiRNA at hsiRNA-to-exosomes ratios of 3000, 10 000 and 
100 000. UNT=untreated, N=3 ± SEM 
 
  Contrary to conventional siRNA exosomes loading approaches (i.e. electroporation or 
overexpression in parent cells), hydrophobic modifications of siRNA enable association of large 
number of RNA molecules per exosome. To define an optimal hsiRNA-to-exosome ratio, i.e. ratio 
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supporting productive target mRNA silencing, we evaluated the effect of hsiRNA concentration 
during the loading process (1,000 to 100,000 hsiRNA copies per exosome added to the loading 
mixture). Addition of  6,000 hsiRNAs per exosome into the loading mixture resulted in ~ 2,600 
hsiRNAs associated per vesicle (Figure  3.13A), leading to  43% loading efficiency (Figure  
3.13B).  Further increase in the amount of hsiRNA added to the loading mixture (9,000 and 12, 
000 per vesicle) did not support an increase in the amount of exosome-associated hsiRNAs (Figure 
3.13A), indicating a level of intermediate saturation at ~ 2,500-3000 hsiRNAs per vesicle. As the 
amount of loaded hsiRNAs stayed constant, the estimated loading efficiency decreased from 43 to 
23% (Figure 3.13B). Following this initial saturation phase, we observed a linear increase in the 
amount of hsiRNAs loaded per exosome starting at approximately 20,000 hsiRNA per exosome 
added to the loading mixture, representing a constant loading efficiency of 18% (Figure 3.13B). 
Transmission electron microscopy showed similar lipid bilayer surrounded vesicles post loading 
at hsiRNA-to-exosome ratios below the initial saturation phase (3,000), at the initial saturation 
phase (10,000), and in the linear increase phase (100,000) (Figure 3.13A). Increasing hsiRNA-to-
exosome loading ratio beyond 20,000 resulted in increased total particle number (Figure 3.13C), 
suggesting hsiRNA aggregation. Formation of extra particles was only observed in the presence 
of vesicles. 
Next, we evaluated how hsiRNA-to-exosome ratio affected the ability of loaded exosomes 
to silence Huntingtin mRNA in primary neurons. 3,000, 10,000 and 100, 000 hsiRNAs (per 
vesicle) were added to the loading mixture generating exosomes with 1,000, 3,000 and 18,000 
RNA molecules per vesicle, respectively. From three hsiRNA-to-exosome ratios tested, exosomes 
containing 3000 hsiRNA per vesicle performed the best with an IC50 of 37 nM (Figure 3.13D). 
In contrast, exosomes underloaded (1,000 hsiRNA/exosome) or overloaded (18,000 
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hsiRNA/exosome) were less efficient in Huntingtin mRNA silencing (IC50 1330 nM and 1164 
nM, respectively) (Figure 3.13D).  As exosomes loaded with 3000 hsiRNA (saturation level) were 
36-fold more potent than underloaded and 31-fold more potent than overloaded exosomes, 
exosomes loaded with 3000 hsiRNAs were used for subsequent experiments.  
 
Full chemical stabilization of RNA cargo improves productive loading into exosomes. 
Figure 3.14 Full stabilization 
of hsiRNA is beneficial for 
exosome-mediated delivery.  
A. Scheme of chemically 
modified hsiRNAs. P-PM 
partially modified backbone 
with 5′-phosphate on guide 
strand, P-FM fully modified 
backbone with 5′-phosphate on 
guide strand, VP-PM partially modified backbone with 5′-(E)-vinylphosphonate on guide strand, 
VP-FM fully modified backbone with 5′-(E)-vinylphosphonate on guide strand B. Primary murine 
cortical neurons were incubated for one week with cholesterol-hsiRNA variants with different 
extent of 2′ ribose and 5′ end modifications either alone (carrier-free), target Huntingtin mRNA 
silencing was measured, and silencing potency calculated (IC50). N=3 Pairwise comparison of 
curves was conducted using two-way ANOVA with Tukey’s post-hoc test.  Significance is 
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depicted in grey. C. Experiment from panel B conducted with exosome-mediated delivery. D. 
Experiment from panel B conducted with liposome-mediated delivery. 
 
To evaluate the impact of chemical modifications on exosomal delivery of hsiRNAs, we 
synthesized four different hsiRNA variants: (1) partially modified (all pyrimidines modified, 
similar to commercially available siRNAs 213, 257),  (2) partially modified with 5′-(E)-
vinylphosphonate 201, 229-231,  (3) fully modified (100% of riboses modified 77, 202, 214, 218, 244, 258), 
and (4) fully modified with 5′-(E)-vinylphosphonate (Figure  3.14A). In fully modified hsiRNA 
variants, four additional phosphorothioate modifications were introduced compared to partially 
modified variants, to provide additional stabilization from exonuclease activity (Figure 3.14A).  
Figure 3.15 Full 
stabilization of hsiRNA 
is beneficial for 
exosome-mediated 
delivery.  
Primary murine cortical 
neurons were incubated for one week with cholesterol-hsiRNA with different extent of 2’ ribose 
and 5’ end modifications either alone (carrier-free), or loaded to exosomes or liposomes and target 
Huntingtin mRNA silencing was measured. UNT=untreated, P-PM=5’phosphate with partially 
modified backbone, VP-PM=5’vinylphosphonate with partially modified backbone, P-
FM=5’phosphate with fully modified backbone, VP-FM= 5’vinylphosphonate with fully modified 
backbone, N=3. mean ± SEM 
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Surprisingly, only 5′-(E)-vinylphosphonate modification improved Huntingtin mRNA 
silencing activity of hsiRNA-loaded exosomes (p = 0.009), whereas full modification of hsiRNA 
backbone alone had no effect (p > 0.05) (Figure 3.14C and Figure 3.15 middle panel). However, 
when combined with 5′-(E)-vinylphosphonate, full hsiRNA backbone modification further 
improved silencing (p < 0.0001) compared to 5′-(E)-vinylphosphonate alone (p = 0.009) (Figure 
3.14C and Figure 3.15 middle panel). Thus, phosphatase resistance provided a larger benefit than 
nuclease resistance during exosome-mediated delivery of hsiRNAs to neurons. An opposite effect 
was observed with carrier-free (i.e. no exosomes, liposomes or transfection reagents used for 
delivery) hsiRNA uptake, where full modification of hsiRNA backbone improved silencing (p = 
0.0004), whereas 5′-(E)-vinylphosphonate did not (p > 0.05) Figure 3.14C and Figure 3.15 left 
panel). Indeed, previous data showed no effect of 5′-(E)-vinylphosphonate modification on 
silencing activity of siRNAs delivered carrier-free to HeLa cells 201. As another control we used 
liposomes with a size range (Figure 3.16) and loading technique identical to that of exosomes (i.e. 
hsiRNAs residing predominantly on the surface of liposomes). When hsiRNAs were delivered in 
neutral liposomes, the effect of chemical modifications resembled carrier-free delivery with full 
modification of hsiRNA backbone improving silencing activity the most (p = 0.006).  
Figure 3.16 
Characterization 
of liposomes and 
umbilical cord, 
Wharton-s jelly 
derived exosomes.  
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A. Nanoparticle Tracking Analysis shows homogenous exosome size distribution with mean 
diameter 141± 40 nm, N=3 B. Nanoparticle Tracking Analysis of neutral liposomes, mean 
diameter 144 ± 47 nm, N=3 C. Transmission Electron Microscopy image of loaded exosomes, size 
bar shows 500 nm. D. Western blot of positive and negative exosome marker proteins. 
 
Thus, the biological origin and contents of exosomes represent a likely reason for increased 
relative importance of 5′-(E)-vinylphosphonate over chemical modification of siRNA backbone. 
Indeed, a variety of nucleases, including 5′-nucleotidase, was detected in exosomes purified from 
umbilical cord derived mesenchymal stem cells using mass spectrometry (Table 3.2).  
 
Table 3.2 Nucleases detected in exosomes isolated from umbilical cord derived mesenchymal 
stem cells, via mass spectrometry. First column: Uniprot Accession numbers 
 
P49184 DNSL1 HUMAN Deoxyribonuclease-1-like 1 OS=Homo sapiens GN=DNASE1L1 PE=1 SV=1 34 kDa
Q7KZF4 SND1 HUMAN Staphylococcal nuclease domain-containing protein 1 OS=Homo sapiens GN=SND1 PE=1 SV=1 102 kDa
O94919 ENDD1 HUMAN Endonuclease domain-containing 1 protein OS=Homo sapiens GN=ENDOD1 PE=1 SV=2 55 kDa
P13489 RINI HUMAN Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 50 kDa
P21589 5NTD HUMAN 5'-nucleotidase OS=Homo sapiens GN=NT5E PE=1 SV=1 63 kDa
P22413 ENPP1 HUMAN Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 OS=Homo sapiens GN=ENPP1 PE=1 SV=2 105 kDa
P09543 CN37 HUMAN Isoform CNPI of 2',3'-cyclic-nucleotide 3'-phosphodiesterase OS=Homo sapiens GN=CNP 45 kDa
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The stability of the cholesterol linker is essential for productive hsiRNA loading into 
exosomes. 
Figure 3.17 Cleavable 
cholesterol impairs 
activity of cholesterol-
hsiRNA-loaded 
exosomes. 
A. Incorporation of 
moderately (2′-deoxy-DNA, blue) or highly (2′-hydroxy-RNA, green) endonuclease-sensitive 
bases into the sense strand is a strategy to facilitate cleavage of cholesterol from cholesterol-
conjugated hsiRNA.  B. Huntingtin mRNA silencing in primary neurons one week after treatment 
with exosomes loaded with hsiRNA variants alone (carrier-free) or loaded into exosomes or 
liposomes at varying concentrations. UNT=untreated, N=3, mean ± SEM 
 
Loading of hsiRNAs into exosomes is dependent on the presence of the hydrophobic 
cholesterol conjugate 135, which anchors the hsiRNA into the membrane.  Stable association with 
membranes may potentially trap siRNAs in endosomes and limit loading into cytoplasmic RISC, 
thus impairing silencing activity 266. Introduction of cleavable linkers have been used as a 
successful strategy to enhance silencing activity of conjugated siRNAs 267. To test whether the use 
of cleavable linkers is an advantage in exosome-mediated delivery of cholesterol-hsiRNAs, we 
synthesized three hsiRNA variants with varying stability of the linker connecting cholesterol to 
the hsiRNA. We used a fully chemically modified hsiRNA variant containing 5′-(E)-
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vinylphosphonate for these studies. Incorporation of moderately (2′-deoxy-DNA) or highly (2′-
hydroxyl-RNA) endonuclease-sensitive bases between the sense strand and the linker was used to 
modulate rate of cholesterol cleavage (Figure 3.17A). Destabilization of the linker chemistry 
greatly impaired of hsiRNA silencing activity when delivered via exosomes.  Huntingtin mRNA 
silencing was completely abolished (p < 0.0001) upon incorporation of two 2′-hydroxyl RNA 
residues (highly endonuclease sensitive) and significantly reduced (p = 0.024) upon incorporation 
of 2′-deoxy DNA residues (moderately endonuclease sensitive) (Figure 3.17B middle panel). On 
the contrary, chemical stability of the linker had no effect on hsiRNA silencing activity when 
delivered carrier-free (Figure 3.17B right panel) or in neutral liposomes (Figure 3.17B left panel). 
Thus, use of a stable linker is essential for productive loading of exosomes with the RNA cargo.  
 
3.2.5 Discussion 
 
Exosomes are promising delivery vesicles for therapeutic RNAs. Cholesterol conjugation 
to siRNAs is a simple, scalable and widely used method to load exosomes with RNA cargo that 
has proven useful in both in vitro 153-154 and in vivo 135 experiments. However, there is a lack of 
knowledge on the importance of typical siRNA chemical modifications75, 77-78, 213-214 on exosome-
mediated delivery.  
Data presented here the presence of nucleases in exosome preparations bear consideration 
during the rational design of RNA cargo. This study found that previously used partial 
modification of siRNA 135, 153-154 is suboptimal for exosome-mediated siRNA delivery. Instead, 
siRNAs with a combination of 5′-(E)-vinylphosphonate 201, 229-230 and alternating 2′-fluoro and 2′-
O-methyl modifications 77, 202, 214, 218, 244, 258 performed best at exosome-mediated delivery and 
Huntingtin mRNA silencing in neurons. Furthermore, incorporation of nuclease-sensitive bases 
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into the cholesterol-linker impaired exosome-mediated delivery of hsiRNAs. The benefit of 
chemical modifications may stem from the localization of hsiRNAs (i.e. on the surface of 
exosomes 135), altered cellular internalization pathway 135, as well exosomal protein content 
including a variety of nucleases (Table 3.1) 268 and nuclease activity 269. 
Here we showed that the cholesterol conjugation strategy to siRNA plays an important role 
in exosome-mediated delivery and therefore should be included in optimized RNA cargo design. 
Between two commercially available strategies to conjugate cholesterol to the 3′ end of the siRNA 
sense strand, TEG proved to be favorable compared to C7 for productive exosomal loading of 
cholesterol-siRNA. Both length and hydrophilic character of TEG linker might favor the lipid 
bilayer geometry and promote more efficient hsiRNA loading.  
Our data suggests that hsiRNA loading into exosomes saturates at ~3,000 hsiRNAs 
molecules per exosome. In addition, overloading (more than 5,000 hsiRNAs per exosomes) may 
induce aggregation and adversely affect productive gene silencing. Therefore, we suggest ~ 3,000 
hsiRNA per exosome as optimal loading capacity. This number might be altered by the nature of 
the hydrophobic conjugate of hsiRNA (i.e. other than cholesterol) and exosomal membrane 
composition, which varies greatly depending on the source cell 256, 270. Thus, the maximal hsiRNA 
copy number per exosome will need to be defined for each hydrophobic conjugate of siRNA and 
exosomal cell source separately.   
 The data presented here provide a detailed framework for the successful use of hydrophobic 
modification as a strategy for productive loading of RNA cargo into exosomes. A similar chemical 
optimization strategy is likely needed when taking advantage of exosomes to deliver other 
oligonucleotide species, including CRISPR guide RNAs, artificial miRNAs, small mRNAs, RNA 
tethers, aptamers or antisense oligonucleotides.  
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3.3 HYDROPHOBICITY OF LIPID-CONJUGATED SIRNAS PREDICTS PRODUCTIVE LOADING INTO 
EXOSOMES. 
3.3.1 Preface 
Text and figures are reproduced from an accepted manuscript 
 
▪ A Biscans*, RA Haraszti*, D Echeverria, R Miller, MC Didiot, M Nikan, L Roux, N 
Aronin, A Khvorova. Hydrophobicity of lipid-conjugated siRNAs predicts productive 
loading into small extracellular vesicles. Molecular Therapy, Accepted 
 
Annabelle Biscans and I conceptualized this project. Annabelle Biscans designed conjugates, 
Mehran Nikan developed DHA-conjugated compounds and Loic Roux developed 5′-E-
vinylphosphonate. Annabelle Biscans and Dimas Echeverria synthesized and duplexed all 
siRNAs. Annabelle Biscans performed reverse phase chromatography. Marie Didiot intellectually 
contributed to lipid-conjugate mediated loading of siRNAs to exosomes. I was assisted by Rachael 
Miller in EV preparations. I prepared primary neurons, loaded all EVs, measured mRNA silencing 
and siRNA accumulation in neurons, performed Nanoparticle Tracking Analysis and Western 
blotting, measured zeta potential. Annabelle Biscans, Anastasia Khvorova and I wrote this 
manuscript. Annabelle Biscans produced Figures 3.19-3.20 with corresponding legends. 
 
3.3.2 Abstract 
 
Exosomes show promise as natural nano-devices for delivery of therapeutic RNA, but 
efficient loading of therapeutic RNA remains a challenge. We have recently shown that the 
attachment of cholesterol to siRNAs enables efficient and productive loading into exosomes. Here 
we systematically explore the ability of lipid conjugates—fatty acids, sterols, and vitamins—to 
Chapter III Engineered RNA for delivery via EVs 
92 
 
load siRNAs into exosomes and support gene silencing in primary neurons. Hydrophobicity of the 
conjugated siRNAs defined loading efficiency and the silencing activity of siRNA-exosomes 
complexes. Vitamin E-conjugated siRNA supported the best loading into exosomes and productive 
RNA delivery to neurons. 
 
3.3.3 Introduction 
 
Small extracellular vesicles (exosomes) are produced by most cell types and present in 
most body fluids (e.g., blood, saliva, urine, cerebrospinal fluid, and milk).271-273 They possess the 
ability to transport RNA, including mRNA and microRNA, over short and long intercellular 
distances, and thus empower sequence-specific, phenotype-modulating RNA types, to act as a 
messenger.274-277 The intercellular RNA trafficking mechanism via exosomes would make a 
powerful tool to fight disease when used to deliver therapeutic RNA. 
Delivery of small interfering RNAs (siRNAs) to target cells remains an important 
challenge to their development as therapeutics.278-279 Nanoparticle carriers have been explored as 
siRNA delivery vehicles.280-281 Despite some clinical success, the characteristic toxicity, 
immunogenicity, and poor trafficking of nanoparticles has hampered further development as 
therapeutic RNA delivery vehicles.282-283 By contrast, the natural RNA trafficking properties, low 
toxicity and immunogenicity, high stability in circulation, and target-cell specificity137 of 
exosomes offer a promising alternative for efficient and selective delivery of siRNA to target 
cells.153, 284-287 
Loading RNA into exosomes remains a bottleneck for clinical application of exosomes as 
delivery vesicles for therapeutic RNA. The two most common loading strategies have been direct 
electroporation into the vesicles287-289 and transfection into EV source cells.290-291 However, 
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electroporation may induce vesicle damage and siRNA aggregation,292 transfection may disrupt 
EV integrity,287 and both methods lack robust batch-to-batch reproducibility and scalability. 
Recent studies have shown that the covalent conjugation of siRNA to a hydrophobic cholesterol 
moiety can drive efficient and controllable loading of siRNAs to exosomes, yielding thousands of 
copies of RNAs per vesicle.153-154, 286 Conjugation of other hydrophobic moieties (e.g. α-tocopherol 
or docosahexaenoic acid) to siRNAs have been performed and tested for in vivo delivery to liver 
and brain.197-198, 293-294 However, hydrophobic moieties other than cholesterol have never been used 
in EV-mediated delivery of siRNAs.  
We have synthesized a panel of lipid-conjugated hydrophobically modified siRNAs 
(hsiRNAs) to be loaded into exosomes to evaluate how the lipids affect the hsiRNA exosome 
loading efficiency. We found that hydrophobicity drives loading of lipid-conjugated hsiRNAs into 
exosomes. Moreover, the ability of exosome-loaded hsiRNAs to silence Huntingtin mRNA in 
primary murine cortical neurons correlates with the amount of lipid-conjugated hsiRNAs loaded 
into exosomes.  
 
  
Chapter III Engineered RNA for delivery via EVs 
94 
 
3.3.4 Results 
 
Generation of a library of diverse lipid-conjugated hsiRNAs  
Figure 3.18 Cholesterol-conjugated 
hsiRNAs load into small extracellular 
vesicles exosomes.  (A.) Representation of 
exosome membrane loaded with cholesterol-
conjugated hsiRNAs. Cholesterol is the 
driving force for efficient loading of siRNA 
into exosomes. (B.) Schematic of 
hydrophobically modified siRNAs 
(hsiRNAs).   
 
 
 
We have recently shown that cholesterol-conjugated chemically stabilized siRNAs 
efficiently associate with exosomes.286 We hypothesized that the hydrophobicity of cholesterol is 
the driving force behind loading of cholesterol-conjugated siRNAs into membranes (Figure 
3.18A). To define the structure-function relationship between lipid conjugate and its ability to 
drive siRNA loading capacity into exosomes, we synthesized a library of lipid-conjugated siRNAs 
with a broad range of hydrophobicity. In each case, we used the same fully chemically stabilized 
asymmetric siRNA scaffold (i.e., hydrophobically modified siRNA or hsiRNA).295 hsiRNAs have 
a short duplex region (15 base-pairs) and single-stranded fully phosphorothioate-modified tail that 
assists membrane association.296-297 All riboses are fully chemically modified using an alternating 
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2´-O-methyl and 2´-fluoro modification pattern, which confers stability and minimizes innate 
immune activation.263-265 Moreover, the antisense strand is modified with a 5´-(E)-
vinylphosphonate (E-VP) group that mimics the 5´-phosphate of the antisense strand to promote 
recognition by RISC298-299 and provides stability against phosphatases and exonucleases.199, 300-301 
Full chemical stabilization of hsiRNAs improves EV-mediated delivery of hsiRNAs (Haraszti et 
al., 2018, Manuscript in Review, Section 3.2). Compounds were labeled with Cy3 at the 5´-end of 
the sense strand, which allows visualization and quantification of hsiRNAs loaded into exosomes. 
The lipid conjugates were attached at the 3´-end of the sense strand (Figure 3.18B).  
 
Figure 3.19 The chemical compositions of lipid conjugates significantly affect hsiRNA 
hydrophobicity. (A.) Library of lipophilic moieties attached to hsiRNAsHtt. (B.) HPLC retention 
time of lipid-conjugated Cy3-hsiRNAHtt sense strands. (C18, Buffer A = 0.1 M Triethylammonium 
acetate in water, Buffer B = Acetonitrile, Gradient = 0-100 % in B in 15 min, Temperature = 60C, 
Flow = 1 mL/min). 
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A wide range of natural lipids such as fatty acids, sterols and vitamins were conjugated to 
the sense strand of hsiRNAHtt, which targets the Huntington’s disease gene.302 In nature, many 
lipids are esterified (mostly phosphatidyl choline esters), which contributes to the specificity of 
cellular membrane interactions.303 To explore how esterification of the lipid conjugate affects 
hsiRNAs loading into exosomes, all lipid-conjugated hsiRNAs were synthesized with or without 
a phosphocholine (PC) head group.  Because an ester bond is labile and incompatible with solid-
phase oligonucleotide synthesis, we have recently developed a synthetic approach that allows a 
phosphocholine group to be attached to lipid moieties using an amide bond.197 The chemical 
compositions of synthesized lipid-conjugated hsiRNAs are depicted in Figure 3.19A. All lipid-
conjugated hsiRNAs (with the exception of α-tocopheryl succinate hsiRNAs and PC-α-tocopheryl 
succinate hsiRNAs) were synthesized by using a functionalized solid support (Figure 3.20A-
B).197-198 For phosphocholine modified variants, the Fmoc (Fluorenylmethyloxycarbonyl) 
protected PC group (Figure 3.20B compound 7) was first attached to the C7 amino functionalized 
solid support via a peptide bond followed by conjugation of respective lipids (Figure 3.20B solid 
supports 9).197-198 Both α-tocopheryl succinate variants were synthesized using a post-synthetic 
conjugation between an amino group present at the 3´-end of the sense strand and the NHS (N-
hydroxysuccinimide)-α-tocopheryl-succinate compound (Figure 3.20C). For the synthesis of α-
tocopheryl succinate sense strands, a commercial C6 amino solid support was used to synthesize 
the strands. For PC-α-tocopheryl succinate sense strands, the PC amino solid support 8 (Figure 
3.20B) was used to synthesize the strands. 
The relative hydrophobicity of a molecule can be determined by its retention time in 
reverse-phase high-performance liquid chromatography (HPLC). Hydrophobicity increases with 
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retention time.304 Figure 3.19B shows HPLC traces for synthesized sense strands, with retention 
times varying between 1 and 13 minutes, indicating a broad range of hydrophobicity.305 The 
structure of the conjugate principally contributed to hsiRNA retention time and hydrophobicity. 
Compounds with a saturated carbon chain (cholesterol, docosanoic acid and α-tocopheryl 
succinate) were more hydrophobic than those with an unsaturated carbon chain (docosahexaenoic 
acid and eicosapentaenoic acid) or cyclic structure (lithocholic acid and retinoic acid). The 
incorporation of a polar head (phosphocholine group) decreased the hydrophobicity of all lipid-
conjugated hsiRNAs. This synthetic library of 15 different lipid-conjugated hsiRNAs, covering a 
broad range of lipid structures and hydrophobicity allowed us to examine how lipid structure 
affects efficiency of hsiRNA loading into exosomes. 
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Figure 3.20 Synthetic route of lipophilic compounds used for the synthesis of lipid conjugated 
siRNAs. (A) Synthesis of solid supports conjugated with various lipophilic moieties (B) Synthesis 
of solid supports conjugated with various phosphocholine lipophilic moieties attached though a 
C7 linker. (C) Synthesis of NHS-α-tocopheryl succinate compound for post-synthetic conjugation.  
(A) C7 linker (90% purity) 1 (13.00 g, 19.35 mmol, 1.0 equiv.), 4-dimethylaminopyridine (DMAP) 
(cat.) and succinic anhydride (2.68 g, 27.09 mmol, 1.4 equiv.) were dissolved in 120 mL of dry 
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dichloromethane (DCM) and 34 mL of dry pyridine. The mixture was stirred 24h at room 
temperature and then washed with 300 mL of 10% citric acid. The organic layer was then washed 
with water and brine and dried over magnesium sulfate. The solvent was evaporated under 
pressure. A column chromatography on silica gel was performed using a gradient of methanol in 
a mixture of DCM:pyridine 99:1 from 0 to 10% to obtain 2 (12.24 g, 15.87 mmol, 82%). 
Compound 2 (5.72 g, 7.35 mmol, 2.2 equiv.), (Benzotriazol-1-yloxy) tris (dimethylamino) 
phosphonium hexafluorophosphate (BOP) (4.43 g, 10.02 mmol, 3.0 equiv.) and 1-
Hydroxybenzotriazole (HOBt) (1.53 g, 10.02 mmol, 3.0 equiv.) were dissolved in 100 mL of dry 
DCM. The mixture was stirred few minutes and 2,4,6-collidine (2.61 mL, 20.04 mmol, 6.0 equiv.) 
was added. The amino controlled pore glass (CPG) (22.00 g, 3.34 mmol, 152 μmol/g) was added 
after treated with 250 mL of 3% TFA in DCM at room temperature for 4h, filtrated and washed 
first with TEA:diisopropylethylamine 9:1 (250 mL) and then with DCM and ether. The mixture 
was stirred mechanically 24h at room temperature. The CPG was washed with DCM, acetonitrile 
(ACN) and ether and dried under pressure. The CPG was then capped with 16% N-
methylimidazole in tetrahydrofuran (THF) (CAP A) and acetic anhydride:pyridine:THF (1:2:2, 
v/v/v) (CAP B) (1:1, v/v) for 1h and was washed with DCM, ACN and ether and dried under 
vacuum. 3 is obtained with a loading of 75 μmol/g. 
The CPG 3 (1.00 equiv.) was treated with a solution of 20% piperidine in dry dimethylformamide 
(DMF) (150 mL) two times 15 minutes, washed with DCM, ACN and ether and dried under 
pressure.  
The selected lipid R (6.00 equiv.) was dissolved in 150 mL of dry DMF. 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
(HATU) (2.00 equiv.) and diisopropylethylamine (DIEA) (8.00 equiv.) were added and the 
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solution was added to the deprotected CPG. The mixture was stirred overnight under mechanical 
stirring at room temperature. The CPG was washed with DCM, ACN and ether and dried under 
pressure. The CPG was then capped with 16% N-methylimidazole in THF (CAP A) and acetic 
anhydride:pyridine:THF (1:2:2, v/v/v) (CAP B) (1:1, v/v) for 1h and was washed with DCM, ACN 
and ether and dried under vacuum. The lipid functionalized solid supports 4 were obtained with a 
loading of 55 μmol/g. 
(B) Fmoc-L-serine-tBu (2.00 g, 5.21 mmol, 1.0 equiv.) was first dried by co-evaporation with 
toluene. Dry DCM (15 mL) and diisopropylethylamine (DIPEA) (1.54 mL, 8.86 mmol, 1.7 equiv.) 
were added under argon and 2´-cyanoethyl-N,N-diisopropylchlorophosphoramidite (1.60 g, 6.78 
mmol, 1.3 equiv.) was added slowly via a syringe. The reaction mixture was stirred 2h at room 
temperature. After reaching completion, the reaction mixture was quenched with methanol and 
was washed with a solution of sodium bicarbonate and brine. The aqueous phase was extracted 
with DCM. The organic phase was dried on magnesium sulfate, filtrated and evaporated under 
vacuum. The crude mixture was then purified by column chromatography on silica gel using ethyl 
acetate/Hexane (8/2) with 1% pyridine as eluent, to afford 5 as a white solid (2.90 g, 4.97 mmol, 
95%).  
Compound 5 (2.90 g, 5.39 mmol, 1.0 equiv.) was dried with dry toluene and dry ACN. Choline p-
toluenesulfonate (1.63 g, 5.93 mmol, 1.1 equiv.) was dried with toluene and dissolved in dry ACN 
(46 mL). This mixture was added to compound 5 through a cannula. 5-(Ethylthio)-1H-tetrazole 
(ETT) (0.25 M in ACN) (21.6 mL, 5.39 mmol, 1.0 equiv.) was added slowly with a syringe. The 
mixture was stirred 2h at room temperature. After reaching completion, the reaction mixture was 
quenched with methanol. Meta-chloroperoxybenzoic acid (mCPBA) (1.86 g, 10.78 mmol, 2.0 
equiv.) was added by portion to the mixture. After 30 min of stirring, the mixture was reduced 
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under vacuum. The crude was then purified by column chromatography on silica gel using a 
gradient of Methanol in DCM (0-30%) as eluent, to obtain 6 as a mixture of tetrazolium (major 
counter anion) and tosylate (less than 5%) salts (2.70 g, 3.69 mmol, yield 69%).  
Compound 6 (2.30 g, 3.15 mmol, 1.0 equiv.) was dissolved in 60 mL of (1:1) solution of 
trifluoroacetic acid (TFA):dry DCM. Triisopropylsilane (2.39 mL, 11.66 mmol, 3.7 equiv.) was 
added and the mixture was stirred at room temperature for 2h. The solvent and TFA were 
evaporated and the residue was purified by reverse phase HPLC (C18, Buffer A = Water, Buffer B 
= ACN, Gradient = 5-65% of B in 12 min, T = 45°C).  The ACN was removed under vacuum and 
the aqueous solution was freeze-dried. The lyophilized powder was dissolved in 10% 
diisopropylamine (14 mL) in ACN (140 mL) and the mixture was stirred at room temperature for 
2h. The solvent was evaporated under vacuum and the crude was purified by reverse phase HPLC 
(C18, Buffer A = Water, Buffer B = ACN, Gradient = 5-65% of B in 12 min, T = 45°C).  The ACN 
was removed under vacuum and the aqueous solution was freeze-dried to afford 7 as 
diisopropylammonium salt (1.38 g, 2.32 mmol, yield 74% over two steps).  
Compound 7 (1.00 g, 1.69 mmol, 4.75 equiv.) was dissolved in dry DMF (100 mL). (Benzotriazol-
1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (0.59 g, 1.34 mmol, 3.76 
equiv.) and hydroxybenzotriazol (HOBt) (0.21 g, 1.34 mmol, 3.76 equiv.) were added and stirred 
until the solution went clear. 2,4,6-collidine (560 µL, 4.32 mmol, 12.42 equiv.) was added 
followed by 3 deprotected with 20% piperidine in DMF (6.55 g, loading of 55 µmol/g, 360 µmol, 
1.00 equiv.) and the suspension was mixed overnight on a rotary mixer. The CPG was filtered off 
and washed with DCM, ACN and ether and dried under vacuum. The CPG was capped with 16% 
N-methylimidazole in THF (CAP A) and acetic anhydride:pyridine:THF (1:2:2, v/v/v) (CAP B) 
(1:1, v/v) for 1h and was washed with DCM, ACN and ether and dried under vacuum. 
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CPG 8 (6.00 g, 330 µmol, 1.0 equiv.) was first treated with 20% piperidine in dry DMF for 15 
minutes. This procedure was repeated twice to ensure complete deprotection of the Fmoc group. 
The amine-bearing CPG was filtered off and washed successively with DCM, ACN and ether and 
dried under vacuum. Then the CPG was mixed with a mixture of the selected lipid R (6.0 equiv.), 
HATU (2.0 equiv.) and DIEA (8.0 equiv.) in dry DMF. The suspension was mixed on a rotary 
mixer for 24h. The CPG was then filtered off and washed with DCM, ACN and ether and dried 
under vacuum. The CPG was capped with 16% N-methylimidazole in THF (CAP A) and acetic 
anhydride:pyridine:THF (1:2:2, v/v/v) (CAP B) (1:1, v/v) during 15 min and was washed with 
DCM, ACN and ether and dried under vacuum. The PC lipid functionalized solid supports 9 were 
obtained with a loading of 55 μmol/g. 
(C) α-tocopheryl succinate (0.5 g, 0.94 mmol, 1.0 equiv.), N-hydroxysuccinimide (0.21 g, 1.88 
mmol, 2.0 equiv.) and dicyclohexylcarbodiimide (DCC) (0.39 g, 1.88 mmo, 2.0 equiv.) were 
dissolved in 25 mL of anhydrous DMF. The mixture was stirred overnight at room temperature. 
The dicyclohexyl urea was filtrated and the filtrate was evaporated under pressure. The product 10 
was isolated by precipitation with methanol (0.47 g, 0.75 mmol, 80%). 
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Loading efficiency of conjugated-hsiRNAs into exosomes correlates with hsiRNA 
hydrophobicity  
 Figure 3.21 Characterization of umbilical cord, Wharton’s jelly derived exosomes. 
 Umbilical cord, Wharton’s jelly derived mesenchymal stem cells were expanded to passage 9 at 
3600 cm2, medium changed to serum-free RPMI for 24 hours, and exosomes purified from 
conditioned media via differential ultracentrifugation. (A) Nanoparticle Tracking Analysis of 
100,000 g fraction from differential ultracentrifugation protocol (e.g. small EVs). N=11, mean ± 
SEM (B) Transmission Electron Microscopy image of unloaded and loaded exosomes, size bar 
shows 500 nm. (C) Western blot of positive and negative exosome marker proteins. (D) Protein 
enrichment (logarithmic) in exosomes versus cells as detected by LC-MS/MS. INF=infinite 
(detected in exosome fraction but not detected in cells) 
 
Exosomes were isolated by differential ultracentrifugation from Wharton’s jelly-derived 
(umbilical cord) mesenchymal stem cells.204 They displayed uniform size distribution (mean, 140 
nm; Figure 3.21A). Small EVs appeared as lipid bilayer surrounded vesicles on transmission 
electron microscopy (Figure 23B). Western-blot (Figure 3.21C) and LC-MS/MS (Figure 3.21D) 
showed enrichment in positive EV marker proteins (CD63, CD81, CD9, Alix, Tetraspanin-14 and 
Tsg101) and depletion in negative EV marker proteins (Calnexin, Calreticulin, Cytochrome C and 
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HNRPK).   Thus, small EVs used in this study are bona fide extracellular vesicles according to the 
guidelines established by International Society of Extracellular Vesicles.306 
Figure 3.22 Silencing activities of 
cholesterol conjugated hsiRNA-
loaded exosomes using 10,000 
and 100,000 g pellet fractions 
and cholesterol conjugated 
hsiRNA.   
Htt mRNA levels in primary mouse neurons incubated with increasing concentrations of 
cholesterol conjugated hsiRNAHtt-loaded small EVs (100,000 g fraction), large EVs (10,000 g 
fraction) or cholesterol conjugated hsiRNAHtt for one week. Htt mRNA levels were normalized to 
Hprt (Hypoxanthine-guanine phosphoribosyl transferase), and presented as percent of untreated 
control (n=3, mean ± SEM). UNT, untreated 
 
Cholesterol-conjugated hsiRNAs were more efficient at inducing Huntingtin mRNA 
silencing in neurons when they were delivered via small EVs (e.g. 100,000 g fraction of differential 
ultracentrifugation protocol) compared to cholesterol-hsiRNA alone (Figure 3.22).  Cholesterol-
hsiRNAs did not silence target mRNA when delivered via large EVs (e.g. 10,000 g fraction) 
(Figure 3.22). Therefore, we used small EVs (e.g. 100,000 g fraction) to test delivery of all 
conjugated hsiRNA to neurons. exosomes were co-incubated with increasing concentrations of 
Cy3-hsiRNAHtt conjugated to the above described lipids (1:2000, 1:6000, 1:12000, and 1:25000 
exosome-to-hsiRNA ratios). Ultracentrifugation of Cy3-hsiRNA-exosome mixture resulted in a 
fluorescent pink pellet, revealing the association of labeled hsiRNA with exosomes (Figure 3.23). 
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Ultracentrifugation of hsiRNAsHtt without exosome did not generate a pellet, indicating the 
absence of hsiRNA aggregation (Figure 3.24A). The integrity of the exosome membrane after 
hsiRNA loading was confirmed by using transmission electron microscopy (Figure 3.22B). 
 
 
 
 
 
 
 
 
 
Figure 3.23 Pictures of exosomes loaded with lipid-conjugated hsiRNAs after 
ultracentrifugation. 
 
The efficiency of Cy3-hsiRNA loading into exosomes was quantified by 
spectrophotometry (Figure 3.24B). Increasing hsiRNA-to-exosome ratios yielded higher loading 
efficiencies with saturation kinetics: at a 1:25000 exosome-to-hsiRNA ratio, loading was nearly 
saturated for each lipid-conjugated hsiRNA. The loading efficiency depended on the structure of 
the lipid conjugate attached to the hsiRNA. A strong exponential correlation was observed between 
the hydrophobicity of the lipid-conjugated hsiRNA and the exosome loading efficiency (Figure 
3.24C). Thus, hydrophobicity of an hsiRNA directly predicts the number of molecules that can 
that can be loaded into exosomes. Efficient loading (at least 1700 hsiRNAs per vesicle for a 
1:25000 ratio) required the presence of a highly hydrophobic conjugate (Cholesterol, PC-
cholesterol, Docosanoic acid, PC-docosanoic acid, α-tocopheryl succinate and PC-α-tocopheryl 
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succinate) attached to the hsiRNA. Unsaturated fatty acid chains (docosahexaenoic acid and 
eicosapentaenoic acid) conferred less hydrophobicity and therefore less vesicle loading efficiency 
to hsiRNAs. Conjugation of α-tocopheryl succinate (vitamin E) to hsiRNA yielded the best 
exosome loading efficiency, outperforming cholesterol. Docosanoic acid was as effective as 
cholesterol at loading hsiRNAs into exosomes. Despite being structurally similar to cholesterol, 
the reverse sterol conjugate formed by lithocholic acid is not as efficient as the cholesterol 
conjugate, indicating that the saturated carbon tail of cholesterol is important for exosome loading. 
These data suggest the model that anchoring of hsiRNA to the surface of EV is mediated by the 
insertion of the saturated carbon chain into the vesicular membrane.  
  
Figure 3.24 The number of hsiRNAs loaded into exosomes depends on the hydrophobicity of 
the conjugate.  
(A.) Ultracentrifugation of conjugated Cy3-hsiRNAs incubated without exosome (left) showing 
absence of pellet and after co-incubation of Cy3-hsiRNAs and exosomes (right) showing 
formation of pellet. Representative pictures are shown. (B.) Cy3-hsiRNA accumulation in pellet 
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following co-incubation of hsiRNAs and exosomes with varying hsiRNA:exosome ratio (n=3, 
mean ± SEM for the last point). (C.) Exponential relationship between loading efficiency and 
hydrophobicity of conjugated hsiRNA (n=3, mean ± SEM). (D.) Linear correlation between the 
surface charge of hsiRNA-loaded exosomes and hsiRNA loading efficiency (n=2, mean ± SEM). 
 
Consistent with our previous studies,286 the loading of lipid-conjugated hsiRNAs reduced 
the zeta potential of exosomes (Figure 3.24D), indicating the presence of negatively charged 
hsiRNAs on the surfaces of vesicles. We observed a linear correlation between zeta potential and 
hsiRNA loading efficiency: the lower the surface charge the higher the loading efficiency. α-
tocopheryl succinate (vitamin E) conjugated hsiRNA-loaded exosomes had the highest hsiRNA-
to-exosome ratio and displayed a zeta potential of –35mV, a significant change relative to unloaded 
exosomes (–13mV). We have shown previously that the majority of hsiRNAs are bound to the 
outside of the exosomes.286 However, since the hsiRNAs are stable against RNases in vitro and in 
vivo,199, 263 the presence of hsiRNAs on the surface of exosomes should not reduce siRNA activity. 
Of 15 lipid-conjugated hsiRNA variants evaluated, we identified five additional lipid-
conjugated hsiRNAs that associate with exosomes as well as or better than cholesterol-conjugated 
hsiRNA: PC-cholesterol, Docosanoic acid, PC-docosanoic acid, α-tocopheryl succinate and PC-
α-tocopheryl succinate hsiRNAs. The degree of hydrophobicity of the lipid-conjugated hsiRNA 
seems to defines the efficiency of loading into exosomes. Loading efficiency of lipid-conjugated 
hsiRNAs correlates with a decrease in exosome surface charge, which indicates of the amount of 
hsiRNAs bound to the surface of the exosome. 
 
 
Chapter III Engineered RNA for delivery via EVs 
108 
 
Lipid-conjugated hsiRNA-loaded exosomes induce gene silencing in primary mouse neurons  
We next asked whether the change in the charge and perhaps other properties of exosome 
membranes loaded with hsiRNA affect the trafficking of exosomes to target cells. We incubated 
primary mouse neurons with increasing concentrations of exosomes loaded with lipid-conjugated 
hsiRNAHtt for one week and measured Htt mRNA levels (Figure 3.25A). We assigned lipid-
conjugated hsiRNAs to groups based on their hydrophobicity and chose to test only a subset of 
representative hsiRNAs: (i) low hydrophobicity: phosphocholine, lithocholic acid, and 
unconjugated hsiRNAs; (ii) medium hydrophobicity: docosahexaenoic acid; and (iii) high 
hydrophobicity: docosanoic acid, PC-docosanoic acid, cholesterol, PC-cholesterol, α-tocopheryl 
succinate, and PC-tocopheryl succinate. Only lipid-conjugated hsiRNAs with high hydrophobicity 
resulted in a visible pink pellet upon loading (Figure 3.23). Dose-dependent silencing of Htt 
mRNA was observed for medium and high hydrophobicity lipid-conjugated hsiRNAs loaded into 
exosomes (Figure 3.25A). Non-conjugated hsiRNAs or lipid-conjugated hsiRNAs with low 
hydrophobicity did not induce silencing when loaded into exosomes. These results are consistent 
with hsiRNAs levels detected in neurons (Figure 3.26). Medium and high hydrophobic enabled 
the accumulation of 2-6 folds more hsiRNA in neurons than low hydrophobic compounds when 
delivered via exosomes.  
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Figure 3.25 Silencing activity of hsiRNA-loaded exosomes correlates with the loading 
efficiency of hsiRNAs. (A.) Htt mRNA levels in primary mouse neurons incubated with 
increasing concentrations of hsiRNAHtt-loaded exosomes (exosome:hsiRNA ratio = 1:25000) for 
one week. Htt mRNA levels were normalized to Hprt (Hypoxanthine-guanine phosphoribosyl 
transferase), and presented as percent of untreated control (n=3, mean ± SEM). UNT, untreated 
(B.) Correlation between IC50 of hsiRNA-loaded exosomes and loading efficiency of hsiRNAs 
(n=2). 
Figure 3.26 Uptake 
efficiency of hsiRNA loaded 
exosomes by neurons.  
hsiRNAs levels in neurons 
were quantified using PNA 
hybridization assay after 
incubation of neurons with increasing amounts of loaded exosomes for one week. (n=3, mean ± 
SEM).  
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In general, only hydrophobic conjugates that support loading of more than 1000 hsiRNAs 
per vesicle enabled productive silencing (Figure 3.24B). exosomes loaded with lipid-conjugated 
hsiRNAs induced sequence-specific silencing, since exosomes loaded with non-targeting control 
hsiRNAs of similar chemical composition were ineffective (Figure 3.25A). We observed a linear 
correlation between the half-maximal inhibitory concentration (IC50) of hsiRNA-loaded 
exosomes and the amount of loaded hsiRNAs, which defines the activity of hsiRNA-loaded 
exosomes (Figure 3.25B). Thus, hydrophobic conjugates that efficiently load hsiRNAs into 
exosomes induce productive silencing of Htt mRNA in primary neurons. The direct correlation 
between efficiency of loading and silencing indicates that, independent of the structure of the 
conjugate, loaded hsiRNA can induce functional silencing. 
 
3.3.5 Discussion 
 
The simple and scalable loading of cholesterol-conjugated siRNAs provides an attractive 
strategy for loading RNA cargo into exosomes.153-154, 286 We used the principle to expand the range 
of lipid conjugates that can drive efficient loading of therapeutic RNA into exosomes. Notably, 
docosanoic acid and α-tocopheryl succinate, and their PC-derivatives supported siRNA loading 
into exosomes as well as or better than cholesterol. 
Because loading into exosomes is proportional to hydrophobicity, a range of available lipid 
conjugates enables dynamic modulation of RNA cargo levels in exosomes for a range of 
applications. Particle charge may influence pharmacokinetic behavior in vivo or interfere with the 
natural trafficking pathways of exosomes. Titrating the amount of RNA cargo in exosomes will 
therefore be essential to accurately set the charge and function of the vesicle. 
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We expect that exosomes purified from various sources will be loaded by lipid-conjugated 
siRNAs. Indeed, in addition to Wharton’s jelly-derived mesenchymal stem cells (umbilical cord) 
used in this study, we have successfully used cholesterol-conjugated siRNAs to load exosomes 
from U87 glioblastoma cells,286 bEND3 endothelial polyoma cells, bone marrow-derived and 
adipose-derived mesenchymal stem cells. Nevertheless, because hsiRNA loading is driven by 
lipid-conjugate hydrophobicity, the exact level of loading may depend on the specific membrane 
composition and therefore cell source270, 307 of the exosomes. Future work is needed to identify the 
optimal hsiRNA for a given exosome source. 
The structure-activity relationship between lipid conjugates and exosome loading of 
siRNA creates a framework for the rational design of RNA cargo for exosome delivery. The 
covalent lipid-conjugation strategy could be used to load exosomes with other types of therapeutic 
oligonucleotides, including CRISPR guide RNAs or miRNAs. Using lipid-conjugated small RNA 
tethers, the loading of larger oligonucleotide species might also be possible.  
Finally, we observed a correlation between the exosome loading efficiency of hsiRNAs 
and target gene silencing in neurons. We believe that exosomes loaded with lipid-conjugated 
siRNA could be used to deliver therapeutic nucleic acids to recipient cells other than neurons.  
Indeed, exosomes administered by injection efficiently distribute in the brain182, 185, 286, 308 and other 
tissues.134, 136-137, 309 Thus, a simple and scalable method of efficiently loading therapeutic 
oligonucleotides into exosomes is a significant advance toward the treatment of neurodegenerative 
disorders,310 inflammatory diseases,311-312 and cancer.136 
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CHAPTER IV DEVELOPMENT OF A LARGE SCALE EV ISOLATION STRATEGY 
4.1 PREFACE 
 
Text and figures are reproduced from a submitted manuscript 
▪ Haraszti RA, R Miller, M Stoppato, YY Sere, A Coles, MC Didiot, R Wollacott, E 
Sapp, J Leszyk, M Dubuke, S Shaffer, M DiFiglia, Y Wang, N Aronin, A Khvorova. 
Exosomes produced from three-dimensional cultures of mesenchymal stem cells by 
tangential flow filtration show higher yield and improved activity. 
This project was conceptualized by Neil Aronin, Anastasia Khvorova, Yang Wang and me. I 
conducted two-dimensional cultures and EV isolation by differential ultracentrifugation with the 
assistance of Rachael Miller. Matteo Stoppato conducted three-dimensional cell culture and Yves 
Sere isolated EVs via tangential flow filtration with my intellectual guidance. siRNAs were 
synthesized by Dimas Echeverria and duplexed by me. Ellen Sapp and Marian DiFiglia conducted 
transmission electron microscopy. Michelle Dubuke, John Leszyk and Scott Shaffer conducted 
mass-spectrometry for proteomics. Marie Didiot intellectually contributed to establishing loading 
of cholesterol-siRNAs to EVs. Andrew Coles assisted in primary neuron preparations.  I performed 
Nanoparticle Tracking Analysis, Western blotting, Bredford assays, siRNA loading to EVs, 
silencing and live uptake in primary neurons and all data analysis. I wrote this manuscript with the 
assistance of Anastasia Khvorova and Neil Aronin. 
4.2 ABSTRACT 
 
Exosomes can deliver therapeutic RNAs to neurons. The composition and the safety profile of 
exosomes depends on the type of the exosome-producing cell. Mesenchymal stem cells are 
considered to be an attractive cell type for therapeutic exosome production. However, scalable 
methods to isolate and manufacture exosomes from mesenchymal stem cells are lacking, a 
limitation to the clinical translation of exosome technology. We evaluate mesenchymal stem cells 
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from different sources and find that umbilical cord-derived mesenchymal stem cells produce the 
highest exosome yield. To optimize exosome production, we cultivate umbilical cord-derived 
mesenchymal stem cells in scalable microcarrier-based three-dimensional cultures. In combination 
with tangential flow filtration, three-dimensional mesenchymal stem cell cultures yield fifty-fold 
more exosomes (TFF-exosomes) than the conventional methodology of differential 
ultracentrifugation and two-dimensional culture (UC-exosomes). TFF-exosomes are fifteen times 
more potent in siRNA transfer to neurons compared to UC-exosomes. Microcarrier-based three-
dimensional culture and tangential flow filtration allow scalable production of biologically active 
exosomes from mesenchymal stem cells. These findings lift a major roadblock for the clinical 
utility of mesenchymal stem cell exosomes. 
 
4.3 INTRODUCTION 
 
Exosomes are nano-sized (40 to 150 nm) extracellular vesicles are surrounded by a lipid bilayer, 
and are derived from internal cellular compartments313.  Exosomes are released by most cell types 
and are considered to be part of the intercellular communication system, carrying RNAs and 
proteins locally and systemically 132, 138, 180, 182, 314-316. Information transferred via exosomes 
influences the phenotype of recipient cells 134-136, 155, 309, 317.  Stem cell-derived exosomes are 
believed to mediate cellular restorative function 134, 318-319 and to modulate the inflammatory state 
320-326. Due to their unique trafficking characteristics, exosomes are being explored as therapeutic 
RNA delivery vehicles 135-136, 153-155. 
The preclinical and clinical development of exosome technology as a delivery platform 
requires large quantities of exosomes.  The isolation method of exosomes is required to be easily 
expandable to support large-scale manufacturing (e.g. scalable)327-328. Current methods generate 
low yields of exosomes and are not scalable, a situation that so far has impeded studies to evaluate 
preclinical efficacy of exosomes in animals. A dose of 109 to 1011 exosomes administered per 
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mouse is typically used to achieve biological outcomes 134-136, 155. Isolation of this exosome 
quantity requires the processing of liters of conditioned media to treat one animal. Therefore, 
exosome production to support a well-powered animal study can take several months. Exosomes 
are usually purified by size exclusion 329-330 or affinity chromatography 331, or by density gradient 
332-333 or differential ultracentrifugation 204. The gold standard for exosome retrieval, differential 
centrifugation, requires 4 to 5 sequential centrifugation steps. None of these methods is scalable. 
Unlike immortal tumor cells lines, the expansion of mesenchymal stem cells is limited in culture. 
Low yields is exosomes impede the use of mesenchymal stem cells for exosome production, 
We combined the strengths of three production strategies to develop a robust and scalable 
strategy compatible with good manufacturing practices (GMP) for exosome production from 
mesenchymal stem cells. (1) Microcarrier-based three-dimensional cell culture is commonly used 
to grow adherent cells in bioreactors334.  (2) Tangential flow filtration is a method to concentrate 
proteins or viruses from large amount of cell culture media335-337. (3) Xenofree (i.e. not containing 
animal-derived material) medium is typically used to manufacture cell therapies338. The 
physicochemical characteristics of exosomes produced by three-dimensional cultures in xenofree 
medium and tangential flow filtration were compared to those of exosomes produced by traditional 
two-dimensional cultures and differential ultracentrifugation. Compared to standard methods, we 
show that three-dimensional culture, xenofree medium and tangential flow filtration yielded 50-
fold more exosomes and that these exosomes were 15-fold more active in their ability to transfer 
therapeutic siRNAs to primary neurons. Thus, the method reported here advances the yield of 
mesenchymal stem cell exosomes and enables their preclinical exploration. 
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4.4 RESULTS 
 
Wharton’s jelly-derived mesenchymal stem cells produce the most exosomes 
To develop a scalable method for exosome production suitable for manufacturing, we compared 
exosome yields and doubling times of mesenchymal stem cells derived from common sources: 
bone marrow, adipose tissue, and umbilical cord Wharton’s jelly (i.e., connective tissue of 
umbilical cord). Umbilical cord mesenchymal stem cells are distinct from cord blood 
hematopoietic stem cells. In traditional plastic flask-based cultures, umbilical cord mesenchymal 
stem cells grew faster (~3 day doubling time) than mesenchymal stem cells from bone marrow or 
adipose tissue (~7 day doubling time). Umbilical cord mesenchymal stem cells yielded four times 
as many exosomes per cell than did mesenchymal stem cells from bone marrow (p=0.0063) or 
adipose tissue (p=0.006) (Figure 4.1A). Exosomes derived from umbilical cord mesenchymal 
stem cells were also larger (140±18 nm) than exosomes from bone marrow (116±9 nm, p=0.01) 
and adipose tissue (105±12 nm, p=0.0004) mesenchymal stem cells (Figure 4.1B). Based on their 
availability, favorable doubling time, and high yield of exosomes per cell, we used umbilical cord 
mesenchymal stem cells for the development of a scalable exosome isolation method. 
Figure 4.1 Umbilical 
cord mesenchymal stem 
cells yield the most 
exosomes.  
(A) Yield of exosomes 
isolated by differential ultracentrifugation from mesenchymal stem cells derived from umbilical 
cord (U-MSC), bone marrow (BM-MSC), or adipose (A-MSC). Yield calculated as the number of 
exosomes in the isolated sample measured by Nanoparticle Tracking Analysis divided by the 
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number of cells in the source cultures. Results of 7 experiments shown, with mean ± SD, one-way 
ANOVA. (B) Average sizes of U-MSC, BM-MSC, or A-MSC exosomes purified in (A). 
 
Three-dimensional culture and tangential flow filtration enhances exosome yield 
Large-scale cell culture is a prerequisite for exosome production on a manufacturing scale. 
Exosomes are standardly concentrated by differential centrifugation of conditioned media from 
two-dimensional adherent cell cultures in plastic flasks (Figure 4.2A). From two-dimensional 
cultures of adherent umbilical cord mesenchymal stem cells grown in three-layer plastic culture 
flasks, we typically obtain a density of 20,000 cells/cm2 at confluence. To increase the expansion 
of umbilical cord mesenchymal stem cells, we used microcarrier-based three-dimensional 
culture—a strategy commonly used for large-scale culture of adherent cells334. Cells are grown on 
the surfaces of spherical support matrix beads and distributed in medium by stirring in a spinner 
flask (Figure 4.2B). In this three-dimensional culture system, umbilical cord mesenchymal stem 
cells reached 40,000 cells/cm2, double the density obtained in two-dimensional cultures. 
Figure 4.2 Scheme of 
mesenchymal stem cell 
culturing methods and 
exosome isolation methods.  
(A) Schematic of flask-based 
(two-dimensional) 
mesenchymal stem cell 
culture and isolation of 
exosomes by differential ultracentrifugation. (left) Cells are cultured in triple-layer flasks in 
mesenchymal basal medium to a density of 20,000 cells/cm2. (right) Exosomes are enriched from 
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culture supernatants by sequential ultracentrifugation, with filtration and wash steps, as indicated. 
(B) Schematic of microcarrier-based (three-dimensional) MSC cultures and isolation of exosomes 
by tangential flow filtration. (left) Cells are cultured on microcarriers in serum-free/GMP-
compatible medium in 250-ml spinner flasks to ~40,000 cells/cm2. (right) Exosomes are enriched 
from culture supernatants by tangential flow filtration using a 500-kDa cutoff cartridge, as 
indicated. 
 
Differential ultracentrifugation of exosomes relies on their vesicle size and sedimentation 
properties. Sequential centrifugation steps with increasing force of centrifugation deplete the 
conditioned medium from large particles and/or vesicles with high sedimentation rates. A final 
ultracentrifugation step sediments small vesicles or exosomes, leaving the smaller proteins in the 
supernatant204. We adapted this method to include 300 × g, 10,000 × g and 100,000 × g 
centrifugation steps (Figure 4.2A), a filtration step through a 200-nm pore size membrane, and a 
wash step135.  
Tangential flow filtration is a concentration and buffer exchange strategy used during 
large-scale manufacturing of biologics 335-336 and viruses 337. In this method, a pump circulates the 
conditioned culture medium through membranes or filters with pores that are sized for a specific 
application. Particles that are smaller than the pore size pass through and are removed from the 
system (e.g. permeate). Larger particles than the pore size are withheld in the lumen of the fibers 
(e.g. retentate) and circulated back into the product. Multiple rounds of the ultrafiltration step lead 
to efficient particle concentration. In particular, we first passed the conditioned cell culture 
supernatant through a 200-nm pore size membrane to remove large vesicles and particles (Figure 
4.2B). The filtered conditioned medium was subjected to tangential flow filtration using a hollow 
fiber filter with a 500-kDa molecular weight cutoff (MWCO) and concentrated 9-fold (volume 
reduced 9-fold). In the next step the cell culture medium was exchanged with phosphate-buffered 
saline (PBS), by continuously feeding the system with PBS to replace the loss of permeate. The 
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final product was sterile filtered using 200 nm filter, resulting in a filtrate that contains exosomes 
in PBS (Figure 4.2B). 
We compared exosomes produced in microcarrier-based three-dimensional cultures in 
xenofree medium and isolated by tangential flow filtration (TFF-exosomes) and exosomes 
produced in conventional two-dimensional culture and isolated by differential ultracentrifugation 
(UC-exosomes). TFF-exosomes and UC-exosomes were similar in size (100 to 200 nm), with the 
same mean size, though TFF-exosomes were more heterogenous in size than UC-exosomes 
(Figure 4.3A-B). TFF-exosomes and UC-exosomes were structurally similar by electron 
microscopy (Figure 4.3C), and both contained exosomal marker proteins (Figure 4.3D). The main 
difference between TFF- and UC-exosomes was yield and protein-to-vesicle ratio. Tangential flow 
filtration yielded ~50-fold more exosomes than differential ultracentrifugation (Figure 4.3E). In 
addition, TFF-exosomes had a 10-fold higher protein-to-vesicle ratio than UC-exosomes (Figure 
4.3F).  
Figure 4.3 
Characterization of 
exosomes.  
(A) Size distribution of 
exosomes isolated by 
differential 
ultracentrifugation (UC, 
solid) or tangential flow 
filtration (TFF, dashed). 
Concentration and size 
of exosomes were 
measured by Nanoparticle Tracking Analysis. UC exosomes purified from two-dimensional 
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cultures, and TFF exosomes purified from three-dimensional cultures. (B) Average size of 
exosomes isolated by UC (N=6) or TFF (N=4) plotted, showing the mean ± SD of all 
measurements, Student’s t-test. (C) Transmission electron microscopy images of exosomes 
isolated by UC or TFF. 
 
Proteomics analyses showed that 66% of TFF-exosome proteins were present in UC-
exosomes, and 82% of UC exosome proteins were present in TFF exosomes (Figure 4.4A). In 
addition, TFF-exosomes contained 62 high-abundance proteins (34% of all TFF-exosome 
proteins) not present in UC-exosomes, and UC-exosomes contained 484 low-abundance proteins 
(18% of UC exosomes proteins) (Figure 4.4A). Proteins unique to TFF-exosomes were smaller 
(48±27 kDa) than proteins present in both (73±75 kDa, p=0.049) or proteins unique to UC-
exosomes (80±80 kDa, p=0.0048) (Figure 4.4B). Gene ontology analysis revealed that proteins 
unique to TFF-exosomes were enriched in secreted proteins (in particular albumin), lipoproteins, 
immunoglobulins, and complement (Figure 4.4C). Proteins present in both TFF- and UC-exosome 
types were enriched in integrin binding, heparin binding, ribosomal, and generally extracellular 
exosomal proteins (Figure 4.4C). These findings suggest (i) that TFF- and UC-exosomes have a 
similar protein composition, and (ii) that high levels of secreted proteins are responsible for higher 
protein-to-vesicle ratio in TFF-exosome samples. 
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Figure 4.4 Proteomic 
content of exosomes.  
(A) Schematic summary 
of proteomic studies 
showing percent of total 
protein content specific 
(solid) or common 
(opaque gray overlay 
between vertical dashed 
lines) to UC (blue) and TFF (orange) exosome preparations. The number of unique proteins in 
each category charted below. Protein content was determined by intensity-based absolute 
quantification (iBAQ) analysis 256. (B) Size distribution of proteins specific to or unique to UC-
exosomes and TFF-exosomes, from panel (A), one-way ANOVA. (C) Gene ontology analysis of 
proteins shared or unique to UC-exosomes and TFF-exosomes, from panel (A). 
 
TFF-exosomes deliver siRNA to neurons better than UC-exosomes 
Exosome integrity is essential for biological activity and is therefore a major requirement for the 
development of large-scale isolation methods. We have previously shown that UC-exosomes can 
efficiently deliver therapeutic siRNAs to primary neurons 135. Loading of cholesterol-conjugated, 
fully chemically modified siRNAs into exosomes is efficient, fast, easily scalable, and supports 
potent mRNA silencing in recipient cells (Haraszti et al, in review). We therefore compared the 
ability of TFF-exosomes and UC-exosomes to deliver Huntingtin siRNA to neurons, using 
Huntingtin silencing as a readout for efficient neuronal delivery.  
Seven days after treatment, we found that TFF-exosomes were ~15-fold more efficient at 
siRNA transfer and Huntingtin silencing in neurons compared to UC-exosomes (TFF IC50, ~8 
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nM; UC IC50 ~122 nM; p<0.0001) (Figure 4.5A). To address whether the increased potency 
reflects better vesicle uptake or increased biological availability of internalized siRNAs, neurons 
were treated with both types of exosomes loaded with equal amounts of fluorescently labeled 
siRNAs. Neurons internalized TFF-exosomes faster (9 minutes half-life) than UC-exosomes (2 
hours half-life) (p<0.0001) (Figure 4.5B). In addition, total fluorescence was higher in primary 
neurons treated with TFF-exosomes (Figure 4.5B). These findings suggest that enhanced 
trafficking of TFF-exosomes into neurons likely underlies their ability to support more efficient 
silencing. 
Figure 4.5 TFF-
exosomes are more 
efficient at delivering 
siRNAs to neurons.  
(A) Dose response 
analysis showing 
Huntingtin (Htt) mRNA 
levels in mouse primary neurons treated with UC (solid) or TFF (dashed) exosomes containing the 
indicated doses of siRNA. Each data point represents the mean ± SEM of N=3 experiments, each 
experiment was run in duplicates. UNT= untreated, two-way ANOVA. (B) Time course of 
fluorescence in primary neurons treated with UC (solid) or TFF (dashed) exosomes containing 
Cy3-labeled siRNA. Each data point represents the mean ± SEM of 5 images per timepoint, two-
way ANOVA. 
  
Chapter IV Development of a large scale EV isolation strategy 
122 
 
4.5 DISCUSSION 
 
The development of exosomes as therapeutic delivery vehicles requires production and 
purification methods compatible with good manufacturing practices (GMP). Three-dimensional 
culture systems, xenofree medium and tangential flow filtration are suitable for GMP-grade 
biologics335-337, 339. Here we show that three-dimensional xenofree cultures of umbilical cord 
mesenchymal stem cells and tangential flow filtration of the conditioned supernatants produced 
substantially higher yields of exosomes than standard two-dimensional culture and 
ultracentrifugation. Whereas TFF- and UC-prepared exosomes have similar size distributions and 
protein contents, TFF-exosomes are more efficient at siRNA delivery to neurons and at inducing 
mRNA silencing. 
The differences in protein-to-vesicle ratios as well as in activity between TFF- and UC-
exosomes probably reflect differences in their production and preparation methods. The high 
protein-to-vesicle ratio in TFF-exosome preparations might result from protein aggregates that 
form in GMP-compatible xenofree medium used for three-dimensional cultures. Optimization of 
xenofree culture and purification conditions will undoubtedly be required to identify and generate 
exosomes with desired protein content and protein-to-vesicle ratios. Thus, the functional difference 
between exosomes prepared by tangential flow filtration and differential ultracentrifugation likely 
reflects physical differences in the preparation methods. The high centrifugal forces applied to 
exosomes may damage the integrity of exosomal membranes 330 and thus compromise cellular 
uptake 137. The gentler tangential flow filtration is widely used to purify biologics and viruses, 
which are highly sensitive to structural alterations.  
Cell culture conditions and exosome isolation methods should be developed together to 
advance exosome technology. Therapeutic virus production might serve as an example for 
exosome technology development340. Though we use umbilical-cord derived mesenchymal stem 
cells, the cell culture and exosome isolation methods described here should work for other cell 
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sources. Quality control steps for large scale exosome production need to be worked out in detail 
based on published recommendations for small-scale exosome isolation methods 306, 341. Protein-
to-exosome ratio should be considered as part of the quality control protocols327.  
Genetic interference strategies are being developed into promising therapeutic drugs to 
treat genetically defined diseases. Here we used delivery of Huntingtin siRNAs and silencing as a 
readout for exosome activity produced at a large scale. We speculate that exosomes produced from 
microcarrier-based three-dimensional xenofree cultures by tangential flow filtration will prove 
useful as delivery vehicles for other therapeutic oligonucleotides that target numerous diseases: 
siRNAs, antisense oligonucleotides, and CRISPR guide RNAs. The effective, scalable exosome 
isolation method described here will facilitate the successful transition of the exosome technology 
to clinical applications. 
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CHAPTER V EV CHARACTERIZATION 
5.1 PREFACE 
 
Figures and text are reproduced from a scientific article 
▪ Haraszti RA, Didiot MC, Sapp E, Leszyk J, Shaffer SA, Rockwell HE, Gao F, Narain 
NR, DiFiglia M, Kiebish MA, Aronin N, Khvorova A. High-resolution proteomic and 
lipidomic analysis of exosomes and microvesicles from different cell sources. J 
Extracell Vesicles. 2016 Nov 17. 
 
Anastasia Khvorova and I conceptualized this project. Ellen Sapp and Marian DiFiglia performed 
transmission electron microscopy. John Leszyk and Scott Shaffer performed mass spectrometry 
for proteomics. Hannah Rockwell and Michael Kiebish performed mass spectrometry for 
lipidomics. Marie Didiot established EV isolation protocols. I isolated all EVs, prepared short gels 
for proteomics, transported samples for mass spectrometry analysis, analyzed all data and 
performed Western blotting. Anastasia Khvorova and I wrote this manuscript. 
 
5.2 ABSTRACT 
 
Extracellular vesicles (EVs), including exosomes and microvesicles, are explored for use 
in diagnostics, therapeutics and drug delivery. However, little is known about the relationship of 
protein and lipid composition of EVs and their source cells. Here, we report high-resolution 
lipidomic and proteomic analyses of exosomes and microvesicles derived by differential 
ultracentrifugation from three different cell types: U87 glioblastoma cells, Huh7 hepatocellular 
carcinoma cells, and human bone marrow-derived mesenchymal stem cells (MSC). We identified 
3532 proteins and 1961 lipid species in the screen. Exosomes differed from microvesicles in 
several different areas: (i) The protein patterns of exosomes were more likely different from their 
cells of origin than were the protein patterns of microvesicles; (ii) The proteomes of U87 and Huh7 
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exosomes were similar to each other but different from the proteome of MSC exosomes, whereas 
the lipidomes of Huh7 and MSC exosomes were similar to each other but different from the 
lipidome of U87 exosomes; (iii) Exosomes exhibited proteins of extracellular matrix, heparin 
binding, receptors, immune response, and cell adhesion functions, whereas microvesicles were 
enriched in endoplasmic reticulum, proteasome and mitochondrial proteins. Exosomes and 
microvesicles also differed in their types of lipid contents. Enrichment in glycolipids and free fatty 
acids characterized exosomes, whereas enrichment in ceramides and sphingomyelins characterized 
microvesicles. Furthermore, Huh7 and MSC exosomes were specifically enriched in cardiolipins; 
U87 exosomes were enriched in sphingomyelins. This study comprehensively analyzes the protein 
and lipid composition of exosomes, microvesicles and source cells in three different cell types.  
 
5.3 INTRODUCTION 
 
Extracellular vesicles occur in most bodily fluids and cell culture supernatants. With the 
advent of parallel sequencing technologies, the RNA content of EVs is being heavily investigated 
as a new type of diagnostic biomarker 342. The RNA contents of EVs from a variety of bodily 
fluids, including urine, saliva, blood, and cerebrospinal fluid, have been explored as biomarkers 
for indications throughout the body 343-349. EVs as tumor biomarkers are especially valuable, since 
bodily fluid EVs provide an alternative to repeated biopsies for continuous monitoring and an 
option for tumors inaccessible to biopsies (i.e. brain tumors). Extracellular vesicles are also being 
explored as natural carriers of therapeutic RNAs 350-351. EVs for therapeutic applications are 
typically derived from mesenchymal stem cells, a cell type well characterized for cell-based 
therapies 341, 351.  
Two EV subgroups in particular, exosomes and microvesicles (MVs), have the ability to 
carry biomarkers or therapeutic RNA. Exosomes are small vesicles (traditionally considered 50-
150 nm) that originate from endocytic compartments within the cell. During endosome maturation, 
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intraluminal vesicles are formed by endosomal membrane budding inside multivesicular bodies, 
and intraluminal vesicles become exosomes upon the exocytosis of multivesicular bodies 313. 
Compared to exosomes, microvesicles are larger vesicles (traditionally considered 200-1000 nm) 
and are formed by budding directly from the plasma membrane 352. Available purification methods 
include separation based on size (differential ultracentrifugation 204 and ultrafiltration 353), density 
(OptiPrepTM 332, sucrose 333), floatation velocity 354, immunoaffinity 331 and PEG-based 
precipitation 353. These strategies enrich EVs within certain size ranges but are not able to fully 
separate EV subgroups, resulting in mixed EV populations in the isolates 355. The purification 
strategy defines the nature of EV subgroup mixture in the isolate, which in turn will determine its 
biological function and biochemical properties. Furthermore, EV purification strategies can co-
isolate non-vesicular extracellular proteins and lipoprotein particles with EVs.  
The protein and lipid composition of EVs from various sources have been studied via 
biochemical assays and mass spectrometry 356-369 and provide a robust basis for protein biomarker 
identification in EVs for research quality control purposes. Exosomal isolates commonly contain 
membrane proteins, specifically tetraspanins, as well as various amounts of extracellular matrix 
proteins; they are devoid of nuclear proteins332. Microvesicular isolates may contain proteins of 
mitochondrial or endoplasmic reticulum origin332. A detailed understanding of the biochemical 
(protein and lipid) composition of EV subgroups and the extent to which EV composition reflects 
source cell composition is necessary for further development into diagnostics and therapeutics. To 
address this question, we performed a comparative analysis of the protein and lipid composition 
of two EV subgroups and their source cells. We chose a glioblastoma (U87) and a hepatocellular 
carcinoma (Huh7) cell line, since the EVs of these tumor types are in the focus of interest for 
diagnostic biomarker development347, 370. We further chose bone marrow-derived mesenchymal 
stem cells (MSC), since this cell type is frequently used for therapeutic vesicle production351. For 
EV purification, we sought a strategy that would not introduce bias into the composition of EV 
isolates (unlike immunoaffinity-based purification), would not co-enrich non-vesicular 
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extracellular proteins (unlike PEG-precipitation) 353 and would provide sufficient yield for mass 
spectrometric measurement. Differential ultracentrifugation is considered the gold standard of EV 
purification and met the above requirements.  
5.4 RESULTS 
 
We sought to characterize the protein and lipid composition of exosomes and microvesicles 
and to determine whether protein and lipid content depends on source cell type. Although it does 
not provide full separation of microvesicles and exosomes, differential ultracentrifugation is 
currently the gold standard method of EV purification 204. Hence, for the purposes of this 
publication, we will refer to the 10 000 g pellet as microvesicles, and to the 100 000 g pellet as 
exosomes (Figure 5.1). We purified exosomes and microvesicles from the conditioned cell media 
of U87, Huh7 and MSC cells (Figure  5.1). As expected, exosomes were relatively homogenous 
with an average diameter of approximately 135 nm (50 to 200 nm; Figure  5.1A). Microvesicles, 
however, were more heterogeneous in size (50 to 600 nm). We then analyzed the protein content 
of EVs and source cells by liquid chromatography followed by tandem mass spectrometry (LC-
MS/MS) and the lipid content using an information-independent acquisition method known as 
MS/MSALL 208. Protein and lipid contents of EVs from each cell type were compared to the total 
protein and lipid contents of the respective source cell type in downstream analyses (Figure  5.1). 
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Figure 5.1 Workflow of EV preparation and 
Mass Spectrometry.  Mesenchymal Stem 
Cells (MSC), glioblastoma cells (U87) and 
hepatocellular carcinoma cells (Huh7) were 
cultured and EVs prepared on six different days 
by differential ultracentrifugation. Resulting 
samples (cells, microvesicles and exosomes, 
altogether 54 samples) were subjected to 
proteomic (27 samples, LC-MS/MS) and 
lipidomic (27 samples, MS/MSALL) analysis. 
Proteins were quantified by the label-free quantification method iBAQ (intensity-based absolute 
quantification, see details in Methods). Analysis detected 3531 proteins and 1961 lipid species 
(defined by headgroup identity, length, saturation and number of fatty acid tails) in 22 lipid classes 
(defined by headgroup identity). Level of proteins and lipids in exosomes and microvesicles were 
later normalized to their respective source cells and expressed on a log(2) scale. 
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Figure 5.2 Quality control of EV 
preparations. (A) Representative 
size distribution profiles of EVs from 
three different cell sources as 
obtained by Nanoparticle Tracking 
Analysis (NanoSight NS300, 
Malvern). Microvesicles were more 
heterogenous in size independently 
of cell source. (B) EVs are depleted 
in proteins of nuclear or Golgi origin. 
Origin of proteins identified by 
Scaffold Proteome Software. (C) 
Enrichment of exosomal marker proteins in EVs. Fold change of proteins in EVs versus source 
cells is color-coded on a log(2) scale. Enrichment of established protein markers in exosomes was 
source cell type dependent and most exosomal markers were, although to a lower extent, also 
enriched in microvesicles.  
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Figure 5.3 Isolates purified by differential 
ultracentrifugation are bona fide extracellular 
vesicles. (A) Transmission electron microscopy 
images show that all isolates consisted of vesicles 
surrounded by bilayer membranes. Scale bar 
represents 500 nm. (B) Western blot analysis of EV 
isolates. Calnexin is present in cells and 
microvesicles but absent from exosomes. CD9 and 
CD81 are enriched in all EVs but enrichment level is 
higher in exosomes. CD63 is present in all EVs, but 
only enriched in U87 and Huh7 vesicles, where it 
maintains a higher enrichment level in exosomes than 
in microvesicles. Tsg101 was only detected in U87, where it was enriched in exosomes. 
Exosomes differ from microvesicles in protein composition 
To assure that we purified bona fide extracellular vesicles, we confirmed membrane-
surrounded vesicular structures in all the EV isolates on EM (Figure 5.3) and investigated the 
presence of known exosomal marker proteins and absence of non-vesicular proteins in our EV 
preparations. As expected, nuclear and Golgi-resident proteins were few or absent from 
microvesicles and exosomes (Figure 5.2B), while the ER marker calnexin was absent from 
exosomes but present in microvesicles (Figure 5.3B). Enrichment of EV marker proteins showed 
significant source cell type dependence. Traditional exosome markers CD81 and CD9 268 were 
enriched in both exosomes and microvesicles, with level of enrichment being higher in exosomes 
(Figure 5.2C and Figure 5.3B). CD63 enrichment was specific to U87 and Huh7 exosomes, while 
Tsg101, PDCD6IP (Alix) and CD82 were only enriched in U87 exosomes (Figure 5.2C and 
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Figure 5.3B). Flotilin 1 and Tetraspanin 4 were highly enriched in all U87 and Huh7 EVs, while 
PLP2 enrichment was unique to MSC MVs (Figure 5.2C). The immunoblot of individual protein 
markers corresponded well with label free quantification of proteomics.  Generally, 91% of top 
EV marker proteins (n = 100; ExoCarta 371) were present in our EV samples (Table 5.1).  
Gene Symbol Number of times identified (ExoCarta) Present in EV samples of current study 
CD9 98 all samples 
PDCD6IP 96 all samples 
HSPA8 96 all samples 
GAPDH 95 all samples 
ACTB 93 all samples 
ANXA2 83 all samples 
CD63 82 all samples 
SDCBP 78 all EV samples 
ENO1 78 all samples 
HSP90AA1 77 all samples 
TSG101 75 yes, except Huh7 MV and MSC exo 
PKM 72 all samples 
LDHA 72 all samples 
EEF1A1 71 all samples 
YWHAZ 69 all samples 
PGK1 69 all samples 
EEF2 69 all samples 
ALDOA 69 all samples 
HSP90AB1 67 all samples 
ANXA5 67 all samples 
FASN 66 all samples 
YWHAE 65 all samples 
CLTC 64 all samples 
CD81 64 all samples 
ALB 63 all samples 
VCP 62 all samples 
TPI1 62 all samples 
PPIA 62 all samples 
MSN 62 all samples 
CFL1 62 all samples 
PRDX1 61 all samples 
PFN1 61 all samples 
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RAP1B 60 all samples 
ITGB1 60 all samples 
HSPA5 58 all samples 
SLC3A2 57 all samples 
HIST1H4A 57 all samples 
GNB2 57 yes, except MSC exo 
ATP1A1 57 all samples 
YWHAQ 56 all samples 
FLOT1 56 all EV samples 
FLNA 56 all samples 
CLIC1 56 all samples 
CCT2 56 all samples 
CDC42 55 all samples 
YWHAG 54 all samples 
A2M 54 all EV samples 
TUBA1B 53 none, instead TUBA4A is present in all samples 
RAC1 53 all samples 
LGALS3BP 53 only in MSC exo, U87 exo and U87 MV 
HSPA1A 53 all samples 
GNAI2 53 all EV samples 
ANXA1 53 all samples 
RHOA 52 all samples 
MFGE8 52 all EV samples 
PRDX2 51 all samples 
GDI2 51 all samples 
EHD4 51 all samples 
ACTN4 51 all samples 
YWHAB 50 only in Huh7 MV, MSC MV, U87 exo and U87 MV 
RAB7A 50 all samples 
LDHB 50 all EV samples 
GNAS 50 all samples 
RAB5C 49 all samples 
ARF1 49 all samples 
ANXA6 49 all samples 
ANXA11 49 all samples 
ACTG1 49 none 
KPNB1 48 yes, except MSC exo 
EZR 48 all samples 
ANXA4 48 all samples 
ACLY 48 all samples 
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TUBA1C 47 none 
TFRC 47 all samples 
RAB14 47 all samples 
HIST2H4A 47 none 
GNB1 47 all samples 
THBS1 46 yes, except U87 MV 
RAN 46 none 
RAB5A 46 all samples 
PTGFRN 46 yes, except MSC MV 
CCT5 46 all samples 
CCT3 46 all samples 
AHCY 46 all samples 
UBA1 45 all samples 
RAB5B 45 all samples 
RAB1A 45 none 
LAMP2 45 all samples 
ITGA6 45 all EV samples 
HIST1H4B 45 none 
BSG 45 all samples 
YWHAH 44 all samples 
TUBA1A 44 none 
TKT 44 all samples 
TCP1 44 all samples 
STOM 44 all EV samples 
SLC16A1 44 all samples 
RAB8A 44 none 
MYH9 44 all samples 
MVP 44 yes, except Huh7 MV 
 
Table 5.1 List of EV-enriched proteins. 
 
Pairwise Pearson’s correlation of protein levels (iBAQ scores) revealed that exosomes 
were more different from source cells (R2 < 0.1) than microvesicles were (R2 = 0.28 to 0.66). 
Exosomes also differed from microvesicles (R2 < 0.2) (Figure 5.4A). Hence, exosomes and 
microvesicles displayed a very different protein profile, despite overlap in their size range (Figure 
5.4A).  
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Figure 5.4 Protein and lipid 
sorting into EVs are not linked. 
Pairwise Pearson’s correlations 
of protein and lipid levels in cells, 
microvesicles and exosomes 
derived form three source cell 
types.  Numbers represent R2. (A) 
Microvesicular proteome was 
more similar to the source cell 
than the exosomal proteome was 
in all three cell types investigated. 
(B) Cancer cell derived 
proteomes (U87 and Huh7) were 
increasingly similar to each other 
and increasingly different form 
stem cell proteome (MSC) while 
moving from cells towards 
microvesicles and exosomes. (C) Principal component analysis of protein levels in exosomes 
(round) and microvesicles (square) normalized to their respective source cell.  MSC derived 
exosomes and microvesicles segregate from cancer cell EVs. (D) Lipidomes of exosomes, 
microvesicles and source cells are more similar to each other than their proteomes are. (E) Huh7 
and MSC lipidomes showed increasing level of similarity moving from source cells to 
microvesicles to exosomes. (F) Principal component analysis of lipid levels in exosomes (round) 
and microvesicles (square) normalized to their respective source cell.  MSC and Huh7 derived EVs 
increasingly cluster together and segregate from U87 moving from microvesicles to exosomes. 
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Exosomal proteomes effectively distinguish between cancer origin and mesenchymal stem 
cell origin 
Huh7 and U87 exosomes had similar protein compositions (R2=0.8), despite poor correlations 
between MV (R2=0.23) and source cell (R2=0.37) protein levels (Figure 5.4B). These data 
suggested that exosomal proteome was similar between source cell types, whereas microvesicle 
proteome differed between source cell types. However, MSC exosomes markedly differed from 
U87 and Huh7 exosomes (R2=0.035 and 0.004). Furthermore, this contrast could not be explained 
by the difference in source cell protein compositions (MSC to U87 R2=0.57 and MSC to Huh7 
R2=0.28). To look at cell type specific protein enrichment in EVs, we normalized EV protein levels 
(iBAQ scores) to their respective source cell type’s protein levels. Then we used principal 
component analysis to determine whether source cell type affected which proteins were enriched 
in EVs. Indeed, MSC-derived exosomes and microvesicles clustered very close together and 
clearly segregated from U87 and Huh7 vesicles (Figure 5.4C).  
Overrepresented protein pathways depend on vesicle type 
To compare functional content of exosomes and microvesicles, we conducted Gene Ontology 
(GO) analysis on the list 719 proteins present in exosomes from all three cell types (n=719) and 
the 1357 proteins present in microvesicles from all three cell types using DAVID version 6.7 209-
210 (NIH) (Figure 5.5A). Gene Ontology is a knowledgebase where genes are assigned to 
molecular functions, cellular components or biological processes (GO terms). GO analysis tests, 
whether the representation of GO terms in a specific set of genes could be explained by random 
chance or does it enrich for certain GO terms. We found that exosomes and microvesicles were 
both enriched in vesicle proteins, membrane-associated proteins, and GTPases 355 (Figure 5.5B). 
Both exosomes and microvesicles also enriched for translation and glycolysis pathways.  
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Figure 5.5 
Overrepresented 
protein pathways 
depend on vesicle type.  
(A) Venn diagrams of 
detected proteins in 
exosomes and 
microvesicles of three 
different source cell types. 
MSC EVs had a lower 
diversity of proteins. (B) 
Proteins shared among 
exosomes or microvesicles derived from all three source cell types (middle section in the Venn 
diagrams) underwent Gene Ontology analysis. The negative logarithm of p values is shown for 
each GO term, colorful lines represent significance threshold (p=0.05). Common (depicted in 
black), as well as distinct (depicted in color) pathways emerged in exosomes versus microvesicles.  
Meanwhile, certain GO terms were differentially enriched in exosomes and microvesicles. 
Extracellular matrix, receptors, heparin-binding, phospholipid-binding, integrin, immune 
response, and cell adhesion functions were characteristic for exosomes, whereas mitochondrial, 
endoplasmic reticulum, and proteasomal functions were exclusive to microvesicles (Figure 5.5B).  
To examine how cell type influences protein enrichment in EVs, we normalized EV protein 
content (iBAQ values) to the respective source cell protein content and performed unsupervised 
cluster analysis, which revealed nine clusters described below (Figure 5.6).  
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Figure 5.6 Heatmap of all 
protein levels in EVs 
normalized to their respective 
source cells. iBAQ values of 
proteins in EVs were 
normalized to the corresponding 
protein levels in source cells, 
expressed on a log(2) scale and 
color-coded. Depletion is 
depicted in blue and enrichment 
in red. Clusters from heatmap 
underwent Gene Ontology 
analysis, and terms significantly enriched are shown on the right.  
Clusters 1, 7, and 8: Proteins in clusters 1, 7, and 8 were depleted from vesicles of U87 
cells, Huh7 cells, or both, and absent of all MSC samples. These clusters comprised nuclear 
proteins, consistent with quality control experiments showing the depletion of nuclear proteins 
(Figure 5.2B). 
Cluster 2: Proteins in cluster 2 were depleted from exosomes but not from microvesicles. 
This cluster consisted of proteins that function in mitochondria or endoplasmic reticulum, 
consistent with the microvesicle-specific GO terms we identified above (Figure 5.5) and with an 
analysis of the relative abundance of endoplasmic reticulum and mitochondrial marker proteins 
(Figure 5.7). 
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Figure 5.7 Exosomes are depleted in mitochondrial 
and endoplasmic reticulum marker proteins, 
whereas microvesicles are not. Mitochondrial and ER 
marker protein levels in EVs were normalized to the 
respective source cell. Origin of proteins identified by 
Scaffold Proteome Software. 
 
 
 
 
Clusters 3 and 9: Proteins in clusters 3 and 9 were enriched or unchanged in EVs 
regardless of cell type or vesicle type. These clusters consisted of membrane proteins, vesicular 
proteins, extracellular matrix, heparin-binding, cell adhesion and blood coagulation pathways. 
Furthermore, Gene Ontology analysis detected enrichment in certain protein motifs (e.g., EGF-
like domain) and post-translational modifications (e.g., disulfide bonds and glycosylation), 
consistent with the enrichment of membrane proteins. We did not observe an enrichment of 
proteins known to be palmitoylated, a posttranscriptional modification that has been shown to 
direct protein accumulation in exosomes 146.  
Clusters 5 and 6: Proteins in clusters 5 and 6 were enriched in vesicles of Huh7 (cluster 
5) or U87 (cluster 6) cells. Huh7-specific cluster 5 consisted of proteins involved in exocytosis, 
whereas U87-specific cluster 6 included endocytosis pathway proteins. These observations show 
source cell-dependent EV content, which may suggest source cell-dependent exosome production 
and maturation mechanisms. When focusing on two protein classes, vesicular trafficking regulator 
Rabs (Figure 5.8) and EV organotropism regulator integrins137 (Figure 5.9), source cell influence 
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on EV content is particularly clear. Endocytotic Rab34 and Rab23 were highly enriched in U87 
exosomes, retrograde transport Rab9 and Rab6 were enriched in Huh7 exosomes, and exocytotic 
Rab27 was enriched in MSC exosomes (Figure 5.8). While integrin β3 was enriched in all EVs 
except Huh7 microvesicles, integrins α2b (indicated in lung-tropism137) and α6 were specific to 
MSC EVs, integrins α1, α2 and α5 were characteristic to Huh7 EVs, and integrins α3, α7, αV 
(liver-tropic137), β1 (lung-tropic137) and β5 (liver-tropic137) were characteristic to U87 EVs (Figure 
5.9). 
Figure 5.8 Rab protein enrichment in 
EVs depends on source cell type. 
Heatmap shows enrichment (red) or 
depletion (blue) of Rab proteins in EVs 
relative to source cells (log(2) scale). Rab 
proteins are involved in vesicle trafficking 
and their enrichment in EVs clearly 
depends on source cell type.  
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Figure 5.9 Integrin enrichment in EVs 
depends on source cell type. Heatmap 
shows enrichment (red) or depletion (blue) 
of integrins in EVs relative to source cells 
(log(2) scale). On the left organotropism 
associated so some of the integrins137 are 
depicted.  
 
 
Lipid and protein enrichment in EVs are not linked  
MS/MSALL analysis identified 22 lipid classes (defined by headgroup) and almost 2000 
lipid species (defined by headgroup, fatty acid tail length and saturation) across all samples. Lipid 
content was more similar between samples (R2 = 0.41 to 0.93) than was protein content (R2 = 0.004 
to 0.66) (Figure 5.4D-E). Surprisingly, lipid enrichment in EVs did not follow the pattern of 
protein enrichment we observed earlier (Figure 5.4A-C): lipid content of U87 and Huh7 exosomes 
was different (R2=0.47), despite their protein content being very similar (R2=0.8) (Figure 5.4B 
and 5.4E). Instead, lipid composition of Huh7 and MSC exosomes showed striking similarity 
(R2=0.93). This similarity was present, although less pronounced, between Huh7 and MSC 
microvesicles as well (R2=0.73; Figure 5.4E). Again, similarity in lipid profiles did not correlate 
with difference in protein profiles of Huh7 and MSC exosomes (R2=0.004), or microvesicles 
(R2=0.13) (Figure 5.4B). High degree of similarity between Huh7 and MSC exosomes could not 
be explained by source cell lipid profiles either (Figure 5.4E, R2=0.5). When lipid levels in EVs 
were normalized to their respective source cells and underwent principal component analysis, 
Huh7 and MSC exosomes clustered very close to each other and segregated from U87 vesicles 
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(Figure 5.4F). Huh7 and MSC microvesicles showed a less clear segregation from U87 EVs. 
Taken together, certain source cells differing in protein and lipid composition enriched the same 
proteins but not the same lipids (U87 and Huh7), and yet other source cells enriched the same 
lipids but not the same proteins (Huh7 and MSC) in their EVs. This data suggested that protein 
and lipid enrichment mechanisms were not linked.  
Next we asked, whether Huh7 and MSC cells shared characteristics that could possibly 
relate to their similar exosomal lipid composition. We observed that Huh7 and MSC cells yielded 
significantly fewer and smaller exosomes (73 /cell and 36 /cell, 129±14 nm and 131±12 nm, 
respectively) than U87 cells (1382 /cell, 148±8 nm).  
Lipid enrichment in EVs correlates with headgroup charge, tail length and saturation 
Figure 5.10 Lipid enrichment in 
EVs correlates with headgroup 
charge and fatty acid tail length 
and saturation. Lipid species 
levels in EVs were normalized to 
the corresponding lipid levels in 
source cells, expressed on a log(2) 
scale and color-coded. Depletion is 
depicted in blue and enrichment in 
red. Sidebar on the left encodes 3 
characteristics of a lipid species: 
headgoup charge (in color), average 
length of fatty acid tails (greyscale) 
and average level of saturation of 
fatty acid tails (greyscale). Lipid 
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species clustered not only according to headgroup charge but also according to length and 
saturation of tails.  
 
 Concentration of the 1961 detected lipid species (defined by headgroup, number, length 
and saturation of fatty acid tails) in EVs were normalized to respective source cell lipidome. Color-
coding of enrichment (red) and depletion (blue) of lipids (Figure 5.10) in EVs versus source cells 
showed a good concordance between triplicate measurements and confirmed that MSC and Huh7 
exosomes displayed a very similar lipid composition. Next, we were interested whether enrichment 
or depletion in EVs versus source cells depended on headgroup or fatty acid tail characteristics. 
Hence, we created a sidebar on the left, which color-coded three characteristics of each lipid 
species: charge of its headgroup (negative (green), neutral (navy) or zwitterionic (magenta)), 
average length (the darker, the longer) and average saturation (the darker, the more double bonds) 
of its fatty acid tails. The colors and gray shades partially followed unsupervised clustering of 
lipids indicating that headgroup charge as well as tail length and saturation correlated lipid 
enrichment in EVs. Specifically, MSC microvesicles (p=0.007), U87 exosomes (p=0.004) and U87 
microvesicles (p=0.006) were enriched in zwitterionic lipid headgroups (phosphatidylcholines 
and/or phosphatidylethanolamines) and depleted in other headgroups. MSC exosomes, MSC 
microvesicles and Huh7 exosomes were enriched in long lipid species (more than 60 carbons, 
p≤0.001, p=0.041 and p≤0.001, respectively) and polyunsaturated lipid species (more than 10 
double bonds, p=0.006, 0.038 and 0.001, respectively). 
Lipid class enrichment in EVs depends on vesicle type and source cell type 
The 22 lipid classes detected could be sorted into groups marking enrichment in 
microvesicles or exosomes, depletion in most EVs or no change in EVs relative to source cells 
(Figure 5.11)  
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Ceramides and sphingomyelins were consistently enriched in all microvesicles, whereas 
cholesterol esters showed enrichment only in MSC and Huh7 MVs and acyl carnitines and 
lysophosphatidylcholines only in MSC MVs (Figure  5.11 upper panel). These lipid classes were 
depleted from or unchanged in exosomes, with the exception of marked sphingomyelin enrichment 
in U87 exosomes. 
Glycolipid, free fatty acid and phosphatidylserine enrichment characterized all exosomes 
and were depleted from or unchanged in MVs, except for phosphatidylserine enrichment in U87 
MVs (Figure  5.11 upper middle panel). The free fatty acids most enriched in MSC and Huh7 
exosomes were fully saturated (data not shown). Cardiolipins were markedly enriched in MSC and 
Huh7 exosomes only. Lyso derivatives (where one fatty acid tail is removed by hydrolysis) of 
phosphatidylserines, phosphatidylglycerols and phosphatidylinositols showed enrichment in MSC 
and Huh7 exosomes, whereas lyso-phosphatidylethanolamines were rather enriched in U87 
exosomes. These lysoderivatives were also enriched in MSC MVs but depleted from U87 and 
Huh7 MVs. 
Structural membrane lipids, including phosphatidylglycerols, phosphatidylinositols, and 
phosphatidylethanolamines showed depletion from all exosomes and most microvesicles (Figure  
5.11 lower middle panel). Phosphatidylcholines were depleted in exosomes but unchanged or 
enriched in microvesicles. Depletion in diacyl and triacylglycerols in EVs was most pronounced 
in Huh7 cells, which had a high baseline level of these lipid classes. 
Concentration of phosphatidic acids and their lysophosphatidyl derivatives did not differ 
between source cells and EVs (Figure  5.11 lower panel).  
Taken together, both vesicle type and source cell type affected the lipid composition of 
EVs. 
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Figure 5.11  Lipid class enrichment in 
EVs depends on vesicle type and source 
cell type. Percentage of each lipid class 
within a sample is depicted on slope charts 
and lipid class grouped according to their 
enrichment in microvesicles (upper panel), 
enrichment in exosomes (upper middle 
panel), depletion in most EVs (lower 
middle panel) or no difference between 
EVs and source cells (lower panel). Source 
cells are depicted in black, exosomes in 
red and microvesicles in blue. Since 
different lipid classes represent vastly 
different percentage of cells’ or vesicles’ 
lipid composition, the scale of the y axes shows a corresponding variability. 
5.5 DISCUSSION 
 
Extracellular vesicles consist of heterogeneous subgroups, which are difficult to fully 
distinguish by current purification methods. Here we showed that (i) exosomes and microvesicles 
could be well distinguished on the proteome level but did not display source cell-independent, 
vesicle type-specific protein markers, (ii) proteome but not lipidome of EVs distinguished 
cancerous source cells from stem source cells, (iii) protein and lipid enrichment in EVs compared 
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to source cells were not linked. Furthermore, the current study provides the largest dataset of EV 
lipid content to date.  
We observed cell-type-specific enrichment of proteins and lipids in EVs. The clear 
difference between composition of source cells and EVs indicated that lipids and proteins are likely 
actively sorted into EVs. However, the enrichment of commonly used exosome markers was 
source cell type dependent, and although to a different extent, all exosomal markers were enriched 
in microvesicles as well. Enrichment of Rab proteins in EVs, a protein family indicated in 
exosomal biogenesis372, showed marked source cell dependency, suggesting that protein sorting 
mechanisms into EVs may depend on source cell type. Commonly enriched pathways in EVs 
correlated well with previously described behaviors of EVs (such as heparin binding373, immune 
response stimulation325, 367, integrin content137 and antiphagocytic CD47374 of exosomes and 
mitochondrial, proteasomal and ER content of microvesicles332, 375). Gene ontology analysis found 
enrichment of certain posttranslational modification motifs (e.g., glycosylation and prenylation) 
common to all EVs, although the exosome targeting palmytoil modification146 was not detected. 
We were not able to detect any protein biomarkers that were enriched in exosomes of all source 
cells and at the same time depleted in microvesicles of all source cells. Nevertheless, we showed 
that exosomal content and microvesicle content on the proteome level differed significantly from 
each other independent of source cell type. Therefore, we suggest that the correlation between 
exosome and microvesicle content could be explored as an additional biomarker for “vesiculome” 
(mass spectrometry and RNASeq) studies.  
Protein enrichment in exosomes distinguished cancer cells from the stem cells used in this 
study. If further studies on EVs derived from multiple malignant and benign cell types will confirm 
this observation, then protein enrichment in exosomes might become a particularly useful general 
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cancer marker. Furthermore, this phenomenon suggests that stem cells and cancer cells may use 
different mechanisms to sort proteins into EVs. Hence, the biomarker value of exosomes might lie 
in indicating sorting dysregulation in their source cells, whereas microvesicles are valuable for 
reflecting the content of their source cells.  
Protein and lipid sorting into EVs did not appear to be linked: U87 and Huh7 (cancerous) 
cells enriched similar proteins but different lipids in their EVs, while Huh7 and MSC (yielding 
few and smaller exosomes) cells enriched similar lipids but different proteins in their EVs. Hence 
protein sorting into EVs associated best with stem or cancer cell origin in this study, whereas lipid 
sorting associated best with yield and size of exosomes. Further studies are needed to confirm 
whether these associations explain EV biogenesis mechanisms. 
The current study mapped EV lipidome to a great depth, identifying almost 2000 lipid 
species. Since lipids are not coded in the genetic code and biological functions of most lipids 
detectable by mass spectrometry are unknown, data interpretation may follow 
biochemical/structural principles. Here we showed that not only headgroup identity, but also 
headgroup charge, fatty acid tail length and saturation contributed to lipid enrichment in EVs. 
These parameters modify the headgroup-to-tail size ratio, which, in turn, defines the spontaneous 
curvature of a lipid monolayer. Since EVs are small vesicles, their limiting bilayer membranes are 
highly curved. We found exosomes to be enriched in positive curvature promoting (free fatty acids 
and lysophosphatidyl derivatives, both having one tail only and favoring outer membranes) as well 
as negative curvature promoting (cardiolipins having four tails and favoring inner membranes) 
lipids. While cardiolipin is believed to exclusively reside in the inner mitochondrial membrane (a 
highly curved membrane itself), other mitochondrial contents (proteins) were specifically depleted 
from the same Huh7 and MSC exosomes. This data suggest that cardiolipin must be actively sorted 
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into exosomes of Huh7 cells and MSCs and it might function to stabilize these unusually small 
vesicles. However, a wider screen of source cell types is necessary to establish a firm correlation 
between cardiolipin content and exosome size. Furthermore, it is intriguing to speculate that anti-
cardiolipin antibodies present in several autoimmune diseases376 might partially be generated due 
to the presence of cardiolipin on circulating exosomes. 
Sphingomyelins and ceramides have been implicated in exosomal biogenesis in brain cells 
(oligodendrocytes377,neurons184, neuroblastoma 310) but not in in PC-3 cells378. We found 
enrichment of sphingomyelins in U87 glioblastoma (a brain cell type) exosomes only, whereas 
both sphingomyelins and ceramides were characteristically enriched in all microvesicles. 
Ceramide-triggered exosome formation pathway is thought to be independent of the ESCRT-
mediated exosome formation pathway377 and controls the packaging of only a subset of proteins 
into exosomes184. Hence, source cell type may influence which pathway is predominantly involved 
in exosome formation and which lipid sorting mechanism is applied. Different exosome formation 
pathways may overlap with microvesicle formation pathways in a source cell type dependent 
manner.  
We found that structural plasma membrane lipids, including phosphatidylcholines, 
phosphatidylinositols, phosphatidylglycols and phosphatidylethanolamines, were depleted, 
whereas phosphatidylserines showed a mild enrichment in exosomes but not in microvesicles. 
These data are consistent with previous findings showing depletion of phosphatidylcholines and 
enrichment of phosphatidylserines in exosomes363. These lipids comprise the majority of 
membranes and their levels in microvesicles were more similar to source cells than their levels in 
exosomes.  
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CHAPTER VI EXOSOMES’ COMPOSITION–ACTIVITY RELATIONSHIP: A PATH TOWARD THE 
RATIONAL DESIGN OF ARTIFICIAL EXOSOMES 
6.1 PREFACE 
 
Text and figures are reproduced from a submitted manuscript 
▪ Haraszti RA, Miller R, Dubuke ML, Rockwell HE, Coles AH, Sapp E, Didiot MC, 
Echeverria D, Stoppato M, Sere YY, Leszyk J, Alterman JF, Godinho BMDC, Hassler 
MR, McDaniel J, Narain NR, Wollacott R, Wang Y, Shaffer SA, Kiebish MA, DiFiglia 
M, Aronin N, Khvorova A. Exosomes’ composition–activity relationship: a path 
toward the rational design of artificial exosomes for siRNA delivery 
Anastasia Khvorova, Neil Aronin and I conceptualized this project. siRNAs were synthesized by 
Dimas Echeverria and duplexed by me. Matthew Hassler maintained oligonucleotide synthesizers 
and HPLCs. I was assisted in EV preparations by Rachael Miller and Marie Didiot. Michelle 
Dubuke, John Leszyk and Scott Shaffer performed mass spectrometry for proteomics. Hannah 
Rockwell and Michael Kiebish performed mass spectrometry for lipidomics. Matteo Stoppato, 
Yves Sere, Rachael Wollacott and Yang Wang prepared large-scale exosomes following three-
dimensional cultures. Ellen Sapp and Marian DiFiglia performed transmission electron 
microscopy. Andrew Coles implanted Alzet pumps to mouse brain. I was assisted by Julia 
Alterman and Bruno Godinho at animal harvests. I prepared liposomes, performed Western 
blotting, Nanoparticle Tracking Analysis, Bredford assays, loaded all vesicles, prepared primary 
neurons, measured all mRNA silencing and all siRNA levels in cells or tissues, performed confocal 
microscopy, analyzed data including proteomics and lipidomics, palmitoylated proteins and 
constructed artificial exosomes. I wrote this manuscript with the assistance of Anastasia Khvorova 
and Neil Aronin.  
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6.2 ABSTRACT 
 
Exosomes can serve as delivery vehicles for advanced therapeutics. The components 
necessary and sufficient to support exosomal delivery properties has not been established. Here, 
we connect exosomal biochemical composition and activity to optimize artificial exosome-
mediated delivery of small interfering RNAs (siRNAs). This information is used to create effective 
artificial exosomes. We show that serum-deprived mesenchymal stem cells produce exosomes up 
to-twenty-two-fold more effective at delivering siRNAs to neurons than exosomes derived from 
control cells. Proteinase treatment of exosomes stops siRNA transfer, indicating that surface 
proteins on exosomes are essential for trafficking. Proteomic and lipidomic analyses show that 
exosomes derived in serum-deprived conditions are enriched in six protein pathways and one lipid 
class, dilysocardiolipin. Based on this information, we engineer an “artificial exosome,” in which 
the incorporation of one lipid (dilysocardiolipin) and three proteins (Rab7, Desmoplakin, and 
AHSG) into conventional neutral liposomes produces vesicles that replicate cargo delivering 
activity of natural exosomes. Data presented here lay out a path toward the capacity to rationally 
design and produce artificial exosomes in bulk for the delivery of advanced therapeutics.  
6.3 INTRODUCTION 
 
Extracellular vesicles (EVs), including exosomes (small EVs) and microvesicles (large 
EVs), transfer molecules, such as therapeutic RNAs136, 308, 341, to induce phenotype change in 
recipient cells 132, 138, 182, 323, 379. Critical questions impede the use of exosomes for clinical 
applications: (1) production of exosomes from cells is a tedious, low yield and difficult to control; 
(2) the essential components of active exosomes are not established; and (3) the fundamental 
mechanisms of exosomal delivery need to be clarified to produce artificial exosomes in bulk. We 
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optimized conditions to improve the delivery of exosomal cargo (siRNA), and used these 
optimized exosomes to find the necessary and sufficient molecules that affect exosome activity. 
Finally, we constructed artificial exosomes based on these findings. Our strategy aims to (1) 
substitute natural exosomes with reverse engineered artificial exosomes appropriate for large-scale 
production; (2) establish exosome composition – activity relationship via comparing exosomes 
from stressed and control cells; and (3) identify proteins and lipids mediating exosome trafficking.  
Cellular stress of EV producer cells can alter the activity380-382 as well as the protein382-385 
and RNA composition386-387 of EVs. Therefore, relating the change in composition of EVs to the 
change in their activity under stressed and control conditions can establish their 
composition−activity relationship. Serum deprivation is a common means of inducing cellular 
stress388 , is widely used in extracellular vesicle production, and has been found to alter EV 
number384, 389-390, activity384, 388, 390, and composition332, 385. Surface proteins384 as well as 
intravesicular proteins390 have been linked to improved EV activity upon serum deprivation. We 
speculate that the membrane composition (proteins and lipids) of EVs is responsible for EV 
intercellular trafficking activity. We show that upon serum deprivation, producer cells release 
exosomes, but not microvesicles, that are more efficient at delivering siRNAs to neurons (a model 
for intercellular trafficking). This activity change is accompanied by substantial protein and lipid 
composition changes. We then screen several proteins and lipids, which ae enriched in stressed 
exosomes, for enhancement in vesicle-mediated siRNA delivery to neurons. Subsequently we 
combine a candidate lipid (dilysocardiolipin) and three candidate proteins (Rab7, AHSG and 
Desmoplakin) from the screen into liposomes in order to construct “artificial exosomes.” These 
artificial exosomes replicate the siRNA delivery activity of natural stressed exosomes both in vitro 
and in vivo. 
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6.4 RESULTS 
 
Characterization of extracellular vesicles produced from control and serum-deprived 
mesenchymal stem cells 
We incubated mesenchymal stem cells derived from umbilical cord, adipose tissue, and 
bone marrow in either the recommended stem cell medium depleted of EVs (Control) or serum-
free RPMI medium for 24 hours (Stressed). We used differential ultracentrifugation to generate 
two EV populations, small and large EVs, enriched based on their sedimentation properties204. We 
refer to the EVs from a 10,000 g pellet as microvesicles, and EVs from the 100,000 g pellet as 
exosomes. Throughout this study we compare stressed conditions with control conditions within 
the same sample type: stressed cells versus control cells, microvesicles from stressed versus from 
control cells, and exosomes from stressed versus from control cells.  
Mesenchymal stem cells tolerated serum deprivation for up to 4 days (Figure 6.1A) without loss 
of viability. EVs showed homogenous size distribution (Figure 6.1B). Exosomes and 
microvesicles isolated from both the control or stressed (serum deprived for 24 hours) conditions 
displayed positive and were devoid of negative protein markers of EVs (Figure 6.1C) and 
appeared as lipid bilayer-surrounded vesicles on transmission electron microscopy (Figure 6.1D). 
Serum deprivation did not affect the exosome yield from umbilical cord-derived cells (p=0.3) but 
significantly decreased the exosome yield from both adipose= and bone marrow-derived cells (6-
fold, p=0.04 and 10-fold, p=0.002 respectively, Figure 6.2A). Serum deprivation did not alter the 
amount of microvesicles (Figure 6.2B). Exosomes derived from umbilical cord mesenchymal 
stem cells were slightly larger than exosomes from either adipose tissue and bone marrow cells 
(142±14 nm, 110±19 nm, and 117±10 nm, respectively). Serum deprivation did not affect EV size 
(Figure 6.2C-D). Protein-to-particle ratio varied substantially between vesicles from different 
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sources and was affected by serum deprivation for some EV populations (Figure 6.2E-F). 
Umbilical cord-derived exosomes had the lowest protein-to-particle ratio, which remained 
unchanged upon serum deprivation (Figure 6.2E-F).  
Figure 6.1 
Characterization of cell 
culture conditions and 
extracellular vesicles.  
A. Umbilical cord derived 
mesenchymal stem cells 
were cultured in either the 
recommended stem cell 
medium or in RPMI for 
differing times. Alamar 
Blue® was added an 
incubated at 37℃ for 12 
hours, and fluorescence 
measured at 570 nm 
excitation, 585 nm 
emission. Signal is 
normalized to not serum 
deprived samples. N = 8, mean ± SD, one-way ANOVA. B. Representative size distribution curves 
of EVs enriched from umbilical cord derived mesenchymal stem cells, N=3, mean, Nanoparticle 
Tracking Analysis. C. Western blots of cells, microvesicles and exosomes derived under control 
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or serum deprived conditions from umbilical cord, adipose tissue or bone marrow derived 
mesenchymal stem cells. Negative marker: calnexin. Positive markers: CD63, Tsg101, CD81. 
Proteins shown to be enriched in ExosomesStressed or CellStressed: Desmoplakin, AHSG, Rab7. D. 
Representative transmission electron microscopy images of EVs derived under control or serum 
deprived conditions from umbilical cord, adipose tissue or bone marrow derived mesenchymal 
stem cells. 
Figure 6.2 Serum 
deprivation of source cells 
alters yield and protein-to-
vesicle ratio of 
extracellular vesicles. 
Extracellular vesicles (EVs) 
were purified from umbilical 
cord, adipose tissue or bone 
marrow derived 
mesenchymal stem cells via 
differential 
ultracentrifugation. Cells 
were cultured under control 
condition or serum deprived 
for 24 hours. N=7, lines represent mean, boxes represent 25-75 percentile range and whiskers 
represent the minimum and maximum value in each group. n.s. = non-significant (p>0.05), Mann-
Whitney test A. Yield, C. Size, and E. Protein-to-particle ratio of exosomes enriched from 
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conditioned media of control or stressed mesenchymal stem cells via differential 
ultracentrifugation (100 000 g fraction). B. Yield, D. Size, and F. Protein-to-particle ratio of 
microvesicles enriched from conditioned media of control or stressed mesenchymal stem cells via 
differential ultracentrifugation (10 000 g fraction).  
Upon serum deprivation, mesenchymal stem cells release exosomes (but not microvesicles), 
which are more efficient in delivery of siRNA 
 Extracellular vesicles transport RNA between cells132, 138, 190. We previously have shown 
that exosomes can  productively transfer loaded cholesterol-conjugated siRNAs to neurons135. 
Here we loaded Huntingtin-targeting, cholesterol-conjugated siRNA233 to exosomes and treated 
primary neurons as a model for exosome trafficking. We evaluated the rates of exosome uptake to 
neurons using confocal microscopy and quantified the level of guide strand accumulation and 
target mRNA silencing in neurons.  
 First, exosomes isolated from serum-deprived cells (ExosomesStressed) delivered more 
siRNA to target neurons compared to ExosomesControl across all mesenchymal stem cell origins 
tested (Figure 6.3A-C). Second, when loaded with fluorescently labeled siRNA, ExosomesStressed 
showed an approximately two-fold faster neuronal uptake kinetic (half-time 1.7 versus 3.8 hours, 
p<0.0001) (Figure 6.4A-B). Finally, siRNA-containing ExosomesStressed were five-to-twenty-two-
fold more efficient at inducing Huntingtin mRNA silencing than ExosomesControl (Figure 6.3D-F). 
Stress-dependent enhancement in activity was characteristic of  exosomes and not of 
microvesicles, where serum deprivation impaired activity (Figure 6.3G-I). These data indicated 
that activity enhancement upon stress depended on an exosome-specific characteristic. Protein 
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composition is one characteristic that differs between exosomes and microvesicles332, 391, therefore 
worth investigating in this context. 
Figure 6.3 Serum 
deprivation of 
mesenchymal stem cells 
improves exosome 
activity but impairs 
microvesicle activity. 
Primary neurons were 
treated with fluorescent 
siRNA-containing 
exosomes or 
microvesicles derived 
from control or stressed 
(serum deprived) cells. 
After 7 days of 
incubation, siRNA levels 
and target mRNA levels 
were quantified in neurons. mRNA levels were normalized to housekeeping gene and to untreated 
control. N=3, mean ± SEM, curves were compared using two-way ANOVA. A-C. uptake of 
siRNA into neurons delivered via exosomes. D-F. mRNA silencing induced by treatment of 
siRNA-containing exosomes. G-I. uptake of siRNA into neurons delivered via microvesicles. J-
L. mRNA silencing induced by treatment of siRNA-containing microvesicles. A., D., G., J. EVs 
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enriched from umbilical cord derived mesenchymal stem cells. B., E., H., K. EVs enriched from 
adipose tissue derived mesenchymal stem cells. C., F., I., L. EVs enriched from bone marrow 
derived mesenchymal stem cells.  
Figure 6.4 Neuronal 
uptake of control and 
stressed exosomes.  
Primary cortical neurons 
were cultures on glass bottom 
plates and treated with 
fluorescent siRNA 
containing ExosomesControl or 
ExosomesStressed. A. 
Fluorescence was monitored over time using confocal microscopy. Red: siRNA, Blue: nuclei. B. 
Red signal in images were quantified in ImageJ software, N= 39-50 cells per timepoint and kinetic 
curves compared using two-way ANOVA. 
 
Serum deprivation of mesenchymal stem cells substantially alters protein composition of 
exosomes 
To evaluate serum deprivation-induced changes in the protein composition of exosomes, 
we performed LC-MS/MS proteomic analysis. We collected data from three independent repeats 
of (1) control or serum-deprived mesenchymal stem cells (derived from umbilical cord, adipose 
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tissue, or bone marrow); (2) microvesicles from control or serum-deprived cells; and (3) exosomes 
from control or serum-deprived cells. 
As expected, serum deprivation had a profound effect on the proteome of cells, 
microvesicles, and exosomes, consistent in biological replicates (Figure 6.5A-C., Figure 6.6-6.8). 
Protein composition differed substantially between exosomes and microvesicles (Figure 6.6-6.8). 
Proteins enriched in stressed exosomes were either unchanged or depleted in corresponding 
microvesicles and source cells (Figure 6.6-6.8, Figure 6.5D-F). 
 Gene Ontology analysis showed enrichment of extracellular exosome, proteasome, 
membrane, desmosome, cell-cell adhesion, ribosome, and Golgi proteins in ExosomesStressed 
fractions throughout all cell sources tested (Figure 6.5G-I). We speculated that membrane, 
desmosome and cell-cell adhesion proteins may play a role in enhanced cellular uptake of stressed 
exosomes. In addition, categories often described in exosomes (multivesicular body, endosome, 
histone, tetraspanin) and categories not yet  endoplasmic reticulum, ER-to-Golgi transport, and 
chaperone proteins were enriched in ExosomesStressed derived from at least two of three cell sources 
tested (Figure 6.5G-I).   
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Figure 6.5 Serum 
deprivation of source 
cells alters protein 
content of released 
exosomes. Exosomes, 
microvesicles and 
cells derived from 
control conditions or 
stress conditions 
(serum deprivation) 
underwent LC-
MS/MS proteomics 
analysis. N=3 
biological replicates 
were analyzed and 
label-free quantification carried out using intensity-based absolute quantification method. A-C. 
volcano plots of proteins detected in exosome. Orange dots represent proteins enriched at least 2-
fold in ExosomesStressed and blue dots represent proteins enriched at least 2-fold in ExosomesControl. 
Dashed line marks the threshold of significance (p=0.05, t-test with Benjamini-Hochberg 
correction for multiple comparison). Proteins above the dashed line significantly differ between 
ExosomesStressed and ExosomesControl. Proteins detected in one group and absent in the other group 
were arbitrarily assigned the fold change of 20 or -20. D-F. Heatmaps of proteins different (p<0.1) 
in ExosomesStressed versus ExosomesControl. Orange represents enrichment in stressed conditions 
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versus control conditions (ExosomesStressed versus ExosomesControl, MicrovesiclesStressed versus 
MicrovesiclesControl, and CellsStressed versus CellsControl), whereas blue represents enrichment in 
control conditions versus stress conditions. G-I. Gene Ontology analysis of proteins at least 2-fold 
enriched in ExosomesStressed or ExosomesControl (e.g. proteins labeled orange or blue in panels A-
C.). A., D. and G. Umbilical cord derived mesenchymal stem cells. B., E. and I. Adipose tissue 
derived mesenchymal stem cells. C., F. and J. Bone marrow derived mesenchymal stem cells.  
 
Figure 6.6 Proteomics analysis of umbilical cord derived mesenchymal cells and EVs under 
control or stressed conditions. Label-free quantification was carried out using the intensity-
base absolute quantification method. Heatmap was then generated in R, using “pheatmap” 
package, hierarchical clustering of rows, scaling method: “row”. 
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Figure 6.7 Proteomics analysis of adipose tissue derived mesenchymal cells and EVs under 
control or stressed conditions. Label-free quantification was carried out using the intensity-
base absolute quantification method. Heatmap was then generated in R, using “pheatmap” 
package, hierarchical clustering of rows, scaling method: “row”. 
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Figure 6.8 Proteomics analysis of bone marrow derived mesenchymal cells and EVs under 
control or stressed conditions. Label-free quantification was carried out using the intensity-
base absolute quantification method. Heatmap was then generated in R, using “pheatmap” 
package, hierarchical clustering of rows, scaling method: “row”. 
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Several proteins enriched in stressed exosomes contribute to improved siRNA transfer to 
neurons 
 Altered surface protein composition may explain the enhanced activity of ExosomesStressed. 
Proteinase K treatment (degrades surface proteins) impaired the exosome-mediated siRNA 
transfer and resulted in Huntingtin silencing (Figure 6.9A-B), confirming that exosomes’ surface 
proteins are essential for the delivery of cargo into neurons. The difference in the activity of 
ExosomesStressed over ExosomesControl is not related to potential inhibition by serum proteins 
present, as incubation with serum-containing (EV-depleted) media had no effect on 
ExosomesStressed activity (Figure 6.9A).  
To establish a protein composition–activity relationship in exosomes, we selected proteins 
that (1) have an established role in vesicle trafficking or membrane adhesion, and (2) were enriched 
in stressed exosomes derived from at least two of three mesenchymal stem cell sources. Based on 
these criteria, the shortlist included proteins from endosomal pathways (Rab5 and Rab7392), 
plasmamembrane budding (ARRDC1393), secreted proteins interacting with membranes 
(dermcidin394), desmosome (Desmocollin, Desmoplakin395), and nucleo-extracellular shuttles 
(AHSG and Histone 1396) (Figure  6.9C). AHSG has been reported to shuttle histones from the 
nucleus to exosomes396 and was consistently enriched in stressed cells (not present in EVs) (Figure  
6.9C), whereas histones were specifically enriched in stressed exosomes (Figure 6.5G-I, Figure  
6.9C). The enrichment of Desmoplakin and Rab7 in stressed exosomes and AHSG in stressed cells 
has been independently confirmed on Western blots (Figure 6.1D).  
Purified proteins were chemically palmitoylated and co-incubated with neutral liposomes 
(dioleoyl-phosphatidylcholine: cholesterol, 7:3) in order associate to the liposome surface. 
Palmitoylation has been reported as a strategy to enrich proteins associated to exosomal 
Chapter VI Exosomes’ composition–activity relationship: a path toward the rational design of 
artificial exosomes 
163 
 
memrbanes146. Incorporation of Rab7, Desmoplakin, and AHSG improved liposome-mediated 
siRNA transfer to neurons and improved Huntingtin mRNA silencing (p<0.0001 two-way 
ANOVA, Figure 6.9D). Incorporation of Rab5, Desmocollin, ARRDC1, Dermcidin, and Histone 
1 had no effect (Figure 6.9D). Thus, incorporation of at least three candidate proteins from the 
proteomic analysis to the liposome surface affected the efficiency of vesicle transfer to neurons. 
 
Figure 6.9 Proteins 
enriched in stressed 
exosomes contribute to 
improved siRNA transfer 
to neurons. 
A-B. Exosomes were 
enriched from serum 
starved (A.) or control (B.) 
umbilical cord derived 
mesenchymal stem cells 
and either not further 
treated or treated with 
proteinase K or EV-depleted serum containing medium (serum). Primary neurons were then 
treated with the above exosome variants containing siRNAs and mRNA levels in neurons 
quantified after seven days of incubation. N=5, mean ± SEM, curves compared using two-way 
ANOVA. C. Enrichment of selected proteins in ExosomesStressed versus ExosomesControl (orange) 
or in CellsStressed versus CellsControl (grey). Proteins detected in stressed conditions but absent in 
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control conditions were arbitrarily assigned the fold change of 20. N=3, mean ± SEM. Two-way 
ANOVA, **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05. E. Primary neurons were treated 
with siRNA containing liposomes alone or liposomes incorporating purified proteins from panel 
C. and target mRNA levels in neurons quantified after 7 days of incubation. N=4, mean ± SEM, 
two-way ANOVA. 
 
Dilysocardiolipin enrichment in stressed exosomes contributes to improved trafficking to 
neurons 
 Membrane composition is a likely contributor to the enhanced trafficking activity of 
stressed exosomes. Membrane trafficking is regulated by both proteins and lipids397-398. To 
evaluate the effect of serum deprivation on the lipid composition of exosomes, we performed 
MS/MSALL lipidomic analysis. Among all lipid classes detected, only cardiolipins showed 
significant enrichment in exosomes derived from serum-deprived cells (p=0.004, two-way 
ANOVA) (Figure 6.10A and Figure 6.11A). Similar to protein enrichment, cardiolipin 
enrichment was specific to stressed exosomes and did not occur in corresponding cells and 
microvesicles (Figure 6.10A). In addition, we have observed a modest but statistically significant 
enrichment in unsaturated and long-tailed cardiolipins in stressed exosomes (Figure 6.11B-C). 
Cardiolipin is a diphosphatidylglycerol lipid with four fatty acid tails (Figure 6.10B). 
Hydrolytic removal of one or two fatty acid tails results in the formation of monolysocardiolipin 
(Figure 6.10C) or dilysocardiolipin (Figure 6.10D), known intermediates in cardiolipin 
remodeling399. Cardiolipin remodeling has been associated with highly curved membranes400.  
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Among different cardiolipin subclasses, dilysocardiolipins showed the highest enrichment 
in stressed exosomes (sixteen-fold, p<0.0001), followed by intact cardiolipins (nine-fold, 
p<0.0001), and monolysocardiolipins (six-fold, p<0.0001) (Figure 6.10E), compared to control 
exosomes. Cardiolipin subclass enrichment was specific to stressed exosomes and was not 
observed in corresponding microvesicles and cells (Figure 6.10E).  
 To test whether cardiolipins play a role in vesicle trafficking to neurons, we incorporated 
intact cardiolipin, monolysocardiolipin, or dilysocardiolipin (30% of total lipid amount) in 
conventional liposomes (dioleoyl-phosphatidylcholine, cholesterol). Incorporation of 
dilysocardiolipin but not other variants into liposomes improved siRNA transfer to neurons and 
resulted in Huntingtin silencing (p=0.007, two-way ANOVA) (Figure 6.10F). Thus, 
dilysocardiolipin enrichment in stressed exosomes might be a contributing factor to enhanced 
neuronal uptake.   
Chapter VI Exosomes’ composition–activity relationship: a path toward the rational design of 
artificial exosomes 
166 
 
Figure 6.10 
Dilysocardiolipin 
enrichment in 
stressed exosomes 
contributes to 
improved 
trafficking to 
neurons. 
Exosomes purified 
from umbilical cord 
derived mesenchymal 
stem cells under 
control conditions or 
stress conditions 
(serum deprivation) 
underwent 
MS/MSALL 
lipidomics analysis. 
N=2-5 biological replicates were analyzed per group. A. Heatmap of lipid classes in stressed 
conditions versus control conditions. Orange represents enrichment in ExosomesStressed versus 
ExosomesControl, MicrovesiclesStressed versus MicrovesiclesControl, and CellsStressed versus CellsControl, 
whereas blue represents enrichment in control conditions versus stress conditions. B. Scheme of 
cardiolipin. Length and saturation of fatty acid tails depicted is representative only and varies 
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between natural cardiolipin species. C. Scheme of monolysocardiolipin. Differences to cardiolipin 
is shown in red. Length and saturation of fatty acid tails depicted is representative only and varies 
between natural monolysocardiolipin species. D. Scheme of dilysocardiolipin. Differences to 
cardiolipin is shown in red. Length and saturation of fatty acid tails depicted is representative only 
and varies between natural dilysocardiolipin species. E. Enrichment of cardiolipin subclasses from 
panels B-D. in ExosomesStressed versus ExosomesControl (dark orange), MicrovesiclesStressed versus 
MicrovesiclesControl (light orange), and in CellsStressed versus CellsControl (grey). Two-way ANOVA, 
**** p<0.0001. F. Primary neurons were treated with siRNA containing liposomes alone or 
liposomes incorporating lipids from panel E. and target mRNA levels in neurons quantified after 
seven days of incubation. N=4, mean ± SEM, two-way ANOVA. 
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Figure 6.11 Serum 
deprivation of umbilical 
cord derived 
mesenchymal stem cells 
alters lipid composition of 
exosomes.  
Umbilical cord derived 
mesenchymal stem cells and 
EVs from control or stress 
conditions (serum 
deprivation) underwent 
MS/MSALL lipidomics 
analysis. A. Bar graph 
shows of lipid classes in 
stressed conditions versus 
control conditions. ExosomesStressed versus ExosomesControl (dark orange), MicrovesiclesStressed 
versus MicrovesiclesControl (light orange), and CellsStressed versus CellsControl (grey). N = 2-5, mean 
± SD, two-way ANOVA. B. Correlation of enrichment in ExosomesStressed versus ExosomesControl 
with the cumulative number of double bonds in the fatty acid tails of a cardiolipin species (N = 
149). Each dot represents a cardiolipin species. C. Correlation of enrichment in ExosomesStressed 
versus ExosomesControl with the cumulative length of the fatty acid tails of a cardiolipin species (N 
= 149). Each dot represents a cardiolipin species. 
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Artificial exosomes are equally active at siRNA delivery as natural exosomes in vitro and in 
vivo 
 Having identified three proteins and one lipid class to be enriched in ExosomesStressed and 
thereby improve vesicle uptake into neurons, we decided to explore whether we can engineer an 
artificial exosome displaying similar activity to that of ExosomesStressed. We combined common 
liposome components (dioleoylphosphatidylcholine and cholesterol) with dilysocardiolipin and 
palmitoylated Rab7, Desmoplakin, and AHSG in a proteoliposome (ExosomeArtificial). 
Incorporation of three proteins and one lipid to liposomes significantly improved liposome-
mediated siRNA transfer to neurons (p<0.0001, two-way ANOVA) (Figure 6.12A). The 
efficiency of siRNA-containing artificial exosomes in Huntingtin silencing was indistinguishable 
from that of stressed exosomes (Figure 6.12A)  
To evaluate if siRNA-containing artificial exosomes will support Huntingtin silencing in 
vivo, we compared siRNA-containing natural exosomes and artificial exosomes infused into 
mouse brain. For the in vivo study, natural exosomes were produced using a combination of three-
dimensional xenofree mesenchymal stem cell culture and tangential flow filtration-based exosome 
isolation (ExosomesLarge-Scale) (Haraszti et al. in review). This method enabled us to collect a 
sufficient number of exosomes necessary to power the in vivo studies. Natural exosomes 
(ExosomesLarge-Scale) showed an activity indistinguishable from that of ExosomesStressed and 
ExosomesArtificial in vitro in primary neurons (Figure 6.12A). When infused to the lateral ventricle 
of the mouse brain, both siRNA containing ExosomesLarge-Scale and ExosomeArtifical induced 
Huntingtin mRNA (Figure 6.12B-C) silencing, whereas control liposomes, non-targeting-control 
siRNA containing vesicles, and non-formulated siRNA were inactive (Figure 6.12B-C).  
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 This study introduces the concept of reverse engineering exosomes using mass 
spectrometry data of exosome composition with different activities (Figure 6.12D). First, the 
introduction of a stress factor (i.e., serum deprivation) into exosome-producing cells improves 
exosome activity by altering protein and lipid composition. Second, proteins and lipids enriched 
in stressed exosomes are validated for contribution to enhanced vesicle trafficking to target cells. 
Finally, purified versions of the proteins and lipids identified in the second step are associated with 
neutral liposomes. This proof-of-concept study introduces a reverse engineering approach to 
building protein and lipid components into artificial exosomes, which then exhibit the essential 
biological activity of natural exosomes, similar to the construction of minimal artificial cells401. 
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Figure 6.12 
Artificial exosomes 
recapitulate the 
activity of stressed 
exosomes. 
A. Primary neurons 
were treated with 
siRNA containing 
ExosomesStressed, 
ExosomeLarge-Scale or 
ExosomesArticial and 
target mRNA levels 
in neurons quantified 
after seven days of 
incubation. 
ExosomesStressed and ExosomeLarge-Scale were enriched from umbilical cord derived mesenchymal 
stem cells via differential ultracentrifugation or tangential flow filtration, respectively. 
ExosomesArticial consisted of dioleoylphosphatidylcholine, cholesterol, dilysocardiolipin, Rab7, 
Desmoplakin and AHSG. N=5, mean ± SEM, two-way ANOVA. B-C. Huntingtin (HTT) – 
targeting or non-targeting control (NTC) siRNAs were infused into the lateral ventricle of mice 
either alone, or in liposomes, ExosomeLarge-Scale or ExosomesArticial . Huntingtin mRNA were 
quantified four weeks after infusion in striatum (B.) and motor cortex (C.). N = 5-7, mean ± SD, 
one-way ANOVA. D. Exosomes enriched from cells in control conditions contain a lipid bilayer, 
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specific (blue) proteins (shapes) and nucleic acids (lines) as well as universal (grey) lipids, proteins 
and nucleic acids. Cholesterol-siRNA associates to the membrane of vesicles (cholesterol: dark 
blue, siRNA: black). Upon serum deprivation (Step 1), exosomes contain a lipid bilayer with 
specific (orange) lipids, proteins and nucleic acids as well as universal (grey) lipids, proteins and 
nucleic acids. Proteins and lipids enriched in ExosomesStressed (orange) are identified and validated 
(Step 2) for enhancing vesicle trafficking to target cells based on Figures 4. and 5. Then, purified 
versions of above lipids and proteins are obtained (magenta, Step 3) and incorporated into lipid 
bilayer liposomes (ExosomesArtificial , Step 4).  
6.5 DISCUSSION 
 
Extracellular vesicles (EVs) exhibit specific and efficient intercellular trafficking 
activity132, 138, 182, 323, 379 and therefore are promising delivery vehicles of various classes of 
therapeutic proteins and RNAs136, 308, 341. However, the mechanisms imparting specific trafficking 
activity to EVs are unknown. The identification of components necessary and sufficient to make a 
vesicle behave like an EV would open a new chapter to overcome the delivery challenge of protein- 
and nucleic acid-based advanced therapeutics. 
Serum deprivation is often used to enhance EV activity 384, 388-390 and induces an integrated 
cellular stress response402-404 supporting a considerable change in the cellular403-405 and secreted 
proteome406-407. Here we relate serum deprivation-induced changes in EV membrane composition 
to EV-mediated siRNA delivery with the aim of identifying EV components capable of replicating 
EV activity.   
Serum deprivation of source cells may differentially influence the yield and activity of 
released EVs. Here we find that serum deprivation of mesenchymal stem cells increases the 
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activity but decreases the yield of exosomes. In contrast, serum deprivation decreases the activity 
but does not alter the yield of microvesicles. The concept that serum deprivation may alter the 
yield of different EV subclasses into different directions has been raised before332. However, the 
notion that serum deprivation may increase the activity of one EV subclass but decrease the activity 
of another EV subclass produced from the same cells is novel. This observation indicates that 
exosome and microvesicle production pathways are differentially regulated in stress conditions.  
 Exosomes released from stressed cells exhibit a specific enhancement in activity and a 
specific protein composition. Therefore, stressed exosomes are ideally suited for composition–
activity relationship studies. The protein content of EVs from serum-deprived and control cells has 
been shown to differ332, 385. The functional 20S proteasome, all subunits of which we find 
specifically enriched in stressed exosomes, has been detected in EVs before332, 408 and has been 
proposed to be of therapeutic value409. We also observe enrichment in desmosomal proteins, 
ribosomal proteins, histones, and endosomal proteins, all of which have been reported in EVs and 
are proposed to play a role in an EV release mechanism396, 410-415. Several strategies have been 
successfully applied to modulate the surface of EVs: expressing proteins fused to palmitoylation 
signals167, to transmembrane domains167, or to exosomal marker proteins149, 163 in source cells; 
CLICK chemistry-based conjugation170; fusing EVs with liposomes416-417; and loading cholesterol-
conjugated aptamers onto the surface of EVs155. Here we show that three out of eight proteins 
(Desmoplakin, AHSG, and Rab7) enhance vesicle trafficking to neurons. We used the chemical 
palmitoylation to enable protein loading into the vesicle membrane. Different proteins may have 
different sensitivity to this treatment (i.e., high pH and palmitoylation on lysine residues instead 
of the naturally occurring cysteine, serine, and threonine residues). Thus, the lack of enhancement 
in liposome neuronal uptake may not indicate a lack of contribution to vesicle trafficking. Further 
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advancement of the technology presented here will require combinatorial optimization of protein 
loading-to-membrane as well as lipid-to-protein ratios. 
A pioneering finding of this study is showing a functionally relevant difference in the lipid 
content of EVs derived from serum-deprived cells and control cells. We previously have reported 
on cardiolipin enrichment in exosomes compared to cells and microvesicles256. Here we show that 
dilysocardiolipins are enriched in stressed exosomes and that this enrichment is functionally 
relevant. Lysocardiolipins are substrates of a cardiolipin remodeling enzyme residing in the 
endoplasmic reticulum (acyl-coA:lysocardiolipin acyltransferase 1)399. We find proteins of ER-to-
Golgi transport also are enriched in stressed exosomes. Thus, dilysocardiolipin may use the ER-
Golgi secretory pathway to enter exosomes under stress conditions. The ER-Golgi secretory 
pathway may overlap with the release of exosomes from the multivesicular body418-420. 
Artificial exosomes constructed from purified lipid and protein components would have 
several advantages over natural exosomes. First, the manufacture of proteoliposomes is an easily 
scalable process and may be more cost-effective than manufacturing cell-derived exosomes. 
Second, the quality control of cell-free artificial exosomes could follow established guidelines 
from the liposome field, whereas the quality control requirements of natural therapeutic exosomes 
remain unclear327, 341. Third, loading therapeutic cargo (proteins or RNA) into or onto artificial 
exosomes could be a simple step added to the manufacturing process, whereas efficient loading of 
therapeutic cargo to natural exosomes still is challenging. The activity of artificial exosome 
composition identified here might be limited to neuronal uptake, and alteration or optimization of 
this composition likely is necessary to tune artificial exosomes for delivery to other cell types.  
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CHAPTER VII DISCUSSION 
 
This dissertation lays out a path for the rational design of either natural or artificial 
exosomes for the delivery of advanced therapeutics. Exosome technology can combine RNA 
therapeutics (Chapter III), stem cell therapeutics (Chapter IV) and gene therapies148, 157-158 in one 
particle. This combinatorial potential represents a leap forward in the development of advanced 
therapeutics. 
When I started my thesis work, the RNA therapeutics field was in the need of diversifying 
delivery strategies in order to successfully treat organs other than the liver. At the same time, the 
extracellular vesicle field wished to enhance intrinsic therapeutic effects of exosomes by enriching 
therapeutic RNA content. Work in this dissertation fills those gaps by developing siRNAs with 
increased stability and activity in vivo (Section 3.1) and optimizing productive loading of these 
siRNA compounds to exosomes (Sections 3.2 and 3.3).  
Extracellular vesicles encompass a very heterogenous group of vesicles. At the beginning 
of my thesis work the EV field dogma defined proteins specific to certain EV subclasses, such as 
exosomes and microvesicles, and absent from other EV subclasses. The work described in 
Chapters V and VI contributed to the change of this dogma. The current view is that no protein 
and no isolation method can fully differeniate between EV subclasses and EV content is largely 
dependent on the producer cell. The work in Chapters V and VI coincided with other proteomic 
studies comparing different classes of EVs332 and different EV isolation methods332 that also 
contributed to the change of the EV dogma. However, Chapter V was crucial in showing the high 
producer cell dependence in EV content. The term “extracellular vesicle” became similar to the 
term “cancer”, where both terms mark highly heterogenous entities with high source-cell-
Chapter VII Discussion 
176 
 
dependence, diversity on the benign/therapeutic – malignant axis, lack of specific markers, and 
need for characterization at the omics level (e.g. genome, transcriptome, proteome, lipidome).  Just 
like there is no single marker of a malignant tumor, there is no single marker of therapeutic EVs. 
However, similar to how the growing resolution of cancer characterization has enabled effective 
target-therapies, growing resolution of EV characterization will enable further EV classification 
into specific, maybe even personalized therapeutic vesicles. 
The lack of specific markers impedes our understanding on composition – activity 
relationship of different EV classes. At the beginning of my thesis work there were speculations 
about the RNA content of EVs being responsible for their therapeutic effect351. Antiphagocytotic 
molecules have also been described on EV surface374. However, the components making EVs good 
delivery vesicles were unknown. The work in Chapter VI identified four molecules, 
dilysocardiolipin, Rab7, AHSG and Desmoplakin, that contribute the EV-mediated delivery to 
neurons. The mechanism, how these molecules enhance vesicle uptake remains to be elucidated. 
Independent of the mechanism, however, the strategy described in Chapter VI enables the large-
scale development of reverse engineered exosomes for targeting specific cells. Furthermore, the 
four molecules identified can be considered as components or coating for a variety of delivery 
vehicles, including not only artificial exosomes, but also liposomes, lipid nanoparticles and 
polymer-based nanoparticles. Cardiolipins and its lyso-derivatives, monolysocardiolipins and 
dilysocardiolipins, are known regulators of membrane organization and membrane curvature400 
and therefore may be used to fine-tune vesicle membrane structure and size as well as to enhance 
delivery. Immunogenicity of such new delivery vesicles needs to be elucidated. 
When I joined my thesis laboratory, a new mechanism of siRNA loading to exosomes just 
have been developed: cholesterol-conjugated siRNAs passively associated to the EV membrane135. 
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Beyond contributing to this work, this dissertation further optimized the lipid conjugate and the 
scheme for chemical modifications of RNA cargo for EV-mediated delivery (Chapter III). These 
strategies can be extended to load mRNAs via lipid-conjugated tethers (collaboration with Alexis 
Forterre and AC Matin), miRNAs (collaboration with Sicheng Wen and Peter Quesenberry), 
aptamers155 and presumably antimiRs, antisense oligonucleotides and sgRNAs for CRISPR. 
Furthermore, Chapter VI showed that there is a functional difference between two EV subclasses, 
exosomes and microvesicles, in their siRNA delivering capacity. 
During my thesis work I adopted chemical palmitoylation for the loading of protein cargo 
on vesicle membranes (Chapter VI). This method requires the presence of lysines in the protein 
and stability of the protein at pH 8. All proteins with these characteristics can be loaded onto 
vesicles using chemical palmitoylation. Thus, chemical palmitoylation may enable exosomes to 
deliver therapeutic antibodies, Cas proteins for CRISPR or proteins for enzyme replacement. 
Most of RNA and protein therapeutics can be delivered to target tissues without the use of 
exosomes or EVs. The advantage of using exosomes for delivery lies in better spread (Chapter VI 
and 135), lower doses needed (Chapter VI and 135), and in the combinatorial potential: combining 
different classes of RNA therapeutics in one exosome (e.g. targeting different pathways via 
different mechanisms in the same target cell), or combining RNA therapeutics with proteins or 
viruses. CRISPR is a classic example of such combinatorial therapeutic: it requires the delivery of 
an sgRNA and a protein or an sgRNA and an mRNA. Exosomes, therefore, represent an ideal 
delivery platform for CRISPR148, 162. Another advantageous combination is AAV and siRNA in 
exosomes: both exosomes and siRNAs can provide temporary immune modulation to overcome 
the largest impediment of AAV therapeutics today: pre-existing antibodies157. Immune modulation 
may be advantageous for antibody therapies and protein replacement therapies as well. Yet, 
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another combination could be that of therapeutic cargo with targeting moiety, such as a protein or 
an aptamer.  
Chapter VI describes a first proof-of-concept experiment for artificial exosomes. Artificial 
exosomes stand at the crossroad of cell-derived therapeutics (extracellular vesicles) and drug-
delivering synthetic nanoparticles. Therefore, artificial exosomes may combine the advantages of 
both approaches: minimal toxicity and high delivering efficiency of EVs with scalable 
manufacturing and straightforward quality control procedures of synthetic nanoparticles. 
Quality control of natural exosomes remains challenging327. As shown in Chapters V and 
VI, EV contents are very complex. Single-vesicle resolution of EV content characterization would 
therefore be desirable.  FACS-based technology is being currently developed for single-vesicle 
characterization of EVs421. FACS may enable further classification of EVs and sorting of EVs 
according to their contents. This will allow more accurate understanding of composition-activity 
relationship of EVs and to better purify EVs for therapeutic use. 
Low yield of EVs is the major rate-limiting factor in advancing the EV technology towards 
preclinical animal experiments and clinical trials327. Work in Chapter IV fills this gap by 
developing a high yield, scalable and GMP-compatible mesenchymal stem cell culture and EV 
isolation strategy. This method allowed us to power mouse experiments (Chapter VI) using 
mesenchymal stem cell derived EVs. However, cost of EV production remains high. Thus, we 
suggest to use natural EVs only to treat diseases that are inaccessible to other therapeutics or other 
delivery vehicles. In organs accessible to various therapeutic classes, artificial exosomes are a good 
and cost-effective alternative to natural exosomes. 
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When I started my thesis work, quantification of chemically modified siRNAs, especially 
cholesterol-conjugated siRNAs, in cells and tissues was challenging. During my thesis work I 
adopted a PNA hybridization assay (originally developed by AxoLabs Gmbh203, see Section 2.5) 
to measure siRNA levels in cells and tissues. I further optimized this assay to be able to detect 
purine-rich sequences: I established that a mismatch in the sequence can prevent aggregation of 
PNAs caused by long purine stretches and does not compromise the accuracy and sensitivity of 
the assay. Using this strategy, I enabled the measurement of Huntingtin-targeting siRNAs used 
throughout this dissertation together with seven other siRNA sequences. My measurements of 
siRNA levels in cells and tissues were used in five first-author publications and thirteen co-author 
publications (see Appendix A). Alnylam, a leading siRNA company, later adopted this assay in a 
modified form422. 
In conclusion, this dissertation enables high-throughput measurement of siRNA levels in 
tissues (Section 2.5), optimizes chemistry of RNA cargo for EV-mediated delivery (Chapter III), 
develops a large-scale EV isolation method (Chapter IV), extensively characterizes EV content 
(Chapter V), establishes composition – activity relationship in EVs (Chapter VI) and describes 
proof-of-concept artificial exosomes (Chapter VI). These findings will accelerate the transition of 
EV technology into therapeutic applications.  
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